IGHID [ZIP_CODE] - A Phase I Study to Evaluate the Safety and Immunogenicity of The 
ChAdOx1.HIVconsv62 - MVA.tHIVconsv4 (C62 -M4) or, ChAdOx1.tHIVconsv1+C62 - 
MVA.tHIVconsv3+M4 (C1C62 -M3m4) PRIME -BOOST REGIMENS in persons with HIV -1 
Suppressed on Antiretroviral Therapy – THE CM (HIV -CORE 008) STUDY  
NCT Number     [STUDY_ID_REMOVED]  
Document Date  23Oct202 3 
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 1 of 143 
 
 
IGHID [ZIP_CODE]  - A PHASE I STUDY TO EV ALUATE THE SAFETY A ND 
IMMUNOGENICITY OF  THE CHADOX1.HIVCONSV62  - 
MV A.THIVCONSV4 ( C62-M4) OR,  CHADOX1. THIVCONSV1+C62  - 
MV A.THIVCONSV3 +M4  (C1C62 -M3M4) PRIME -BOOST REGIMENS 
IN PERSONS WITH HIV -1 SUPPRESSED ON ANTIR ETROVIRAL 
THERAPY –  
THE CM (HIV -CORE  008) STUDY 
 
DAIDS ES -ID Protocol Number : [ZIP_CODE] 
National Clinical Trial (NCT) Identified Number:  TBD  
Grant Principal Investigator: [INVESTIGATOR_356436] , PhD 
Protocol Principal Investigator: [INVESTIGATOR_305595], MD, MPH  
IND Number : IND #  [ZIP_CODE] 
Funded by: [CONTACT_429399] (NIH)  
Division of AIDS (DAIDS) 
Version Number: 3.0 
23 October  2023 
 
      
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 2 of 143 
 
IGHID [ZIP_CODE] - A Phase I Study to Evaluate the Safety and Immunogenicity of the 
ChAdOx1.HIVconsv62 - MVA.tHIVconsv4 ( C62-M4) or, ChAdOx1.tHIVconsv1+C62  - 
MVA.tHIVconsv3 +M4  (C1C62- M3M4 ) Prime -Boost Regimens in Person s with HIV-1 
Suppressed on Antiretroviral Therapy – The CM ( HIV-CORE  008) Study  
THE CM ( HIV- CORE 008) STUDY 
DAIDS ES -ID Protocol Number: [ADDRESS_543384] this study in compliance with [LOCATION_002] (US) Health and Human Service regulations (45 CFR 46); applicable U.S. Food and Drug Administration regulations; standards of the International Conference on Harmonization Guideline for Good Clinical Practice (E6); Institutional Review Board/Ethics Committee 
determinations; all applicable in -country, state, and local laws and regulations; and other 
applicable requirements (e.g., US National Institutes of Health, Division of AIDS) and 
institutional policies.  
 
 
 
Protocol Principal Investigator: _______________________________________________  Print/Type  
  Signed: ___________________________________ Date: ____________________   Title: _____________________________________ 
 
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 3 of 143 
 
PROTOCOL TEAM ROSTER 
Grant Principal In vestigator  
Nilukshi (Nilu) Goonetilleke, PhD  
Associate  [CONTACT_304010]. Microbiology & Immunology / Medicine University of 
North Carolina  
[ADDRESS_543385], CB# 7042 2023 (Office 2017), Genetic Medicine Building  
Chapel Hill, NC [ZIP_CODE]- 7042  
Phone: (919) 962- 3129  
Email: [EMAIL_6019]  
 Protocol Principal Investigator  
[INVESTIGATOR_305595], MD, MPH  
Associate [CONTACT_356531] UNC HIV Cure Center  
University of North Carolina  
Division of Infectious Disease s  
[ADDRESS_543386],  
2135 Bioinformatics Building, CB# 7030  
Chapel Hill, North Carolina [ZIP_CODE] -7030  
Phone: (919) 843- 2726  
Fax: (919) 966- 8928  
Email: [EMAIL_6015]  
Co-Investigator  
Joseph Eron, MD  
Professor of Medicine,  
School of Medicine  
Chief, Division of Infectious Diseases  
Director, Clinical Core, UNC Center for AIDS Research  
University of North Carolina  
[ADDRESS_543387],  
2110 Bioinformatics Building, CB # 7030  
Chapel Hill, North Carolina [ZIP_CODE] -7030  
Phone: (919) 966- 2536  
Fax: (919) 966- 6714  
Email: [EMAIL_6016]   Co-Investigator  
David Margolis, MD  
Professor of Medicine, Microbiology & Immunology , 
and Epi[INVESTIGATOR_146308]  
[ADDRESS_543388],  
2016 Genetic Medicine Building, CB# 7042 Chapel Hill, NC [ZIP_CODE]- 7042  
Phone: (919) 966- 6388  
Email: [EMAIL_6866]  
 
Clinical Program Director  
Susan Pedersen, RN  
UNC HIV Cure Center  
University of North Carolina  
[ADDRESS_543389],  
2100 Bioinformatics Building, CB# 7030  
Chapel Hill, NC [ZIP_CODE]- 7030  
Phone: ([PHONE_8925]  
Fax: (919) 843- 7625  
Email: [EMAIL_8182]  
  Co-Investigator  
Monica Diaz, M.D ., M.S.  
Assistant [CONTACT_3348] of Neurology, University of North Carolina  
[ADDRESS_543390] Chapel Hill, NC [ZIP_CODE]  
Phone : ([PHONE_8926]  
Email: [EMAIL_8183] 
 
Co-Investigator  
Nancie M. Archin, Ph.D.  
Assistant [CONTACT_40758] of North Carolina Division of Infectious Diseases  
[ADDRESS_543391], CB# 7042  
2060 Genetic Medicine Building  
Chapel Hill, NC, [ZIP_CODE]- 7042  
Phone: (919) 962- 0180  
Email : [EMAIL_6018]   Co-Investigator  
Tomáš Hanke, PhD  
Professor of Vaccine Immunology, Distinguished [CONTACT_40758] of Oxford, Nuffield Department of Medicine  
The Jenner Institute  
ORCRB Roosevelt Drive, Oxford OX3 7DQ United 
Kingdom  
Phone: [PHONE_7412]  
Email : [EMAIL_6867]  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543392] Floor, 
Bldg.3  
Durham, NC [ZIP_CODE]  
Phone: (919) 620- 5374  
Emai l: [EMAIL_8184]  Co-Investigator  
Mehri McKellar, MD  
Duke University Medical Center  
[PO_BOX]  
Durham, NC [ZIP_CODE]  
Phone: 919- 613-6129  
Fax: [PHONE_8927]  
Email: [EMAIL_8185]  
Statistician  
Michael Hudgens, PhD  
Professor,  
Department of Biostatistics Director,  
Center for AIDS Research (CFAR) Biostatistics Core  
3107C  McGavran -Greenberg Hall  CB#7420  
Chapel Hill, NC [ZIP_CODE]- 7042  
Phone: (919) 966- 7253  
Email: [EMAIL_6021]  Statistician  
Ann Marie Weideman, MS  
University of North Carolina  
Center for AIDS Research  (CFAR ) Biostatistics Core  
3104A McGavran -Greenberg Hall  
Chapel Hill, NC [ZIP_CODE]- 7042  
Phone: (410) 858- 6447  
Email: [EMAIL_6868]  
Statistician  
Melissa Mischell 
University of North Carolina  
Center for AIDS Research (CFAR) Biostatistics Core  
3105 McGavran -Greenberg Hall  
Chapel Hill, NC [ZIP_CODE]- 7042  
Phone: (609) 235- 5837  
Email: [EMAIL_8186]  DAIDS Program Officer  
Steve Smiley, PhD  
Program Officer  
Therapeutics Research Program  
Division of AIDS, NIAID, NIH, DHHS  
[ADDRESS_543393], Room 9E59  
Bethesda, MD [ZIP_CODE]- 9830  
Phone: 240- 627-3071  
Fax: 240- 627-3106  
Email: [EMAIL_6869]  
DAIDS Medical Officer  
Lawrence Fox, MD, Ph.D.  
Captain, US Public Health Service  
Senior Medical Officer,  
HIV Research Branch Division of AIDS, NIAID, NIH, DHHS  
phone: 240- 627-3069  
FAX: 240- 627-3106  
Email: LFO [EMAIL_8187]    
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 5 of 143 
 
TABLE OF CONTENTS  
SIGNATURE [CONTACT_1783]  ..........................................................................................................2  
PROTOCOL TEAM ROSTER  ........................................................................................3  
TABLE OF  CONTENTS  ..................................................................................................5  
TABLE OF TABLES  .........................................................................................................9  
TABLE OF FIGURES  .......................................................................................................9  
TABLE OF APPENDICES  ...............................................................................................9  
STATEMENT OF COMPLIA NCE  ...............................................................................10  
1 PROTOCOL SUMMARY .......................................................................................11  
1.1 Synops is .................................................................................................................11  
1.2 Schema  ..................................................................................................................15  
1.3 Schedule of Activities (SoA)  ................................................................................[ADDRESS_543394] Vaccination  ..........................36  
2.3 Risk/Benefit Assessment  ......................................................................................37  
2.3.1  Known Potential Risks of C1 and C62 Vaccines  .........................................37  
2.3.2  Known Potential Risks of M3 and M4 vaccines  ..........................................39  
2.3.3  Known Potential Risks Common to Both ChAdOx1 -vectored and 
MVA -vectored Vaccines  ................................................................................40  
2.3.4  Known Potential Risks of Overdose  .............................................................40  
2.3.5  Known Potential Risks of Syncope  ...............................................................41  
2.3.6  Known Potential Risks of Blood Drawing  ...................................................41  
2.3.7  Known Potential Risks of Leukapheresis  ....................................................41  
2.3.8  Unknown Risks ...............................................................................................42  
2.3.9  Known Potential Benefits  ..............................................................................42  
2.3.10  Assessment of Potential Risks and Benefits  .................................................42  
3 OBJECTIVES AND ENDPOINTS  .........................................................................42  
4 STUDY DESIGN ......................................................................................................45  
4.1 Overall Design  ......................................................................................................45  
4.2 Scientific Rationale for Study Design  .................................................................46  
4.3 Justification for Dose  ...........................................................................................47  
4.4 End of Study Definition  .......................................................................................48  
5 STUDY POPULATION ...........................................................................................48  
5.1 Inclusion Criteria  .................................................................................................48  
5.2 Exclusion Criteria  ................................................................................................52  
5.3 Screening  ...............................................................................................................55  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 6 of 143 
 
5.3.1  Re-Screening  ...................................................................................................55  
5.3.2  Screen Failures  ...............................................................................................56  
5.4 Strategies for Recruitment and Retention  .........................................................56  
5.4.1  Co-Enrollment Guidelines .............................................................................56  
6 STUDY INTERVENTION ......................................................................................57  
6.1 Study Intervention(s) Administration ................................................................57  
6.1.1  Study Intervention Description ....................................................................57  
6.1.2  Dosing and Administration  ...........................................................................57  
6.2 Preparation/Handling/Storage/Accountability .................................................[ADDRESS_543395] Storage and Stability  .......................................................................60  
6.2.4  Preparation  .....................................................................................................61  
6.3 Measures to Minimize Bias: Randomization and Blinding ..............................62  
6.3.1  Randomization  ...............................................................................................62  
6.3.2  Un-blinding  .....................................................................................................62  
6.4 Study Intervention Complia nce ..........................................................................63  
6.5 Concomitant Therapy  ..........................................................................................63  
6.5.1  Required Medications  ....................................................................................63  
6.5.2  Prohibited Medications  .................................................................................63  
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ...............................................................64  
7.1 Discontinuation of Study Intervention ...............................................................64  
7.1.1  Premature Treatment Discontinuation Evaluations ...................................64  
7.1.2  Discontinuation of Antiretroviral Therapy  .................................................65  
7.2 Participant Discontinuation/Withdrawal from the Study  ...............................[ADDRESS_543396] 
and are Discontinued or Withdrawn from Study Participation ................66  
7.2.4  Participant May Withdraw or be Withdrawn from the Study ..................66  
7.3 Premature  Study Discontinuation (D/C) Evaluations  ......................................[ADDRESS_543397] to Follow- Up .................................................................................................67  
8 STUDY ASSESSMENTS AND PROCEDURES  ...................................................67  
8.1 Exclusion Efficacy Assessments  ..........................................................................67  
8.1.1  Remote Data Collection  .................................................................................67  
8.1.2  Visit windows  ..................................................................................................67  
8.1.3  Medical History  ..............................................................................................68  
8.1.4  Medication History  ........................................................................................69  
8.1.5  Clinical Assessments  ......................................................................................70  
8.1.6  Laboratory Studies  ........................................................................................72  
8.1.7  Research Assays  .............................................................................................72  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 7 of 143 
 
8.2 Safety and Other Assessments  ............................................................................73  
8.2.1  Screening  .........................................................................................................73  
8.2.2  Participant Enrollment  ..................................................................................73  
8.2.3  Leukapheresis  .................................................................................................74  
8.2.4  Randomization  ...............................................................................................75  
8.2.5  Study Unblinding  ...........................................................................................75  
8.2.6  Unscheduled Visits  .........................................................................................76  
8.2.7  Vaccine and Placebo Administration Visit  ..................................................76  
8.2.8  Administration of study vaccine/Post Vaccine/Injection management  .....[ADDRESS_543398]  .....................................................................78  
8.2.14  Laboratory Evaluations .................................................................................78  
8.3 Adverse Events and Serious Adverse Events  ....................................................80  
8.3.1  Definition of Adverse Events (AE)  ...............................................................81  
8.3.2  Definition of Serious Adverse Events (SAE)  ...............................................81  
8.3.3  Definition of Medically Attended Adverse Events (MAAEs)  ....................[ADDRESS_543399] (AESIs)  ..........................82  
8.4 Time Period and Frequency for Collecting AE and SAE Information...........83  
8.4.1  Classification of an Adverse Event  ...............................................................83  
8.4.2  Time Period and Frequency for Event Assessment and Follow -Up .........84  
8.4.3  Clinical Laboratory Assessments:  ................................................................86  
9 CLINICAL MANAGEMENT  .................................................................................87  
9.1 Toxicities  ...............................................................................................................87  
Table 21  Expedited Reporting Guidelines  .............................................................88  
9.1.1  Grade 1 and Grade 2 Toxicities  ....................................................................90  
9.1.2  Grade 3 and Grade 4 Toxicities  ....................................................................90  
9.2 AESI  ......................................................................................................................91  
9.2.1  Potential blood clots AESIs and Thrombosis with Thrombocytopenia 
Syndrome (TTS)  .............................................................................................91  
9.2.2  Potential Neurological AESIs ........................................................................92  
9.2.3  Delayed Dose ...................................................................................................93  
9.2.4  Consideration for SARS- CoV- 2 Pandemic  ..................................................93  
9.3 Adverse Event Reporting  ....................................................................................93  
9.3.1  Local or Systemic Reactions to Vaccine/Placebo Injections  ......................94  
9.3.2  Allergic or Hypersensitivity Reactions .........................................................95  
9.3.3  Monitoring HIV RNA levels  .........................................................................95  
9.4 Serious Adverse Event Reporting .......................................................................95  
9.5 AESI reporting  .....................................................................................................97  
9.6 Other Reporting Situations  .................................................................................97  
9.6.1  Reporting to DAIDS  ......................................................................................97  
9.6.2  Reporting Events to Participants  .................................................................97  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543400] Quality  ..............................................................................................99  
9.7 New Safety Information  ......................................................................................99  
9.7.1  Definition of New Safety Information (NSI)  ................................................99  
9.8 NSI Reporting .....................................................................................................100  
9.9 Reporting NSI to Participants  ..........................................................................101  
10 STATISTICAL CONSIDERATIONS  ..................................................................101  
10.1  Statistical Hypotheses  ........................................................................................101  
10.2  Endpoints  ............................................................................................................101  
10.3  Sample Size Determination  ...............................................................................101  
10.4  Procedure for missing and invalid data  ...........................................................102  
10.5  Study Duration and Accrual  .............................................................................102  
10.6  Randomization  ...................................................................................................102  
10.7  Statistical Analyses .............................................................................................103  
10.7.1  General Approach  ........................................................................................103  
10.7.2  Analysis of the Primary Safety Endpoint(s)  ..............................................[ADDRESS_543401] Policy  ..................................................................................114  
12 ABBREVIATIONS  .................................................................................................115  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 9 of 143 
 
13 PROTOCOL AMENDMENT HISTORY  ............................................................120  
14 REFERENCES  .......................................................................................................121  
TABLE OF TABLES  
Table 1  Vaccines Vectored by [CONTACT_429400]1  ......21  
Table 2  Vaccines Vectored by [CONTACT_429401]  .....22  
Table 3  Characteristics of individual HIVconsvX immunogens  .......................25  
Table 4  Summary of Safety Data for Recombinant ChAdOx1 Studies at 5 x 1010 
Virus Particles  ..........................................................................................29  
Table 5  Adverse reactions reported following vaccination with AZD1222 COVID-19 
Vaccine1 .....................................................................................................32  
Table 6  Safety Data for selected Recombinant MVA Studies expressing HIV immunogens, given IM at 1-2 x 10
8 vpu .................................................35  
Table 7  Summary of M&M Trial Safety data .....................................................35  
Table 8  Summary of Safety Data for vaccination with a ChAdOx11 prime followed by 
[CONTACT_429402]2...............................................................................................36  
Table 9  Common Local Reactions ........................................................................37  
Table 10  Common Systemic Reactions  ..................................................................37  
Table 11  Local Reactions to MVA vaccine  ............................................................39  
Table 12  Systemic Reactions to MVA vaccine ......................................................40  
Table 13  Objectives and Endpoints for the Clinical Study  ..................................43  
Table 14  Study Randomization  ..............................................................................45  
Table 15  Vaccine Doses  ...........................................................................................47  
Table 16  Adequate Organ Function Values for Inclusion  ...................................52  
Table 17  Study Treatment Administration  ...........................................................58  
Table 18  Medication Complete History or Timeframe  ........................................70  
Table 19  Blood Volumes Associated with Study Visits  ........................................80  
Table 20  Criteria for Grading the Severity of an AE  ...........................................83  
Table 21  Expedited Reporting Guidelines  .............................................................88  
Table 22  Key Roles for Clinical Study  .................................................................110  
TABLE OF FIGURES  
Figure 1  Overview of HIVconsvX Vaccine Immunogens  ....................................23  
Figure 2  Immunogenicity Data from the M&M Study  ........................................[ADDRESS_543402] C62 and C1C62 Vaccine Adverse Reactions  ....138  
Appendix 3   SARS -CoV-2 Pandemic Considerations  .............................................139  
Appendix 4  Neurology Testing ..................................................................................141  
Appendix 5  Diagnosis and Management  ..................................................................142  
Appendix 6  MedDRA Preferred Terms (PTs) for TTS  ..........................................143  
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543403] of this clinical trial will be in accordance with International Conference on 
Harmonization Good Clinical Practice (ICH GCP) and the following: 
[LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812) 
National Institutes of Health (NIH) -funded investigators and clinical trial site staff wh o are 
responsible for the conduct, management, or oversight of NIH- funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training. The Institutional Review Board (IRB) will review and approve the protocol, informed consent 
form(s), re cruitment materials, and all participant materials submitted. Approval of both the 
protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_429403]. In addition, all changes to the consent form will be IRB-approved; a determination will be made regarding whether a new consent needs to be obtained from participants who provided consent, using a previously approved consent form.  
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 11 of 143 
 
1  PROTOCOL SUMMARY  
1.1 Synopsis   
Title:  IGHID [ZIP_CODE] - A Phase I Study to Evaluate the Safety and Immunogenicity 
of the ChAdOx1.HIVconsv62 - MVA.tHIVconsv4 (C62-M4) or, 
ChAdOx1.tHIVconsv1+C62 - MVA.tHIVconsv3+M4 (C1C62- M3M4) 
Prime -Boost Regimens in Persons with HIV -1 Suppressed on Antiretroviral 
Therapy – The CM ( HIV-CORE  008) Study  
Study 
Description : Phase 1, double blind, randomized, placebo-controlled, parallel design study to evaluate the safety and immunogenicity of vaccines C62  followed by M4  
or C62 and C1  together  (C1C62 ) followed by M4 and M3  together  (M3M4 ). 
Serial vaccination will be denoted as C62-M4 or C1C62 -M3M4 . 
 
Hypotheses:  Intramuscular (IM) vaccination with C62-M4 or C1C62 -M3M4  in persons 
with HIV -1 (PWH) on suppressive antiretroviral therapy (ART) will be safe 
and increase HIV -1-specific T cell responses targeting conserved regions of 
HIV-1.  
Administration of C1C62 -M3M4  will result in a greater increase in the 
breadth of HIV-1- specific T cells targeting conserved regions of HIV -1 than 
C62-M4. 
Objectives:  
 Primary Objective:  
Evaluate the safety of vaccination with i) C62-M4 and ii) C1C62 -M3M4  in 
PWH on ART  through [ADDRESS_543404] vaccination or placebo.  
 Secondary Objectives:  
1. Evaluate the safety of vaccination through the end of study 
2. Compare the within -participant relative change in magnitude of 
HIV-1-specific T cell responses following vaccination with C62-M4 or 
C1C62 -M3M4 . 
3. Compare the between -arm change in breadth of HIV-1- specific T cell 
responses following vaccination C62 -M4 or C1C62- M3M4 . 
 
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 12 of 143 
 
Other Objectives:  
1. Compare the change in function and phenotype of HIV-1- specific T cell 
responses in participants from pre-vaccination to post-vaccination with 
C62-M4 or C1C62 -M3M4 . 
2. Evaluate the kinetics of immunologic responses in participants post-vaccination with C62 -M4 or C1C62 -M3M4 . 
3. Evaluate the kinetics of CD8
+ T cell mediated HIV inhibition pre - and 
post-vaccination following vaccination with C62 -M4 or C1C62 -M3M4 . 
4. Explore cellular activation of total CD4+ and CD8+ T cells pre- and post-
vaccination with C62 -M4 or C1C62 -M3M4 . 
5. Explore the impact of vaccination with C62 -M4 or C1C62 -M3M4  on 
low-level plasma viremia.  
6. Explore the impact of vaccination with C62 -M4 or C1C62 -M3M4  on 
cell-associated HIV RNA in CD4+ T cells.  
7. Explore the impact of vaccination with C62 -M4 or C1C62 -M3M4  on 
total HIV DNA in CD4+ T cells  
8. Assess the long -term safety and tolerability  of vaccination with C62 -M4 
and C1C62 -M3M4  
Study Population:  PWH, inclusive of men and women ≥ 18 and ≤ 70 years of age and all 
ethnicities, with viral suppression on ART and a CD4 cell count ≥ 350 cells/mm
3 at screening.  
Phase:  Phase 1  
Description of Sites Enrolling Participants:  The University of North Carolina, Chapel Hill, North Carolina, [LOCATION_003] 
Duke University Health System, Durham, North Carolina, [LOCATION_003] 
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 13 of 143 
 
Description 
of Study Intervention  Double blind, randomized, placebo-controlled, parallel design study in which 18 participants with durable viral suppression are randomly assigned to receive vaccination with :  
1. C62 followed by M4  
2. C1C62 combined followed by M3M4 combined, or  
3. Placebo  (normal saline)   
Participants will be randomized 8:8:2 to one of three study arms, and receive study treatment or placebo at Day s 0 and 28.  
A maximum of 2 participant s will receive the Day 0 vaccination  per week. 
 
Study Schema  
Arm N Day Treatment  Total 
Dose 
(vp) Route  Day Treatment  Total 
Dose 
(pfu)  Route  
1 8 0 C62 5×1010 IM 28 M4 1.8×108 IM 
2 8 0 C1C62 * 5×1010 IM 28 M3M4# 1.9×108 IM 
3 2 0 Placebo◊ - IM 28 Placebo◊ - IM 
C6= ChAdOx1.HIVconsv62 (mosaic 2)  
C1 = ChAdOx1. tHIVconsv1  (mosaic 1)  
M4 = MVA.tHIVconsv4  (mosaic 2)  
M3 = MVA.tHIVconsv3  (mosaic 1 ) 
vp = virus particles  
pfu = plaque forming units  
IM = intramuscular  
*2.5×1010 vp, each vaccine  
# 0.9×108 pfu M4; 1.0× 108 pfu M3  
◊ normal saline  
Primary Endpoint Statistics  
 
  If zero of 8  participants  experience a safety event, a 95% [ADDRESS_543405] 
binomial upper confidence limit for the probability of a safety event will be 
31%. If one participant  experiences a safety event, the corresponding 95% 
1-sided upper confidence limit will be 47%. Each safety endpoint will be 
estimated with an exact binomial 95% 1 -sided upper confidence limit. If no 
safety events are observed in the two vaccine arms and dat a is pooled across 
arms (n=16), then the upper limit of the exact, 1-sided 95% confidence 
interval will be 0.17 .  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 14 of 143 
 
Study 
Duration  The study will take approximately 2.0 years from the time the study opens to enrollment until completion of data analyses.  
Participant Duration:   
Each participant will complete the study in approximately 36 weeks ( 9 
months). 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM (CORE008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ ChAdOx1.tHIVconsv1 boosted with 
M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 15 of 143 
 
 1.2 Schema  
DAY 0 Screen         Enroll     Baseline           Day 28                   D56               D84             D140            D196
Baseline Clinical and
Research Labs Continues ART Therapy 
Leukapheresis Leukapheresis
Enrollment → Day 0
VaccinationArm 2 
M4 + M3
n=8
Arm 3 
Placebo
n=2Continues ART TherapyArm 1 
M4
n=8
Randomization 
& Vaccination Arm 1 
C62
n=8
Arm 3
Placebo
n=2Arm 2
C62 + C1
n=8
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 16 of 143 
 
 1.3 Schedule of Activities  (SoA)  
 
Screening  
 
Enrollment  and 
Baseline  
Day 0             
Vaccination  
Day 2 
Day 7 
Day 14  
Day 28                
Vaccine Booster  
Day 30  
Day 35  
Day 42  
Day 56  
Day 84  
Day 140 
Day 196              
EOS 
D = days      
W = weeks  D-60  0  W1 W2 W4  W5 W6 W8 W12  W20 W28  
Visit wi ndow   ≤ 60 D 
Visit 1  ≤ 10 D 
Visit 2    +/-  
2 D +/-  
2 D   +/- 
2 D  +/-   
2 D +/-        
7 D +/-        
7 D +/-   
14 D 
Visit  1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Clinical Procedures                
Informed consent  X              
Eligibility and 
Demographics  X              
Locator Information X X X X X X X X X X X X X X 
PID Assignment  X              
SID Assignment   X             
RID Assignment    X            
Medical and 
Medication History  X              
Complete PE X             X 
Targeted PE    X  X X X  X X X X X  
Vital Signs (VS) X X X  X X X  X X X X X X 
Height  X              
Review ART 
Adherence  X X X X X X X X X X X X X X 
Targeted Reproductive 
History  X X X X X X X X X X X X X X 
Updated Medical 
History   X X X X X X X X X X X X X 
Concomitant 
medication review  and 
update   X X X X X X X X X X X X X 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543406]  X              
Urine Pregnancy – 
POCT - WOCBP only   X    X        
Coagulation Tests 
(PT/INR/ APTT)  X              
HIV Ag/Ab Test   X              
CD4+ /CD8+  T Cell 
Differential Panel  X            X X 
HIV- 1 RNA PCR  X    X  X  X     X 
RPR  X              
HBsAg & HCV Ab  X              
PF4 antibody ELISA 
(serum)   X4             
COVID -19 RT -PCR 
(nasal swab)   X X    X        
Research Laboratory                
HLA Typi[INVESTIGATOR_007]   X             
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543407] and store sample at enrollment. All other testing (if required) will be performed in real time. 
[ADDRESS_543408] sample.  
AE=adverse events; AESI = AE of special interest; EOS = end of study; MAAE = medically attended AE ; 
PE=physical exam; PID=participant ID; POCT=point of care test; RID=randomization ID; SAE=serious AE; 
SID=study ID; WOCBP=woman of childbearing  potential   
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 19 of 143 
 
 2 INTRODUCTION 
2.1 Study R ationale   
ART has transformed human immunodeficiency virus type 1 (HIV) from a fatal disease to a 
chronic condition for the [ADDRESS_543409] be taken life-long as interruption 
of therapy in PWH mostly results in viral rebound within weeks ( 1-4). This rebound results from 
cells harboring HIV proviral DNA that is integrated into the host genome. While >95% of proviral DNA is replication -incompetent, the remaining fraction that we define as the ‘HIV 
reservoir’, retains the capacity to produce infectious virus particles, either stochastically (5-8
), or 
through interventions to induce coordinated reactivation ( 9-12). The HIV reservoir is highly 
stable, with an estimated half -life of 44 months ( 13, 14). Natural decay of the HIV reservoir 
would take >70 years. Therefore, to enable PWH to cease ART , additional strategies are 
required. 
Current strategies permitting PWH to stop ART without viral rebound aim t o either eliminate all 
HIV-1 infected cells harboring persistent, replication-competent virus (HIV eradication), or to 
achieve a state of durable HIV -1 suppression without rebound (HIV remission). Both approaches 
could harness CD8+ T cell immunity to achieve reservoir reduction or elimination . Clearance of 
reactivated, HIV infected cells by [CONTACT_398]8+ T cells has been demonstrated with in vitro studies ( 15, 
16). These observations are consistent with the extensively documented role of CD8+ T cells in 
control of HIV in untreated infection ( 17-24 ), as well as more recent studies suggesting CD8+ T 
cells contribute to control of HIV reactivation and/or virus rebound ( 25-27 ). 
The frequency and quality of memory T- cells induced by [CONTACT_429404] a large extent 
determined by [CONTACT_429405] -derived 
immunogens ( 28-31 ). While live, replication -competent virus vectors elicit more vigorous 
immune responses ( 32), their immunogenicity has to be balanced with safety. Like replicating 
vaccines, non- replicating vaccines deliver the immunogen to the major histocompatibility 
complex (MHC) class I pr esentation pathway either directly or by [CONTACT_12783]-presentation, ( 33-35) 
however, no infectious vaccine progeny are produced ( 36). This increase in safety does lessen 
immunogenicity (37, 38) that cannot be easily enhanced by [CONTACT_429406], because of a build -up of anti-vector immunity, particularly humoral immunity, which 
dampens insert- specific T -cell induction ( 39, 40) .   
Serial vaccinations are an established approach to increase the frequency of vaccine-induced 
immune responses. In both pre- clinical and clinical testing, heterologous vaccination with 
different viral vectors expressing common or highly related immunogens has been consistently demonstrated to induce higher frequencies of T cells against the immunogen than homologous vaccination with the same viral vector (41-46). Previous studies have shown that vaccination 
with rChAdV followed by [CONTACT_429407] T cells against the vaccine immunogen; this includes studies in HIV seropositive and seronegative participants.  
The goal of this clinical study is to increase the frequency of circulating CD8
+ T cell responses 
against HIV in PWH on ART. This will be achieved by [CONTACT_429408], 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 20 of 143 
 
 attenuated viral vectors  expressing highly related HIV immunogens spanning conserved regions 
of the virus. 
2.2 Background  
2.2.1  T Cell Correlates and HIV Control  
HIV-specific CD8+ T cells contribute to control of HIV in untreated PWH , however the level of 
contribution across individuals is highly variable. A small minority of PWH  are able to maintain 
long-term control of HIV (<50 copi[INVESTIGATOR_014]/ml) without ART ( 47). Certain MHC  Class I alleles such 
as B*27:05, B*57:01 and B*81:01 are highly overrepresented in these ‘elite-controllers’. HIV 
elite controllers maintain high frequencies of HIV -specific CD8+ T cells that are broadl y 
functional, including mediating strong in vitro suppression of HIV-infected CD4+ T cells. Large 
cohort studies have consistently observed an inverse correlation between higher breadth (number 
of epi[INVESTIGATOR_429341]) of IFN- γ producing CD8+ T cells targetin g the HIV Gag protein  measured 
by [CONTACT_429409] ( 48). These studies in humans are 
supported by [CONTACT_429410]-human primates in which CD8+ T cell depletion have defined 
a clear contribut ion of CD8+ T cells, particularly those targeting Gag, against HIV.  
Virus escape from CD8+ T-cell immune pressure is a major and highly successful immune 
evasion mechanism for HIV -[ADDRESS_543410] 
roadblock for HIV vaccine development. In natural infection, mutations in and around T cell 
epi[INVESTIGATOR_429342] T cell responses, limiting CD8+ T cell detection and 
clearance of virus -infected cells  (21). Virus escape occurs are different rates and at different 
regions across the HIV proteome. This is largely because different HIV proteins have different 
levels of tolerance of mutations. Envelope and regions of Nef tolerate higher levels of virus 
mutation than Gag and Pol proteins. HIV fitness is associated with sequence variation  (22). M ore 
conserved mutations in Gag and Pol are more likely to induce fitness costs in the virus ( 49). The 
higher level of Gag conservation is consistent with the observed association between T cell targeting of Gag and lower HIV viremia.  
An additional challenge is that T cell responses targeting structurally/functionally conserved 
regions of HIV-1 proteins are often subdominant relative to T cells targeting highly variable 
regions such as Env. Circulating T cells in PWH on ART are no exception. Mappi[INVESTIGATOR_429343]-
specific T cell responses in PWH on ART by [CONTACT_429411] 
T cell targeting to untreated infection  (50).  Specifically, CD8
+ T cells consistently target Gag  
but also highly variable regions in Env  and Nef. Of note, in these studies, we also observed that 
PWH on ART had a higher proportion T cells targeting Pol.  
While ART prevents virus escape, the persistent HIV reservoir in PWH ‘archives’ previous virus 
escape mutations (50, 51 ). Deep sequencing of replication -competent HIV -1 recovered from 
resting CD4+ T cells in durably suppressed individuals found that, similar to untreated infection, 
approximately one in three circulating T cells harbor escape variants in the HIV reservoir  (52).  
Following virus reactivation (e.g. after treatment interruption), these escape mutations likely limit the effectiveness of circulating HIV -specific T cell responses.  An important observation 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 21 of 143 
 
 from these studies was that  virus escape occurred less frequently in low entropy or more 
conserved regions of HIV ( 50, 51) . These observations indicate that, while T cell escape occurs  
in the replication competent HIV reservoir, it is not ubiquitous and some CD8+ T cell 
populations still effectively detect and clear virus infected cells , consistent with the sustained 
functionality of HIV- specific CD8+ T cells observed over time (53). The implications of these 
data for HIV -[ADDRESS_543411] T-
cell responses from which there is no pre-existing escape and/or induce strong de novo CD8+ T-
cell responses.  
Altogether, these data indicate HIV  vaccin e regimens in PWH should (re)focus  T-cell responses 
on the protective, structurally/functionally conserved regions of HIV-1 proteins, which are often 
subdominant.  
2.2.2  O verview of the Vaccines 
Simian ad enovirus-vectored ChAdOx1.tHIVconsv1 ( C1) and ChAdOx1.HIVco nsv62 ( C62) 
vaccines ( Table 1 ) have been designed to be given serially  with replication -deficient poxvirus 
Modified vaccinia virus Ankara (MVA)-vectored vaccines MVA.tHIVconsv3 ( M3) and 
MVA.tHIVconsv4 ( M4) vaccines ( Table 2 ). All vaccines express highly -related HIV -derived 
conserved immunogens designed to maximize vaccine immunogenicity, maximize coverage of 
HIV viral div ersity and minimize the effects of viral escape.  
Table 1 Vaccines Vectored by [CONTACT_429400]1 
Vaccine  Manufacturer  Description  
ChAdOx1.tHIVconsv1 
(C1) ADVAXIA BIOLOGICS SRL
[ADDRESS_543412] has a genome size of 32,906 bp and is a slightly opaque frozen liquid, essentially free from visible particulates. The appearance is dependent upon the concentration of the virus.  
ChAdOx1.HIVconsv62  
(C62) ADVA XIA 
BIOLOGICS SRL
[ADDRESS_543413] has a genome size of 32,846 bp and is a slightly opaque frozen liquid, essentially free 
from visible particulates. The appearance is dependent upon the concentration of the virus.  
1Manufactur ing authorization MIA a M42/2018, ADVAXIA BIOLOGICS  SRL, Via Pontina Km 30.600- [ZIP_CODE] 
Pomezia, Italy  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 22 of 143 
 
 Table 2 Vaccines Vectored by [CONTACT_429412].tHIVconsv3 
(M3)  IDT Biologika 
GmbH (IDT)[ADDRESS_543414] a genome size of approximately 181, 000 bp and is a white to light brownish opaque homogeneous suspension.  
MVA.tHIVconsv4 
(M4)  IDT Biologika GmbH (IDT)
[ADDRESS_543415]-01_MIA_2016_0017/604.[ZIP_CODE].A.18 Dessau -Rosslau, [LOCATION_013]  
2.2.3  The Immunogens  
[IP_ADDRESS]  Rationale for Design of HIVconsvX 
HIVconsvX is was designed in silico using full -genome sequences of group M HIVs in the Los 
Alamos National Laboratory HIV Sequence Database (LANL -HSD) , as of September 2013 ( 54). 
HIVconsvX is comprised of six conserved regions of the Gag (region 1 and 2) and Pol (regions 
3-6) of HIV computed into two complementary amino acid sequences, Mosaic-1 and Mosaic-2 (Figure 1 A). Mosaic -1 and -2 differ in about 10% of amino acids and between them, maximize 
the match of the vaccine to the global circulating HIV -1 isolates  (Figure 1B). Each  of the four 
vaccines in this study  uses a different order of the six conserved regions to minimize induction of 
T cell responses to potential newly formed and, therefore, irrelevant non- HIV epi[INVESTIGATOR_429344] ( Figure 1 C). 
The six regions in Gag and Pol in HIVconsvX contain a high number of previous ly identified 
CD8
+ T cell epi[INVESTIGATOR_429345], restricted by 84 different  HLA  I alleles  (54). These regions 
maximize epi[INVESTIGATOR_429346] ( 55). The conserved nature of these regions not only increase the 
likelihood of a match between the immunogens and infecting virus/es but also decreases the effects of virus escape, including pre- existing escape in the HIV reservoir  (52).  
The potential immunogenicity and efficacy of HIVconsvX has  been tested  in cohort studies . First  
in a cohort of treatment naïve PWH , higher magnitude and breadth of CD8
+ T-cell responses 
reactive to HIVconsvX -derived peptides correlated with higher  CD4+ T-cell count and low er 
viral load ( 54). More recently , our group used empi[INVESTIGATOR_429347] T cell responses in PWH on ART. Epi[INVESTIGATOR_429348] a cohort of 25 PWH  on ART, found that 32% of T cell epi[INVESTIGATOR_429349]  (50). On average, participants ’s T cells  targeted 3 
epi[INVESTIGATOR_429350] (0-6) , suggesting th at therapeutic vaccination of HIVconsvX will 
successfully increase circulating HIV -specific T cell responses  (50).  Importantly,  T cell escape 
in regions corresponding to HIVconsvX was 2.5-fold lower than escape outside of the immunogen (15.3% vs 43.5%) ( 50).   
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 23 of 143 
 
 These data are consistent with observations to date in the ongoing Phase I M&M Study 
examining the safety and immunogenicity of  M3 and M4 vaccines given alone or in combination 
in PWH  on ART (NCT 03844386) . The M&M study closed to enrolment in December 2021 and 
blinded safety data are summarized  in Section  [IP_ADDRESS]. T cell responses to HIVconsvX, mosaic-[ADDRESS_543416] been measured in 16 participants  to date. Blinded results 
consistent increase in T cell breadth to peptides spanning eithe r the Mosaic -1 or Mosaic-1 
immunogens following vaccination.  In 12 of 16 participants , T cell magnitude also increased  ≥ 
2-fold following vaccination when compared to baseline (average of pre -vaccination visits)  
(Figur e 2).  
Figure 1 Overview of HIVconsvX Vaccine Immunogens  
 
(A) The HIVconsvX immunogens are comprised of six (1 -6) conserved regions of HIV. (B) The vaccine design is 
bivalent, consisting of Mosaic -1 (872aa) and Mosaic -2 (872aa) immunogens that together increase the vaccine 
match to all the circulating HIV strains  globally. (C) The regions in each Mosaic were re- ordered to generate four 
immunogens that were inserted into vaccines, C1, C62 , M3 and M4. The goal of the re -ordering is to minimize 
exposure of participants to non -natural junctions between HIV regions. t=  tPA-leader sequence in C1, M3  and M4, 
Pk= a C -terminal mAb tag, which facilitates protein detection in C62, black arrow= inversion of sections 1 -103 aa 
and 104- 231 aa of region 1(p24 Gag) in HIVconsv62 
  
PolSix highly functionally conserved regions of the HIV -1 proteome
Computed bi -valent mosaic
Mosaic 1
Mosaic 2Mosaic 2
Reshuffled regions for synthetic immunogen genesGag
1
 3 2 6 4 5
1
 3 2 6 4 5
1 2 3 5 6 ttHIVconsv1 1 2 6
 t 4
 5 3
tHIVconsv3
tHIVconsv4
HIVconsv621 3 4 5 6
1 2 3 4 5 6
3 4 5 6
t
t
1 2 3 5 6
1 2 t Pk 4
2
1 1 2 PkC1
C62M3
M4
6 5 4 390.4% 
sequence
identityA.
B.
C.
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 24 of 143 
 
 Figure 2 Immunogenicity Data  from the M&M Study  
 
  
 
 
PWH on ART received a single vaccination of M3, M4, M3+M4,  or placebo in a 7:7:7:2 distribution. (A) T cell 
responses to the HIV immunogens, Mosaic -1 (M3) and Mosaic- 2 (M4) and to Env, Nef and Acc (Rev, Vif, Vpr, 
Vpu,  Tat) proteins  not found in the vaccine immunogen in one participant. (B) T cell responses to peptides spanning 
Mosaic- 1 (M3) or Mosaic -2 (M4) were measured pre- and post - the vaccination visit.  Analysis of unblinded datas  
suggests that vaccina tion increased in T cell breadth to vaccine immun ogens (C) Twelve  of 16 participants  show a 
≥[ADDRESS_543417] -vaccination.
  
[IP_ADDRESS]  Individual Immunogens  
tHIVconsv1 was inserted into ChAdOx1 to generate the C1  vaccine. The tHIVconsv1 
immunogen uses M osaic -1 and the regions are ordered as 1-2-3-4-5-6. tHIVconsv1 does not 
harbor a Pk tag described in (Table 3 ). tHIVconsv3 contains a human tissue plasminogen 
activator leader  sequence (tPA-LS) described in Section  [IP_ADDRESS].  
tHIVconsv3 was inserted into MVA to generate the M3 vaccine. The tHIVconsv3 immunogen 
was generated using Mosaic- 1 sequences. tHIVconsv3  differs from tHIVconsv1 only in the 
order of its 6 conserved regions which are 3-6-2-5-1-4 ( Table 3 ). tHIVconsv3 does not harbor a 
Pk tag described in Section   [IP_ADDRESS]. tHIVconsv3 contains a tPA- LS described i n Section  [IP_ADDRESS].  
HIVconsv62 was inserted into ChAdOx1 to generate the C62  vaccine.  The HIVconsv62 
immunogen uses Mosaic-2 and the regions are ordered as 6-5-4-3-2-1/1. I t uses the same amino 
acids and is immunologically equivalent to a previous design HIVconsv6, but uses different 
codons and has a rearranged region 1 (p24 Gag) ( Table 3 ). Also, region 1 (p24, 231 amino acids) 
has been inverted, with sub-region 104-231 now followed by [CONTACT_429413] 1-103. The inverted region 1 is identified as 1/1. These changes increased the stability of the immunogen during virus propagation ( ChAdOx1.HIVconsv62 IB).
 HIVconsv62 harbors a Pk tag but does not contain a 
tPA-LS. 
The tHIVconsv4 immunogen was generated using Mosaic -2 sequences. The amino acid 
sequence of tHIVconsv4  differs from HIVconsv62 only in the order of its 6 conserved regions 
which are 4 -1-5-2-6-3 ( Table 3 ). Region 1 in tHIVconsv4 is not inverted (see Figure 1 ). 

16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 25 of 143 
 
 tHIVconsv4 does not harbor a Pk tag described in  Section  [IP_ADDRESS]. tHIVconsv4 contains a 
tPA-LS desc ribed  in Section  [IP_ADDRESS] . 
Table 3 Characteristics of individual HIVconsvX immunogens  
Immunogen  Vaccine Parent Mosaic 
(M) Region Order Pk Tag1 tPA-leader 
sequence1 
tHIVconsv1  C1 M-1 1-2-3-4-5-6 - + 
tHIVconsv3  M3 M-1 3-6-2-5-1-4 - + 
HIVconsv62  C62 M-2 6-5-4-3-2- 1/1 + - 
tHIVconsv4  M4 M-2 4-1-5-2-6-3 - + 
1 +, in vaccine construct; -, not in vaccine construct  
HIVconsv62 differs from the other 3 immunogens in that it is flanked by a C- terminal 
monoclonal antibody epi[INVESTIGATOR_429351] ( IPNPLLGLD)  derived from the P and V proteins of the 
paramyxovirus of simian virus 5 (SV5) family ( 56). The Pk tag was included to facilitate 
detection of the full-size HIVconsv62 protein expression from the vaccine dur ing manufacture 
and vaccine quality control.  
HIV-MVA and HIV -DNA vaccines harboring the Pk tag were safely administered to 492 HIV-
negative adults, 97 HIV-negative 20- week -old infants and 30 HIV-positive adults ( 42, 57-59). In 
these studies, no SAEs related to vaccine products were observed in any study participants. 
[IP_ADDRESS]  tPA-LS 
C62 differs  from the other 3 immunogens  in that it does not contain a human tPA -LS; the ‘t’ in 
the tHIVconsvX nomenclature ( Figure 1 ). The tPA -LS was included in the first three 
immunogens because it had been shown to increase in vitro  expression of the vaccine 
immunogen ( 60). The presumption was that increased expression of the immunogen would 
enhance the immune response following vaccination. However, subsequent work found that the 
tPA-LS only enhances T cell induction for recombinant DNA vaccines ( 54, 60), not viral-
vectored vaccines (54), and therefore is not included in the generation of C62. 
Note , the prior eight Phase1/2a clinical studies using vector derived from simian adenovirus 
serotype 63 (ChAdV63) and MVA vectors e xpressing first -generation conserved HIV 
immunogens did not include tPA- LS (reviewed in (61). These studies were conducted in HIV 
seropositive and seronegative participants in Europe and Africa ( 62-65) . In these clinical trials, 
ChAd V63/MVA vaccination induced consistent and strong T-cell responses in people, including 
in PWH on ART (61, 63-70). Murine studies also demonstrated that the inclusion of tPA- LS in 
viral vectors did not lessen immunogenicity in mouse models ( 54). 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543418] regimens describe sequential vaccination with two different recombinant vaccine 
vectors expressing a common immunogen, an approach which focuses the immune response on 
the common immunogen ( 71). Prime -boost heterologous regimens have consistently induced 
higher frequencies of T cells against the immunogen than homologous vaccine boosting. This is likely because homologous vaccination induces anti- vector immunity, limiting the 
immunogenicity of the boosting vaccination. One of the most promising prime boost combinations is a recombinant adenovirus vector (rAdV) prime followed by [CONTACT_429402]. These regimens have demonstrated immunogenicity that h as translated across mice, non -human 
primates and humans. Both clinical and animal data clearly show that rAd V/MVA prime -boost is 
more immunogenic than either vaccine alone (64). One limitation with adenoviral vectored 
vaccination is high, pre -existing immunity for some serotypes. Approximately 40% of the US 
population are seropositive for the HAdV-5 serotype, and seropositivity is substantially higher in sub-Saharan Africa (72). In response, two approaches have been taken. The first approach 
involves the development of human adenoviral vectors (HAdVs) which are genetically distinct from HAdV -[ADDRESS_543419] which the prevalence of pre- existing immunity is considerably lower. 
The second approach employed herein, uses recombinant sim ian adenoviruses (SAdV) against 
which pre-existing human adenovirus immunity has no impact. Animal testing and subsequent clinical studies demonstrate that SAdV vectors are almost, if not equally, immunogenic as 
HAdVs  (73). 
2.2.5  Simian adenovirus viral vectors  
Chimpadenoviruses (Ch AdV) were developed as vaccine vectors following concerns that 
pre-existing immunity to HAdv  serotypes could limit future widespread use of these vaccine 
vectors. Ch AdV and HAdV are not phylogenetically distinguishable and fall into the same eight 
adenovirus groups. ChAdOx1 is replication- deficient in vaccinated animals or humans due to 
deletion of the essential E1 gene region . ChAdOx1  can only propagate in cells complementing 
the E1 functions that are used for manufacture ( ChAdOx1.HIVconsv62 IB Section 2.1). 
ChAdOx1 is closely related to ChAd63 which has been extensively tested as a vaccine vector including as a HIV vaccine in PWH  (74).  
Like all adenoviruses, ChAdVs possess a stable genome such that inserts of foreign genes are not deleted. ChAdVs  and the transgene information remains extra -chromosomal, thus avoiding any 
potential for insertional mutagenesis.  
[IP_ADDRESS]  Generation of C1 and C62 vector s 
Full details of the generation of the C1  and C62  vaccine vectors are provided in 
ChAdOx 1.tHIVconsv1 IB
, and ChAdOx1.HIVconsv62 IB .  
Description of ChAdOx1. tHIVcons 1 (C1) ChAdOx1.tHIVconsv1 vaccine consists of the 
replication -deficient simian adenovirus vector ChAdOx1, which carries a transgene coding for 
the leader sequence of tPA -LS fused to a chimeric protein assembled from 6 conserved regions 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543420] no 
biological or enzymatic activities and are delivered solely for the purpose of inducing T- cell 
responses.  
Description of ChAdOx1.HIVcons v62 (C62 ): ChAdOx1.HIVconsv62 vaccine consists of the 
replication -deficient simian adenovirus vector ChAdOx1, which carries a transgene coding for a 
chimeric protein assembled from [ADDRESS_543421] no biological or enzymatic activities and are delivered solely for the purpose of inducing T- cell responses.  
[IP_ADDRESS]  Clinical Experience with ChAdV -Vectored Vaccines  
Sixteen  clinical trials testing nine different ChAdOx1 vaccines have been or are in clinical 
testing (n > 22,000 participants) ( ChAdOx1.HIVconsv62 IB S ection 6, (75)). This includes 
peer-reviewed  data from 12,[ADDRESS_543422] dose ChAdOx1 nCoV-19 vaccine  in the COV001 and COV002  clinical trial in 
the [LOCATION_008] ( [LOCATION_006]) (EudraCT 2020-001228-32), the COV003  trial conducted  in Brazil 
(ISRCTN89951424), and the COV005 trial conducted in South Africa reported in ( 75). Across 
the four clinical trials with 12,021 participants receiving ChAdOx1 nCoV-19 were included in 
safety analyses. Across this group, there were 79 SAEs (0.7%) (Table S6, supplement, ( 75), <1% 
occurrence of anaphylactic reactions. Only two events were considered possibly related to vaccination with ChAdOx1 nCoV-19, including a case of transverse myelitis reported [ADDRESS_543423] demyelination. A potentially vaccine- related SAE related to fever to 40°C was reported [ADDRESS_543424]-vaccination in 
a participant in South Africa who recovered rapi[INVESTIGATOR_429352]; this participant remains blinded and received a second dose of allocated vaccine wi thout a similar reaction. There were two additional cases of transverse myelitis 
originally reported as potentially related but later determined unlikely to be related to vaccination by [CONTACT_429414]. There was one non- COVID-[ADDRESS_543425] one  IM dose of 5×1010 virus particles (vp); the same dose 
and route of vaccination proposed for this CM Study ( Section  1.1). Data are summarized in 
Table 4  (76). In these studies, solicited AEs have mostly been mild or mode rate with unsolicited 
AEs mostly classed as mild/Grade 1 . 
As noted above, ChAdOx1 is highly related to the ChAd63 (=ChAdV63) vector which has also undergone extensive clinical testing . Participants (n= 1,367) received recombinant ChAd63 
vaccines given IM at  a dose of 5x10
[ADDRESS_543426] combination with MVA-
vectored vaccines. Vaccination has been safe and well tolerated with no SAEs reported 
(ChAdOx.tHIVconsv1 IB S ection 6.5, ChAdOx1.HIVconsv62 IB Section 6).  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543427] majority of humans. Based on this information the Sponsor does not consider toxicology 
testing of C1 or C62 will generate novel safety or reactogenicity to furt her inform this proposed 
vaccination regimen.  
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 29 of 143 
 
 Table 4 Summary of Safety Data for Recombinant ChAdOx1 Studies at 5 x 1010 
Virus Particles  
Country  Trial  Vaccine  Age n Summary of Results  
[LOCATION_006]1 FLU004  ChAdOx1 NP+M1  18-[ADDRESS_543428] vaccinees in the 7 days 
following vaccination. AEs we re mostly mild 
and all were self -limiting.  No SAEs  were 
reported .  
[LOCATION_006]1 CHIK001  ChAdOx1C hik 18-50 9 The majority of local and systemic solicited 
AEs were  mild or moderate in nature. No SAEs 
were reported. All solicited local and systemic 
AEs resolved within 1 -6 days.  
[LOCATION_006]1 MERS001  ChAdOx1 MERS  18-50 9 AEs probably associated with vaccination were 
all experienced by [CONTACT_429415] 7 days 
following vacc ination. Local and systemic AEs 
were mostly moderate and all were self-limiting. Unsolicited AEs in the 28 days 
following vaccination considered related to ChAdOx1 MERS were predominantly mild and 
resolved. No SAEs  were re ported . 
[LOCATION_006]1 COV001  ChAdOx1 nC oV-19 18-55 543 AEs probably associated with vaccination were 
experienced by [CONTACT_429416] 7 days following vaccination and were mostly mild and all self -limiting. Prophylactic 
paracetamol decreased AEs. Unsolicited AEs in 
the 28 days following vaccination considered related to ChAdOx 1 nC oV-19 were 
predominantly mild /moderate and resolved. No 
SAEs  related to ChAdOx1 nCoV-19 were 
recorded.  
10 participants received a second ChAdOx1  
nCoV-19 booster. AEs related to vaccination 
were in the 7 days following booster vaccination and were mostly mild and all self -
limiting.  No SAEs  related to ChAdOx1nC oV-
19 recorded . 
[LOCATION_006]2, 3 COV00 2 ChAdOx1 nC oV-19 
(2·2 × 10¹⁰ vp followed by 3·5– 6·5 
× 10¹⁰ vp  
or MenACWY)  18-55 
56-69 
≥70 50 
30 
46 No severe local symptoms were reported. No 
SAEs related to ChAdOx1nC oV-19 recorded.     
[LOCATION_006]2, 3 COV00 2 ChAdOx1 nC oV-19 
(2 doses of  3·5–6·5 
× 10¹⁰ vp  or 
MenACWY)  18-55 
56-69 
≥70 49 
30 
49 No severe local symptoms were reported. No 
SAEs related to ChAdOx1 nCoV-19 recorded.  
   Total  821  
1 Source:  ChAdOx.tHIVconsv1 IB S ection 6 and ChAdOx1.HIVconsv62 IB Section 6,  
2 Source: Voysey et al Lancet 2021 (75), Ramasamy et al Lancet 2021 (76) 
[ADDRESS_543429] emergency use authorization clinical data relating to ChAdOx1 nCoV -19 are detailed in  Table 5. 
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 30 of 143 
 
 [IP_ADDRESS]  COVID -19 Adenovirus Vectors  
The COVID -19 pandemic resulted in emergency use authorization from the FDA for several 
COVID -19 vaccines, including the Janssen/J&J Ad26COVS1 vaccine as  a single  dose 
recombinant HAd26 vector ( 77). Other adenovirus- vectored COVID -19 vaccines are authorized 
for use in other countries, including AZD1222- ChAd Ox1 nCoV-19 ( 75) and the Russian Gam 
COVID -Vacc, a heterologous HAd26-HAd5 prime-boost ( 78). Overall, there is increased 
likelihood that some potential study participants may have received an adenovirus -based vaccine.  
Pre-existing humoral immunity has been shown to interfere with vaccine-induced immunity, 
inclu ding the induction of T cell immunity to autologous adenoviruses. The best example 
includes Ad5 which is a group C virus. Pre-existing Ad5- specific NAb titers impaired the [COMPANY_006] 
Ad5 vector expressing HIV immunogens ( 72, 79, 80). Similarly, autologous antibodies to rhesus 
adenoviruses were shown to interfere with T cell immunity in mice models (81). By [CONTACT_22242], 
studies in humans, animal models and in vitro cell models, have shown that pre- existing Ab titers 
to adenoviruses from phylogenetically different groups do not impair induction of immunity to 
adenovirus vaccination ( 82). For example, high Ad5 antibody titers did not impair T cell 
responses following vaccination of macaques with Ad26 (group D)-RhAd prime-boost regimens in NHP (81). Lastly, sera from ChAd63 (Group E) vaccinated individuals did not neutralize 
ChAdOx1 (Group E) infection ( 74); though no data are available regarding impact on immune 
responses. Pre-existing Ad26 and Ad35 (Group B) antibodies did not impact the induction of vaccine -specific immune responses following Ad26-Ad35 heterologous vaccination in he althy 
adults in the US, East and South Africa ( 83). Altogether, these studies suggest that adenoviral 
vaccination with phylogenetically different groups will not impede the induction of T cell responses to C1  and or C62 vaccines.  
More data are needed on interactions between adenoviruses within the same phylogenetic group. As such, prior vaccination with Group E vaccine vectors, including  the COVID -[ADDRESS_543430], prior vaccination with the 
Janssen Ad26COVS1  COVID -19 vaccine (and Gam COVID -Vacc) will not be exclusionary. 
Conversely, C62 and, or C1C62 vaccination could impede subsequent vaccination with AZD1222.  
[IP_ADDRESS]  Post- authorization experience with Adenovirus Vectored COVID -[ADDRESS_543431]-authorization experience identified new possible AEs. Given 
these AEs are reported  voluntarily, it is not possible to estimate frequency or as yet establish a 
causal relationship following vaccine exposure. These AEs are listed in the AZD122 and Ad26COVS1 packet inserts as either very rare frequency (< 1in 10,000) ( Table 5 , 
ChAdOx.tHIVconsv1 IB Section 6.2, ChAdOx.HIVconsv62 IB Section 6.2) . Post-authorization 
clinical reporting is addressed  in the Risk/Benefit Assessment  in Section 2.3. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 31 of 143 
 
 Blood and lymphatic system disorders : Review of clinical data in the [ADDRESS_543432] AZ1222 vaccination in the [LOCATION_006] and European Union ( EU) AZ1222 programs (>49 
million Europeans, 09 April 2021) identified  rare cases of unusual thromboses associated with 
thrombocytopenia in people without previous history of prothrombotic medical conditions  (84, 
85), https://www.ema.europa.eu/en/news/astrazeneca-covid-19- vaccine -review -very- rare-cases -
unusual-blood- clots -continues, ChAdOx.tHIVconsv1 IB Section 7.2, ChAdOx.HIVconsv62 IB 
Section 7.2, Table 5 ). Specifically thromboses with thrombocytopenia occurring in the first 3.5 
weeks of vaccination, median of < [ADDRESS_543433]- vaccination (84, 85 ). Thromboses with 
thrombocytopenia were also reported in a smaller number of individuals vaccinated with the 
Janssen Ad26COVS1 COVID -[ADDRESS_543434] platelet factor 4 suggesting immune -related events, independent of heparin-
therapy (84-86). At present, no specific risk factors, such as age, gender or a previous medical 
history of clotting disorders have been identified for these very rare events. A summary of findings reported to the European Medicines Agency ( EMA ) are reported  in Table 5 .  
Immune system disorders
: Events of anaphylaxis following AZ1222 vaccination have been 
reported  (https://www.ema.europa.eu/en/documents/prac- recommendation/prac-
recommendations- signals -adopted-8-11- march -2021- prac-meeting_en.pdf, Table 5 ).   
Vascular Disorders : Very rare cases of capi[INVESTIGATOR_12737] (CLS) have been reported in the 
first days after vaccination with AZD1222 and the Janssen Ad26COVS1 vaccine. A history of CLS was apparent in some of the cases. Fatal outcome has been reported. CLS is a rare disorder 
characterized by [CONTACT_347639][INVESTIGATOR_429353], hypotension, hemoconcentration, and hypoalbuminem ia (ChAdOx.tHIVconsv1 IB Section 7.2, 
ChAdOx.HIVconsv62 IB Section 7.2, Table 5 ). 
Nervous System Disorders : Very rare events of neuroinflammatory disorders have been reported 
following vaccination with AZ1222/Vaxzevria. A causal relationship has not been established (ChAdOx.tHIVconsv1 IB Section 7.1, ChAdOx.HIVconsv62 IB Section 7.1, Table 5 ).  
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 32 of 143 
 
 Table 5  Adverse reactions reported following vaccination with AZD1222 COVID -19 
Vaccine1 
 Very 
Common  
≥1 per 10  Common  
≥1 per 100 to <1 
per 10  Uncommon  
≥1 per 1,000 to 
<1 per 100  Rare  
≥1 per 
10,000 
to <1 
per 
1000  Very Rare  
< 1 per 10,000  Not Known 
(cannot be 
estimated 
from post -
authorization 
data)  
Blood and 
lymphatic 
system 
disorders   thrombocytopenia  lymphadenopathy   Thrombosis in 
combination with throm bocytopenia
2  
Metabolic and 
Nutrition 
system 
disorders    Decreased 
appetite     
Nervous system 
disorders  Headache   Dizziness, 
somnolence    Guill ian-
Barré 
syndrome  
Vascular 
system 
disorders      Thrombosis in 
combination with 
throm bocytopenia2 Capi[INVESTIGATOR_429354], 
diarrhea      
Skin and 
subcutaneous 
tissue disorders    Hyperhidrosis, 
pruritus, rash     
Musculoskeletal 
and connective 
tissue disorders  Myalgia 
arthralgia       
Immune System 
Disorders       Allergic 
reactions 
including 
anaphylaxis  
General 
disorders and administration site conditions  Fatigue, 
malaise, feverishness, chills, injections site tenderness, 
pain, 
warmth, pruritus, 
bruising  Fever 3, injection 
site erythema, injection site swelling,  Injection site 
hematoma     
1Source: Product Information Vaxzevria, COVID -19 Vaccine ANNEX 1 , https://www.ema.europa.eu/ 
https://www.ema.europa.eu/en/documents/product -information/vaxzevria -previously- covid -19-vaccine -astrazeneca -
epar-product -information_en.pdf, Table 1 and EMA EPI[INVESTIGATOR_429355].[ZIP_CODE]  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543435] -
marketing. These included venous thrombosis such as cerebral venous sinus thrombosis (CVST), splanchnic vein 
thrombosis, as well as arterial thrombosis . 
3 Measured fever > 38°C   
[IP_ADDRESS]  Pre-Clinical Experie nce with ChAdV -Vectored Vaccines  
Eight ChAdOx1- vectored vaccines have been examined in seven Good Laboratory Practice 
(GLP ) toxicology studies in BALB/c mice conducted at ENVIGO (formerly Huntingdon Life 
Science) ( ChAdOx.tHIVconsv1 IB  5.3 and ChAdOx1.HIVconsv62 IB  5.3)   
As an overview, adult mice (male and female)  typi[INVESTIGATOR_429356]1 vaccine 14 days apart with up to a 14-day observation window. Across toxicology 
studies, IM doses calculated to be >500-fold the proposed clinical dose of ChAdOx1 (5×1010 vp) 
were tested. All of these studies uniformly concluded IM delivery of the ChAdOx1- vectored 
vaccines was  well tolerated and was  not associated with any adverse effects. Non -adverse effects 
observed were attrib utable to inflammatory and immune responses at the IM injection site and 
induction of immune responses  often reflected as changes in the spleen, drainage and/or 
increased cellularity in lymph nodes, and slight increases in white blood cell count and/or protein concentrations. Of note, one GLP toxicity study ( Study TX05CW ) described in 
ChAdOx1.HIVconsv62 IB S ection 5 .3.2, tested ChAdOx1.HTI and another experimental  
rChAdOx1 vaccine with very similar HIV transgene called HTI (87). For the purposes of 
toxicity, the HIV -1-derived vaccine inserts (=immunogens=transgene products) of HI Vconsv, 
tHIVconsv1, tHIVconsv3, tHIVconsv4, HIVconsv62 and HTI employed by [CONTACT_429417]. They  are assembled from small regions of HIV -[ADDRESS_543436] no known biological or 
enzymatic activity , and are joined into a chimeric protein of 872 amino acids for the sole purpose 
of inducing CD4
+ and CD8+ T-cell responses.  
In two of the seven GLP toxicology studies described, ChAdOx1 vaccinations were boosted with MVA vaccines. Both of these studies tested two IM doses with one study testing a third IV dose of either ChAdOx1 and/or MVA. In both combination studies, >500- fold the proposed clinical 
dose of ChAdOx1 were tested. Study GG05TY used a combination regimen similar to the proposed C62 -M4 and C1C62- M3M4  regimens. Similar to the toxicity studies testing ChAdOx1 
alone, both studies with ChAdOx1 plus MVA booster concluded that ChAdOx1 and MVA were well tolerated and not associated with any adverse effects. Non -adverse effects included local 
inflammatory responses at the IM injection site and induction of immune responses. 
 
2.2.6  MVA Vaccine Vectors  
MVA is a vaccinia virus strain which was attenuated by [CONTACT_429418] (CEF). It has lost 15% of the parental genome, including cytokine and chemokine receptor genes (88). It replicates well in CEFs and baby [CONTACT_429419] (89). The replication defect occurs at a late 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543437] mammalian cells. The DNA sequence of the entire M VA genome 
has been determined (90). 
[IP_ADDRESS]  Generation of M3 and M4 vectors 
Full details of the generation of the M3  and M4  vaccine vectors are provided in IND [ZIP_CODE], 
Investigator Brochures . 
MVA.tHIVconsv3 (M3) : The M3 vaccine is a second-generation HIV- 1 conserved -region 
multi-component vaccine employing tHIVconsv3 immunogens comprised of Mosaic-1 regions. 
MVA.tHIVconsv3 is a recombinant, non-replicating MVA expressing six conserved sub-protein regions (regions 1- 6) of HIV -1 as one chimeric protein designated tHIVconsv3 (
Table 2 ). 
MVA.tHIVcons4 (M4) : The M4 vaccine is a second -generation HIV- 1 conserved -region multi-
component immunization regimen employing tHIVconsv4 immunogens comprised of Mosaic-2 regions. MVA.tHIVconsv4 is a recombinant, non- replicating MVA expressing six c onserved 
sub-protein regions (regions 1- 6) of HIV -1 as one chimeric protein designated tHIVconsv4 
(
Table 2 ).  
[IP_ADDRESS]  Clinical Experience with MVA -Vectored Vaccines  including M3 and M4 
Vaccines  
Despi[INVESTIGATOR_429357], MVA has been shown to induce strong cellular immune responses. MVA was adm inistered to more than 120,[ADDRESS_543438] (UOXF) and other laboratories resulting in considerable cumulative safety data on recombinant MVAs over the last four decades (42, 58, 88, 91-117 ) 
(See IND [ZIP_CODE], 
Investigator Brochures ). 
Over [ADDRESS_543439] TB, MVA85A, was safely injected into 2,400 participants  including adults, 
adolescents, children and 1500 infants. See Table 6 . 
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 35 of 143 
 
 Table 6 Safety Data for selected Recombinant MVA Studies expressing HIV 
immunogens, given IM  at 1-2 x 108 vpu  
Site Trial  Vaccine Age n Summary of Results  
Spain  BCN01ROMI  
[STUDY_ID_REMOVED]  MVA.HIVconsv  
(2 doses)  18-
65yr 15 No SAE relative to vaccination.  
Grade 4 SAE: CPK elevation ; total of 10 Grade 3 
AEs: local pain at injection site, headache, fever 
myalgia, anorexia, abdominal pain  
Spain  BCN01  
[STUDY_ID_REMOVED]  MVA.HIVconsv  18-
65yr 24 No SAE relative to vaccination.  
4 Grade 3 SAE: pain at site of injection, 3x intense tiredness myalgia  
US GV-TH-01 
[STUDY_ID_REMOVED]  MVA62B  
(2 doses)  18-
50yr 9 No SAE relative to vaccination.  
No SAE reported  
Spain  RisVac 03  
[STUDY_ID_REMOVED]  MVAHIV-B 
(3 doses)  18-
65yr 14 No SAE relative to vaccination.  
4 Grade 3  AEs: hypergl ycemia, pneumonia, 
influenza, renal colic  
Twenty -two participants have been randomized to receive M3, M4, M3M4  or placebo given IM 
into the arm in a 7:7:7:3 ratio at final dose of 2×108 pfu in the M&M Study ( [STUDY_ID_REMOVED]; IND 
[ZIP_CODE]) conducted at the University of North C arolina at Chapel Hill (UNC) . Safety data for [ADDRESS_543440] literature summarizing MVA 
clinical safety profiles, data to dat e indicate vaccination with M3 and M4, given alone or in 
combination, is safe and well tolerated  with vaccine-related AEs resolving within 48 hours. 
Table 7 Summary of M&M Trial Safety data  
Site Trial  Vaccine Age n Summary of Results  
UNC - 
Chapel 
Hill M&M  M3, M4, M3M4, placebo  21-60 24
1 • [ADDRESS_543441] probably 
associated with vaccination were experienced by 23 participants  in the 28 days following 
vaccination.  
• 91% were Grade 1 -2  and 9% were Grade 
3and all  resolv ed within 48 hours .  
• 4 participants reported 17 Grade 3AEs (Section 2.3.2 ) 
• [ADDRESS_543442]-vaccination.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 36 of 143 
 
 [IP_ADDRESS]  P re-Clinical Experience with MVA -Vectored Vaccines  
Formal GLP -compliant acute toxicity and biodistribution studies of M3  and M4  was not required 
for Phase I testing of M3 and M4  vaccines. Both vaccines demonstrated to be safe, non-toxic and 
immunogenic in over 1,000 mice during routine experimental immuniz ations (representative 
immunogenicity data published in ( 54, 118), MVA.tHIVconsv3 IB Section 2.3, 
MVA.tHIVconsv4 IB Section 2.3).  
Toxicity studies have been performed by [CONTACT_429420], MVA.HIVA 
also generated by [CONTACT_429421] . No significant toxic effects, either local or systemic, were seen in 
SCID mice receiving two doses of MVA.HIVA by [CONTACT_414871] ( ID)route in study MRC/015 
or in BALB/c mice receiving two doses of MVA.HIVA by [CONTACT_429422]/018 ( 119, 120). The toxicity and persistence of MVA.HIVA in macaques infected with 
pathogenic strains of SIV (SIVmac) was evaluated in a GLP safety and biological clearance study. In SIV- infected macaques, no MVA.HIVA DNA was detected in any organ examined 
(testes, epi[INVESTIGATOR_4046], ovary, blood, brain, heart, spleen, kidney, liver, mesenteric lymph node, draining axillary lymph node, skin and muscle at the site of injection) up to 9 weeks after ID immunization. SIV infection did not enhance the risk of target organ toxicity or persistence of MVA.HIVA or transfer of vaccine genomic DNA into germ cells in these animals (120). 
2.2.[ADDRESS_543443] Vaccination  
[IP_ADDRESS]  Clinical Experience with Chimpadenovirus  OX1 AND MVA- Vectored 
Vaccines  
Heterologous vaccination with simian adenovirus- and MVA- vectors has been tested in multiple 
humans studies ( 91, 92, 121-126), including PWH on ART ( 64, 65
). In these tr ials, MVA has 
been mostly delivered as boosting vaccination 2 or 4 weeks after ChAd- vaccination. In all 
studies, combination vaccination was well -tolerated with few SAEs  reported .  Table 8  
summariz es safety data of ChAd0x1/MVA vaccine regimens.  
Table 8 Summary of Safety Data for vaccination with a ChAdOx11 prime 
followed by [CONTACT_429402]2 
Site Trial  Vaccine Age n Summary of Results  
[LOCATION_006] [STUDY_ID_REMOVED]  ChAdO x1 5T4-
MVA- 5T4 ≥18 40 No SAE related to vaccination.  
[LOCATION_006] [STUDY_ID_REMOVED]  ChAdOx1NP+M1 
-MVA NP+M1  18->50 73 No SAE related to vaccination.  
[LOCATION_006] [STUDY_ID_REMOVED]  ChAdOx185A -
MVA85A  18-55 24 No SAE related to vaccination.  
1 ChAdOx1 dose 2.5x1010vp given IM  
2 MVA dose 1.0- 2.0 x108pfu given IM  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 37 of 143 
 
 [IP_ADDRESS]  Clinical Experience with Simian Adenovirus [ADDRESS_543444] received rChAd63/rMVA expressing a range of immunogens, 
including vaccination of 700 infants (5-17 months) ( 66, 92, 103, 124, 126-130) . All clinical 
studies, including those expressing conserved HIV immunogens, have shown that heterologous ChAd V/MVA vaccination is safe and well tolerated.  Heterologous vector delivery with rChAdV 
(ChAdv63) and rMVA vaccines expressing first generation conserved HIV immunogens has been tested in 154 humans, including PWH on ART. Consistent with all other ChAd V/MVA 
studies, vaccination was safe and well -tolerated  (ChAdOx1.HIVconsv62 IB S ection 6.5). 
[IP_ADDRESS]  P re-clinical Experience with Simian Adenovirus  [ADDRESS_543445] generation HIVconsv vaccines 
using boosting regimens of ChAdV63 or MVA. In both studies, there was 14 days between ChAd63 and MVA boosts. The HIVconsv vaccines were well- tolerated and not associated with 
any adverse effects. The only effects of treatm ent seen were those attributable to inflammatory 
and immune responses at the IM injection site, lymph nodes, and the spleen  
(ChAdOx1.HIVconsv62 IB and ChAdOx1.tHIVconsv1 IB). 
2.3 Risk/Benefit Assessment    
2.3.1  Known Potential Risks of C1 and C62 Vaccines  
Previous experience with other simian adenovirus viral vectored vaccines  suggests AEs  provided 
in Table 9  and Table 10  are expected to occur in some participants after vaccination with C1 , 
C62 or C1C62  vaccines.  
Table 9 Common Local Reactions  
Injection site erythema  Injection site pruritus  
Injection site  pain  Injection site swelling  
Injection site  warmth   
Table 10 Common Systemic Reactions  
Arthralgia  Fatigue  
Malaise  Headache 
Nausea  Fever (>37.7°C or 99.9°F)  
Myalgia  Feverishness  
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543446] C1 , C62, or C1C62  will be mild in intensity 
(ChAdOx1.tHIVconsv1 IB and ChAdOx1. HIVconsv 62 IB). 
Transient l ymphopenia has been observed in the recent HIVCORE 0052 trial and previously in 
trials of other ChAdOx1- vectored vaccines . This is asymptomatic and resolves spontaneously 
within a week (ChAdOx1.tHIVconsv1 IB  and ChAdOx1.HIVconsv62 IB ).  Complete blood cell 
counts will be monitored throughout the study . 
Severe allergic reactions including anaphylaxis may occur, as with receipt of any vaccine or 
medication. Participants will be vaccinated in a clinical area equipped to provide immediate 
advanced life support. Rare Side- effects : Some rare side effects have been observed following 
vaccination with AztraZeneca COVID -19 vaccine (AZ D1222)  (Table 5 ) and the Janssen vaccine 
(Ad26COVS1) COVID -19 vaccine with an estimated 1 case per 100,000 – 250,000 vaccine 
recipi[INVESTIGATOR_840] . These side effects are:  
1. A combination of thrombosis and thrombocytopen ia known as Thrombosis with 
Thrombocytopenia Syndrome (TTS), also termed vaccine -induced prothrombotic immune 
thrombocytopenia (VIPIT)  
2. New onset neurological disease (i.e. Guillain -Barre syndrome or GBS ) 
3. Systemic CLS . Cases of TTS have occurred within the first twenty -four days (range 5 -42 
days) following vaccination and occurred mostly in women under 60 years of age ( 84). This 
includes rare severe cases presenting as venous thrombosis, including unusual sites such as 
CVST , splanchnic vein thrombosis, deep vein thrombosis and pulmonary embolism , as well 
as arterial thrombosis, concomitant with thrombocytopenia with some cases resulting in death. Participants to date have mostly harboured antibodies against the Platelet Factor 4 which is released by [CONTACT_156661] (84, 85). 
 
There have been very rare cases of CLS reported in the first days after vaccination. CLS is a rare disorder characterised by [CONTACT_347639][INVESTIGATOR_429353], hypotension, concentrated blood and hypoalbuminemia. Investigation of some these cases indicated a history of CLS. Some cases were fatal.  
Participants in this study will be followed using a combination of phone call s (n= 5) and in-
person visits (n=2) for the development of symptoms associated with the development of new 
onset blood c lots and neurological deficits  
(Appendix 2) for the [ADDRESS_543447]  (Section 8.2.13), 
describing the study vaccine and  the need to consider TTS if clinically warranted.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543448] been reported in individuals who received the 
[COMPANY_008] and the Johnson and Johnson COVID-19 vaccines . In a  few individuals who 
received the [COMPANY_008] COV ID-19 vaccine (ChAdOx1), a variant of GBS  with significant 
facial weakness  has been described . 
 
2.3.2   Known Potential Risks of M3 and M4 vaccines  
The M&M study conducted at UNC is the first human clinical trial using M3 and M4 . To date, 
there have been no SAEs among 23 PWH on ART  who  received  either M3, M4, M3M4  or 
placebo  (Table 7 ). Ninety -one percent of AEs reported as related to the study product were grade 
1 or 2 (solicited) . Four participants reported 17 Grade 3  events (solicited) and included arthralgia 
(1), headache (1), unexplained diaphoresis (1), myalgia (2), chills  (3), fatigue  (3), flu -like 
symptoms (3), malaise (3) felt to be treatment related, which resolved in 24 hours without 
intervention. A ll AEs resolved  within 24 – 48 hours of vaccination.  
The safety profile of M3, M4  or M3M4  in the M&M Study is consistent with safety data from 
other MVA- vectored vaccines , including those given to PWH. Local and systemic reactions are 
summarized in Table 11  and Table 12 respectively  (See IND [ZIP_CODE], Serial 0004).   
Altogether we anticipate AEs to M4 and M3M4  in this study  will be mild in severity involving 
transient Grade 1 and 2 local reactions such as pain o r erythema at the injection site in addition to 
headache, malaise, and fever (See IND  [ZIP_CODE] Serial Number 0004).   
Standard local (Table 11) and systemic reactions (Table 12 ) can occur, with most appearing 
within the first 24 hours and usually subsiding within 48 – 72 hour s. 
Table 11 Local Reactions  to MVA vaccine  
Injection site erythema (redness)  Injection site pruritus (itching)  
Injection site tenderness  Injection site swelling  
Injection site warmth  Skin discoloration  
Injection site pain  Skin damage (vesiculation or ulceration)  
Induration (hardening or formation of a crust or scab)  
 
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 40 of 143 
 
 Table 12 Systemic Reactions to MVA vaccine  
Vomiting  Fatigue (extreme tiredness)  
Malaise  Headache 
Flu like symptoms  Temperature (fever >37.7°C or 99.9°F)  
Sweating  (diaphoresis)  Chills  
Diarrhea Abdominal pain 
Dizziness  Myalgia (muscle pain)  
Anorexia  Nausea  
Arthralgia  Decreased appetit e 
Syncope  Hypertension 
2.3.3   Known Potential Risks Common to Both ChAdOx1 -vectored and 
MVA -vectored Vaccines  
Viral Reversion: A potential concern regarding the safety of live, attenuated viral vaccines is the 
possibility of pathogenesis caused by [CONTACT_356488]. Any potential risk in this respect aris ing from the administration of M3 or M4 is thought to be very small, due to the 
avirulence and restricted replication of the parental virus MVA and the recombinant vaccine viruses M3  and M4 in human cells. 
Pregnancy: Animal reproduction studies have not been performed and human data on use during pregnancy are not available. Therefore, the vaccine should not be administered to pregnant women or women with the intention to become pregnant. 
Allergy: Serious allergic reactions including anaphylaxis may occur  as with any vaccine. The 
incidence of this is unknown but is estimated at one per 10
5 to 106 vaccinations. Participants will 
be vaccinated in a clinical area that has the capacity to administer medications and utilize 
emergency equipment for the managemen t of serious adverse reactions. 
2.3.4   Known Potential Risks of Overdose  
A drug overdose is defined as the accidental or intentional use of a drug or medicine or an administration error in an amount that is higher than is normally used. Given all doses of C1, 
C62, M3 and M4 will be provided and administered by [CONTACT_429423] , overdose is not anticipated . 
Overdose in this study is specifically defined as any dose greater than the intended protocol dose. In the unlikely event of overdose, it is recommended that the participant be monitored for any 
signs or symptoms of adverse reactions or effects and appropr iate symptomatic treatment be 
administered immediately. Note that administration of the “wrong” vaccine is a protocol deviation, but not, in the absence of associated AE, an SAE. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543449] be reported to the protocol team and sponsor within 24 hour s of awareness . 
Only overdoses associated with a clinical SAE needs to be reported as an SAE. The quantity and 
duration of the excess dose should be documented.  
2.3.5   Known Potential Risks of Syncope  
Syncope (fainting) can occur before or following any vaccination as a stress response to the 
needle injection.  
2.3.[ADDRESS_543450] common  risks : 
• Pain or bruising at the site of needle sticks, 
• Phlebitis ,  
• Citrate toxicity (10%),  
• Oral paresthesia,  
• Paresthesia,  
• Stiffness in the arms due to the immobilization during donation, 
• Fatigue,  
• Temporary fluctuations in hea rt rate , and 
• Temporary increases  in blood pressure. 
 Less common:  
• Infiltration the tissue,  
• Muscle aches or cramps,  
• Chills,  
• Fever,  
• Nausea or vomiting, 
• Lightheadedness or headache, and   
• Vasovagal reaction.  
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 42 of 143 
 
 Rare:  
• Seizures or fainting, 
• Transient weight gain, ankle swelling, or increased urination for 24 hours due to fluid 
retention, 
• Infection due to contamination of equipment, 
• Skin rashes, flushing, or other allergic responses, 
• Damage to or loss of red blood cells due to machine malfunction, and  
• Remote possibility of air entering the vein and causing chest pains, shortness of breath or 
shock or death. 
2.3.[ADDRESS_543451] on the 
participant’s health. Upon confirmation of a potential health or reproductive effect, the study team will notify participants impacted by [CONTACT_429424] . 
2.3.9   Known Potential Benefits    
The addition of the C62 and C1 vaccines boosted by M4, or combined M3M4 to a person’s 
ART reg imen and the donation of one’s blood cells to this research study provides no direct 
medical benefits to participants. However, participation contributes to ongoing HIV research, potentially resulting in new treatments for HIV infection.   
2.3.[ADDRESS_543452] substantial benefits for many individuals if achieved. An effective HIV vaccine represents a key strategy for both HIV prevention and cure. 
Participant s will be informed of potential adverse events associated with study products at the 
time of informed consent by a study investigator and will be encouraged to talk with other 
providers and family/significant others as needed prior to signing the informed consent.  
3 OBJECTIVES AND ENDPOINTS  
The objectives and endpoints for the clinical study are provided in Table 13 . 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543453] vaccination or 
placebo  with:  
C62-M4 
C1C 62-M3M4 
in PWH on ART  Occurrence of at least one ≥ Grade 3 AE 
including signs/symptoms, lab toxicities, and/or clinical events, that is possibly or definitely related to study treatment from 
the first day of treatment (D0) through [ADDRESS_543454] vaccination or D 
56. 
NOTE: The occurrence of a Grade [ADDRESS_543455] safety 
grades used in HIV clinical trials. Should these grades be exceeded, it is currently felt that such risks 
would be unacceptable in a research study of this nature.   
Secondary    
Evaluate the safety of 
vaccination through the end of 
study   
 
    
 
     
 Occurrence of any ≥ Grade 1 AE including 
signs/symptoms, lab toxicities, and/or 
clinical events, that is possibly, or definitely 
related to study treatment any time from the first day of treatment ( D0) through D196 
(Week 2 8). 
NOTE: The occurrence of a Grade 3 elevated blood pressure during 
leukapheresis that resolves following 
completion of the procedure will not be included as a secondary safety endpoint.  
Safety data will include local and systemic signs and symptoms, laboratory measures of safety/toxicity, and all adverse and serious 
adverse events. Safety data will be routinely 
collected throughout the study.   The study will use standard safety 
grades used in HIV clinical trials. 
Should these grades be exceeded, it 
is currently felt that such risks would be unacceptable in a research study of this nature.   
Compare the within -
participant relative change in magnitude of HIV -1-specific 
T cell responses following 
vaccination with C62-M4 or 
C1C62 -M3M4 . Relative change in magnitude of T cell 
responses to HIV -1 conserved regions from 
baseline  (before  C62 or C 1C62 
vaccination) to post- boost  vaccination at 
D35 and D42.  Vaccination of PWH on ART with 
MVA vaccines expressing HIV 
immunogens , given alone or as a 
boosting vaccination , induced the 
peak HIV -specific T cell responses 
at day [ADDRESS_543456] -vaccination  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 44 of 143 
 
 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
Comp are the between -arm 
change in breadth of HIV -1-
specific T cell responses 
following vaccination C62-
M4 or C1C62 -M3M4 . 
 Change in breadth of T cell responses 
targeting HIV conserved regions from 
baseline ( before  C62 or C 2C62 
vaccination) to post- boost vaccination 
measured at D56.  
 The mosaic immunogen design is 
predicted to broaden the number reactive HIV epi[INVESTIGATOR_429358] (i.e. 
breadth) detected by [CONTACT_398]8
+ T cells 
in vaccinees. T cell breadth is 
maintained over time, enabling measur ement  at D56  providing 
economical use of participant 
sample s. 
Assess the long -term safety 
and tolerability of study vaccines  Incidence and severity of SAEs, MAAEs, 
and AESIs through EOS.  Multiple post -vaccination 
timepoints needed to evaluate the longer -term safety of the C1 and/or 
C62 vector.  
Tertiary/ Exploratory    
Compare the change in 
function and phenotype of HIV-1- specific T cell 
responses in participants from 
pre- to post -vaccination with 
C62-M4 or C1C62- M3M4 . Change in function of T cell responses 
targeting HIV conserved regions from 
baseline ( before  C62 or C 1C62 
vaccination) to post- boost vaccination at 
D35 or D42. Vaccination is expected to induce 
temporal changes in memory phenotype and breadth of function 
Evaluate t he kinetics of 
immunologic responses in 
participants pre - and post -
vaccination with C62-M4 or 
C1C62 -M3M4 . Relative change in magnitude of T cell 
responses to HIV -1 conserved regions at 
multiple pre - (minimum 2) and post -
vaccination (D35 or D42) timepoints . Multiple pre - and post -vaccination 
timepoints are needed to evaluate 
the stability of any change 
observed . 
Evaluate the kinetics of CD8+ 
T cell mediated HIV inhibition pre- and post -vaccination with 
C62-M4 or C1C62 -M3M4 . Relative change in magnitude of T cell 
responses to HIV -1 conserved regions at 
multiple pre - (minimum 2) and post -
vaccination ( D35 or D42) timepoints . Anticipate greatest change in T cell 
virus inh ibition will occur at peak -
magnitude of T cell response. 
Explore cellular activation 
status of total CD4+ and CD8+ 
T cells pre - and post -
vaccination with C62-M4 or 
C1C62 -M3M4 . Relative change in magnitude of T cell 
responses to HIV -1 conserved regions at 
multiple pre - (minimum 2) and post -
vaccination (include D35, D 42) timepoints . Anticipate greatest change in T cell 
activation status to occur at peak -
magnitude of T cell response.  
Explore the impact of 
vaccination with C62-M4 or 
C1C62 -M3M4 on low -level 
plasma viremia.  Relative change in low -level viremia  at 
multiple pre - (minimum 2) and post -
vaccination (minimum 2) timepoints . Multiple pre - and post -vaccination 
timepoints are needed to evaluate 
the stability of any change 
observed . 
Explore the impact of 
vaccination with C62-M4 or 
C1C62 -M3M4 on cell -
assoc iated HIV RNA in CD4+ 
T cells . Relative change in cell -associated RNA  at 
multiple pre - (minimum 2) and post -
vaccination (minimum 2) timepoints . 
 Multiple pre - and post -vaccination 
timepoints needed to evaluate the stability of any change observed . 
Explore the impact of 
vaccination with C62-M4 or 
C1C62 -M3M4 on total HIV 
DNA in CD4+ T cells . Relative change in cell-associated RNA at 
multiple pre - (minimum 2) and post -
vaccination (minimum 2) timepoints . 
 Multiple pre - and post -vaccination 
timepoints ne eded to evaluate the 
stability of any change observed . 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 45 of 143 
 
 4 STUDY DESIGN  
4.1 O verall  Design  
This is a Phase 1, pi[INVESTIGATOR_48505] a double blind, randomized, placebo- controlled, parallel 
design  to evaluate safety and immunogenicity  of C62 followed by M4  or, C1C62  given in 
combination followed with M3M4  given in combination.   
The participant s will be  PWH  suppressed on ART with plasma HIV-1 RNA <50 copi[INVESTIGATOR_014]/mL. 
We hypothesize that C62 followed by M4  or, C1C62  given in combination followed with 
M3M4  given in combinati on will be safe and increase HIV -1-specific T cell responses targeting 
conserved regions of HIV-1. We also hypothesize that administration of C1C62 -M3M4  will 
result in a greater increase in the breadth of HIV -1-specific T cells targeting conserved regions of 
HIV-1 than C62 -M4 vaccination . 
Vaccine and placebo doses will be administered to all participants as 2 separate IM injection s in 
the deltoid muscle of each  arm. Participants continue baseline ART regimen throughout the 
study.  
Participants will be randomized 8:8:2 to one of three study arms and receive study treatment or 
placebo at D0 and D28 as in Table 14 .  
Table 14 Study R andomization 
Arm  N Day Treatment  Total Dose 
(vp) Route  Day Treatment  Total Dose (pfu)  Route  
1 8 0 C62 5×1010 IM 28 M4 1.8×108 IM 
2 8 0 C1C62  5×1010 IM 28 M3M4 1.9×108  IM 
3 2 0 Placebo 
(saline)  - IM 28 Placebo 
(saline)  - IM 
 
The primary safety outcome is the occurrence of at least one ≥ Grade 3 Adverse Event (AE) 
including signs/symptoms, lab toxicities, and/or clinical events that are possibly, or definitely 
related to study treatment . The period of observation is from the day of ChAdV vaccination at 
D0 through to D56 which is [ADDRESS_543457] study  participant. 
Participants will be followed and monitored  for clinical events that are possibly , or definitely 
related to  study treatment  per the SoA. All participants will be informed about potential 
contraindications and risks associated with the study vaccines .  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 46 of 143 
 
  
Safety will be assessed for the duration of the study. Solicited AEs will be recorded for 28 days 
after each dose of study intervention (through Day 57), and SAEs, MAAEs, and AESIs will be 
recorded through the EOS .  
 Study analysis plans are discussed i n the Statistical Analyses Section 10.7. 
 4.2 Scientific R ationale for S tudy Design  
The scientific rationale  of this study is that vaccination that shifts CD8
+ T cell targeting  (breadth 
and magnitude) away from variable HIV epi[INVESTIGATOR_429359] T cell mediated control of HIV -reactivation.  
Vaccine Vectors : Immunogenicity - We are testing serial vaccination with two live -attenuated 
vaccine modalities ChAdOx1 and MVA expressing complementary immunogens. This heterologous vector approach is often termed, prime-boost vaccination. Vaccination with heterologous viral vectors consistently elicits higher frequencies of immune res ponses against 
the vaccine immunogen than homologous vaccination regimens (
131).  S afety : As detailed 
above, Both ChAdOx1 and MVA vectored vaccines given IM either alone or serially have been safe and well tolerated. Altogether, the immunogenicity and safety profiles of these vaccines support their choice in this study.  
Immunogens
: The HIVconsvX design targets regions of HIV that are both conserved and harbor 
high numbers of T cell epi[INVESTIGATOR_429360]. T- cell epi[INVESTIGATOR_429361] -likely to harbor virus escape variants in either 
vRNA or the latent HIV reservoir. We therefore hypothesize these conserved immunogens will induce consistent and signif icant increases in circulating T  cell-mediated  immunity in 
participants. W e will compare bivalent  mosaic (C1C62 -M3M4 ) and monovalent mosaic (C62-
M4) immunogens. We hypothesize that following vaccination, the bivalent mosaic  immunogens 
will induce a greater breadth of T-cell response than the monovalent immunogen.    
Cohort : Individuals chronically infected prior to ART treatment will be prioritized for 
enrollment.   
We and others have document ed that individuals treated in chronic infection have sustained and 
detectable HIV specific T -cell responses  (132). This compares with ART  initiated  in acute 
infection where treatment may blunt the induction of T cell responses against HIV. Studies in individuals treated in chronic infection will allow us to better address our study hypothesis which focuses on shift ing T cell dominance away from variable epi[INVESTIGATOR_356446], but more 
conserved epi[INVESTIGATOR_429362].  Accordingly , our endpoint assays are designed 
to also examine de novo induction of HIV- specific T cell responses.  
Our exploratory objectives will examine whether vaccination decreases the si ze of the HIV 
reservoir. Therefore, we are targeting chronically HIV -infected participants who harbor a 
detectable, complex and relatively stable reservoir.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 47 of 143 
 
 Durable Suppression : The  inclusion criterion of > [ADDRESS_543458] shown that HIV T cell responses in durably suppressed 
participants are highly stable, providing a reliable baseline to examine changes in T cell frequencies  (
132).  Second, the size of the HIV reservoir stabilizes after 2 years providing a 
stable baseline to examine change in virologic measurements  (65).  
Placebo Controls : Two placebo controls are included in this study. Powering calculations 
described  Section  10.[ADDRESS_543459] been included to ensure 
real-time objectivity in recording study AEs. Placebo -assoc iated safety and immunogenicity data 
in this study will be co mbined with data collected from placebos (n=3) from our current trial 
IGHID [ZIP_CODE] (The M&M Study), giving a final n=5 of placebo controls.  
4.3 Justification for Do se 
The vaccine doses to be used in the clinical study are provided in Table 15 . 
Table 15 Vaccine Doses  
Group  Vaccine Dose  Route  
1 C62 C62 = 5 x 1010 virus particles (vp)   IM 
 M4 M4 = MVA.tHIVconsv4 = 1.8 x 108 plaque -forming units (pfu)  IM 
2 C1C62  C1 = 2.5 x 1010 vp 
C62 = 2.5 x 1010 vp IM 
 M3M4  M4 = MVA.tHIVconsv4 = 0.9 x 108 pfu 
M3 = MVA.tHIVconsv3 = 1 x 108 pfu IM 
3 Placebo  Normal saline injection  IM  
Justification for ChAdOx1 vaccine dose : Fourteen  clinical trials testing [ADDRESS_543460] been or are in clinical testing (n=872 participants) (ChAdOx.tHIVconsv1 IB 
Section 6, ChAdOx1.HIVconsv62 IB S ection 6). Safety and immunogenicity data are available 
for [ADDRESS_543461] udy participants receiving an IM dose of 5×1010 vp; the same 
dose and route of vaccination proposed for this CM Study. The safety profiles of ChAdOx1 vectors have been well tolerated  to date. Solicited AEs have mostly been mild or moderate with 
unsolicited AEs mostly classed as mild/Grade 1  (ChAdOx.tHIVconsv1 IB Section 6, 
ChAdOx1.HIVconsv62 IB Section  6).  
ChAdOx1 is highly related to the ChAd63 vector which has also undergone extens ive clinical 
testing. Participants ( n=1,367) have received recombinant ChAd63 vaccines given IM at a dose 
of 5×[ADDRESS_543462] combination with MVA- vectored vaccines. Vaccination has 
been safe and well tolerated (ChAdOx.tHIVconsv1 Section 7, ChAdOx1.HIVconsv62 IB Section 
7). This dose has also been consistently immunogenic, either inducing or increasing the 
frequency of circulating T cells against the vaccine immunogen.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 48 of 143 
 
 Justification of the MVA vaccine dose : M4  vaccination will be given at a dose of 1.8×108 pfu 
and M3M4  given at a final dose of 1.9×108 pfu.  W e anticipate dosing to be  immunogenic, well 
tolerated but also provide economical use of M4  Good Manufacturing Practice (GMP)  vaccine.  
In the ongoing UNC Study  [STUDY_ID_REMOVED] ( IND [ZIP_CODE]), M3  and M4 given IM to PLW on ART 
at a final dose of 2×108 pfu has been safe and well tolerated in 21 participants  (Table 7 ). These 
data are consistent with other studies in which recombinant MVA has proven to be safe and 
tolerated when delivered IM at a dose of 2 ×108 pfu (Table 6) ( 92, 97). The AEs reported in prior 
studies were mild (Grade 1) and moderate (Grade 2) local and systemic reactions. Most reactions were reactogenic, involving pain at the injection site (local) and malaise and myalgia (systemic)  
(See IND [ZIP_CODE], Investigator Brochures ).  
Based on data from  all studies, there were very few treatment -related SAEs reported following 
MVA vaccination  (See IND [ZIP_CODE], Investigator Brochures ) (93). In a study of MVA expressing 
influenza antigens delivered as an IM injection (n=8), fe wer local adverse events were observed 
than with intradermal ( ID) injection (n=12) ( 133). Systemic adverse events (AEs) were similar 
for both IM and ID injection.  
Blinded data to date also suggests that both the M3 and M4  vaccines given at similar  doses are 
likely to be immunogenic ( Figure 2 ). These immunogenicity data ([STUDY_ID_REMOVED]; IND [ZIP_CODE]) 
are supported by [CONTACT_429425] 5×10
7 to 2× [ADDRESS_543463] been 
immunogenic, including in PWH  (66, 97, 102, 134 , 135). Across those studies stronger 
immunogenicity has been observed at doses between 1-2× 108 pfu (66, 97, 102).  
4.[ADDRESS_543464] or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and 
confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by [CONTACT_10840]-[ADDRESS_543465] should be confirmed by [CONTACT_429426] E/CIA that is based on a different antigen preparation and/or different test principle  (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load. 
NOTE: The term “licensed” refers to a US FDA -approve
 d kit, which is required for all  IND 
studies. WHO (World Health Organization) and CDC (Centers for Disease Control and 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 49 of 143 
 
 Prevention) guidelines mandate that confirmation of the initial test result must use a test that is 
different from the one used for the initial assessment.  
2. Ages ≥ 18 to ≤ 70 years old  
3. Able and willing to give written informed consent. 
4. Able and willing to provide adequate locator information.  
5. Able and willing to comply with all study  requirements through D1 96/Week [ADDRESS_543466] 3 months prior to screening. 
7. No change in any ART medication in the 30 days prior to screening.  
Permitted ART regimens include:  
a. At least 3 ART agents (not counting ritonavir or cobici stat as one of the agents if 
less than a 200 mg total daily dose). One of the agents must include an integrase inhibitor, NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitors), or a boosted-PI (protease inhibit or).  
OR 
b. Two (2) ART agents in which one of the agents is either a boosted protease inhibitor or an integrase inhibitor. 
NOTE: Other potent fully suppressive antiretroviral combinations will be considered on a case-by-case basis.  
NOTE: Changes in drug formulation or dose are allowed (e g, TDF to TAF, ritonavir to cobicistat or separate ART agent dosing to fixed-dose combination), but none within 30 days prior to screening.  
NOTE: Prior changes in, or elimination of, medications for easier dosing schedule, intolerance, 
toxicity, an improved side effect profile or within a drug class are permitted if an alternative 
suppressive regimen was maintained, but not within 30 days prior to screening. 
8. Ability and willingness of participant to continue ART throughout the study. 
9. Plasma HIV -1 RNA <50 copi[INVESTIGATOR_014]/mL at 2 time points in the 24 months prior to screening 
and never ≥50 copi[INVESTIGATOR_014]/mL on [ADDRESS_543467] 24 months.  
NOTE: Plasma HIV -[ADDRESS_543468] be performed by [CONTACT_429427] y that has a Clinical 
Laboratory Improvement Amendments (CLIA) certification or its equivalent.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 50 of 143 
 
 10. Documented plasma HIV-1 RNA result <50 copi[INVESTIGATOR_014]/mL ≥24 months but ≤ 36 months 
prior to screening. 
11. Plasma HIV -1 RNA level <50 copi[INVESTIGATOR_014]/mL on an FDA-approved HIV RNA assay 
performed at a US CLIA Certified Laboratory (or its equivalent) at screening.  
12. CD4 cell count ≥ 350 cells/mm3 performed at any US laboratory that has a CLIA 
certification or its equivale nt at screening.  
13. Completion  of COVID -[ADDRESS_543469] 14 days prior to enrollment (see 
exclusion criterion regarding COVID-19 vaccination). 
14. Hepatitis C (HCV) antibody negative result at screening or, if the participant is HCV 
antibody positive, a negative HCV RNA at screening.  
15. Hepatitis B surface antigen (HBsAg) negative at screening.  
16. Adequate vascular access for leukapheresis.  
17. Able and willing to receive IM injections in both arms without difficulty.  
18. All women must have a negative serum pregna ncy test with a sensitivity of a least 25 
U/mL at screening regardless of reproductive potential.  
19. All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization, egg donation) while on study.  
NOTE : Women of child-bearing potential is defined as women who have not been post-
menopausal for at least [ADDRESS_543470] not undergone surgical sterilization,  specifically hysterectomy 
and/or bilateral oophorectomy or bilateral salpi[INVESTIGATOR_1656] 
20. All men and women participating in sexual activity that could lead to pregnancy must agree to consistently use at least one of the following forms of birth control for at least 21 days prior to Visit 3 (D0) and for [ADDRESS_543471] vaccination: 
a. Condoms (male or female) with or without a spermicidal agent  
b. Diaphragm or cervical cap with spermicide  
c. Intrauterine device (IUD)  
d. Tubal ligation 
e. Hormone-based contraceptive 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 51 of 143 
 
 NOTE: For female participants receiving ritonavir or cobicistat, estrogen -based contraceptives  
are not reliable and an alternative method should be suggested. 
21. Men and women not of reproductive potential are eligible without requiring the use of 
contraceptives. Acceptable documentation detailing sterilization and menopause are specified below.  
NOTE : Men who have sex with men only will not be required to use contraception.  
NOTE : Women who have sex with women only will not be required to use contraception.  
NOTE: Written/oral documentation communicated by [CONTACT_30223]/ clinician’s staff of one of the 
following: 
a. Physician report/letter  
b. Operative report or other source documentation in the patient record (a laboratory report of azoospermia is required to document successful vasectomy) 
c. Discharge summary  
d. Follicle stimulating hormone -release factor (FSH) measurement elevated into the 
menopausal range as established by [CONTACT_305681] 
22. Agrees not to enroll on another study of an investigational agent during the study period, defined as any unlicensed investigational drug not yet approved for use in humans.  
23. Willingness to defer routine vaccination, including influenza, from 14 days prior to 
enrollment through Day 56  of the study.  
NOTE: Individuals who require vaccination will delay enrollment until [ADDRESS_543472] a hemaglobin A1C <8 within 12 months 
prior to screening. 
26. Adequate organ function as indicated by [CONTACT_429428] 16. 
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 52 of 143 
 
 Table 16 Adequate Organ Function Values for Inclusion 
System  Laboratory Value  
Hematological  
Absolute neutrophil count  ≥ 1,000 /mcL 
Platelets  ≥ 150,000 / mcL  
Hemoglobin ≥ 12 g/dL (male) and ≥ 11.5 g/dL (females)  
Coagulation  
Prothrombin Time or INR  <1.[ADDRESS_543473]  
Chemistry  
Serum potassium levels  WNL  
Serum magnesium levels  >LLN1   
Glucose  Screening serum glucose ≤ Grade 1 (fasting or non -fasting)  
Renal  
Creatinine clearance determined by [CONTACT_941] 2021 
CKD -Epi [INVESTIGATOR_305617]: 
https://www.mdcalc.com/calc/3939/ckd -epi-
equations -glomerular -filtration -rate-gfr eGFR > 60mL/min  
Hepatic  
Serum total bilirubin  Total bilirubin <1. [ADDRESS_543474] be <[ADDRESS_543475]  
If on atazanavir –containing therapy , a direct bilirubin should 
be measured instead and must be ≤1.0mg/dL.  
AST (SGOT) and ALT (SGPT)  <1.[ADDRESS_543476] 
Alkaline Phosphatase  <1.5X ULN 
[ADDRESS_543477] for Mg++ per the clinical laboratory’s normal range used for this study is a grade [ADDRESS_543478] = upper limit of normal  LLN = lower limit of normal  WNL = within normal limits  
5.2 Exclusion Criteria  
1. Women of childbearing age/potential who are breast feeding, pregnant, or planning 
pregnancy from enrollment to [ADDRESS_543479] vaccination. 
2. Untreated syphilis infection defined as a positive rapid plasma reagin (RPR) without clear 
documentation of treatment. 
NOTE: Potential participants  may rescreen with documentation of adequate treatment.  
Participants reporting symptoms consistent with syphilis infection between the screening visit 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 53 of 143 
 
 and the vaccination visit should be assessed to determine the need for repeat testing prior to 
vaccinatio n. 
3. Current treatment for HCV or HCV treatment within 6 months prior to enrollment. 
4. HIV RNA ≥150 copi[INVESTIGATOR_014]/mL in the [ADDRESS_543480] or hematopoetic growth factors within 6 months prior to enrollment. 
NOTE : receipt of COVID convalescent plasma ≥ 90 days prior to enrollment is not exclusionary. 
6. Use of any of the following agents within 90 days prior to enrollment : 
immunomodulatory, cytokine, or growth stimulating factors such as systemic cytotoxic chemotherapy  or immune globulin. 
7. Intent to use immunomodulator y treatment  during the study. 
8. Use of systemic corticosteroids or topi[INVESTIGATOR_305620] a total area exceeding 225 cm
2 
within 30 days prior to enrollment, or anticipated need for periodic use of systemic corticosteroids during the study. 
NOTE: Participants receiving stable physiologic doses of glucocorticoids, defined as the equivalent of prednisone ≤10 mg/day, will not be excluded. P articipants receiving inhaled, 
intranasal, topi[INVESTIGATOR_2855]  (as defined) , intermittent intra -articular corticosteroids, or topi[INVESTIGATOR_429363].  
NOTE:  Concomitant use of oral/systemic  /intra-articular/inhaled/intranasal corticosteroids is 
prohibited for participants receiving ritonavir or cobicistat.  
9. Use of any investigational HIV vaccine or HIV immunotherapy. 
NOTE : Exceptions allowed per PI [INVESTIGATOR_114315]. 
10. Any experimental non -HIV vaccination within the 6 months prior to enrollment.   
NOTE: receipt of FDA or EUA approved or licensed COVID -19 vaccines is not exclusionary if 
≥ 14 days prior to enrollment on a case by [CONTACT_429429] [INVESTIGATOR_1461].  
11. Prior receipt of any adenovirus  Group E- vectored vaccines including those for COVID-
19 (i.e. AZD1222/ [COMPANY_008]).  
NOTE : Prior immunization with smallpox vaccine is not exclusionary.  
NOTE: J anssen Ad26COVS1  COVID -19 vaccine is not exclusionary. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 54 of 143 
 
 12. Prior receipt of a live vaccine within 60 days prior to enrollment (i.e. varicella, measles, 
mumps, rubella (MMR), and yellow fever) .  
NOTE: Individuals who require live vaccination will delay enrollment until 60 days after 
vaccination . 
NOTE: Receipt of Mpox vaccine is not exclusionary as long as the last Mpox vaccination is 
received  at least  60 days prior to enroll ment . 
13. Use of any other investigational treatment within 6 months prior to enrollment, with the 
exception of Phase II or higher studies of antiretroviral agents.  
NOTE: Co -enrollment with other studies under an IND using an FDA approved medication that 
are not otherwise listed as prohibited will be considered on a case- by-case basis.     
14. For any serious illness requiring systemic treatment or hospi[INVESTIGATOR_059], the participant 
must either complete therapy or be clinically stable on therapy, in the opi[INVESTIGATOR_91382], for at least 90 days prior to enrollment.  
15. History of inflammatory diseases involving the peripheral or central nervous system, including but not limited to GBS , myasthenia gravis, optic neuritis, multiple sclerosis, 
transverse myelitis, neuromyelitis optica spectrum disorder (NMOSD) and chronic 
inflammatory demyelinating pol yneuropath y (CIDP) , that in the opi[INVESTIGATOR_60972]. 
16. History of pregnancy, head trauma or major surgery within 90 days prior to enrollment, that in the opi[INVESTIGATOR_61023]. 
NOTE: Minor surgery within [ADDRESS_543481] 3 years.  
NOTE: History of non- melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin 
cancer) is not exclusionary with documentation of resolution per topi[INVESTIGATOR_429364] a dermatologist at least 3 months prior to enroll ment . 
19. Immune deficiency other than that caused by [CONTACT_124794].  
20. Any medical, psychiatric, substance abuse, occupational or other condition that, in the 
judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or assessment of safety.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 55 of 143 
 
 21. Blood pressure consistently > 150 mm Hg systolic and >100 mm Hg diastolic.  
NOTE : Elevated BP during leukapheresis procedures is not exclu sionary. Isolated elevations 
must be noted as acceptable and signed by [CONTACT_115158] [INVESTIGATOR_1461].  
22. History of s eizure(s) within the past 3 years.  
23. History of s plenectomy . 
24. Bleeding disorder including factor deficiency, coagulopathy or platelet disorder that 
requires sp ecial precautions (easy bruising without a formal diagnosis is not 
exclusionary)  or on chronic anticoagulation 
25. Allergy to eggs and/or egg products. 
26. History of anaphylaxis or severe adverse reaction to prior vaccines including symptoms 
such as hives, respi[INVESTIGATOR_60319], angioedema, and/or abdominal pain. 
27. History of hereditary angioedema, acquired angioedema or idiopathic angioedema.  
28. Known allergy/sensitivity or hypersensitivity to components of study vaccines.  
29. Unstable asthma (e.g. sudden acute attacks occurring without an obvious trigger) or 
asthma requiring:  
a. Daily steroid or long- acting beta-agonist prevention 
b. Hospi[INVESTIGATOR_356450]  
30. Active chronic skin problems such as eczema or psoriasis not controlled with topi[INVESTIGATOR_12969] .  
31. Inabilit y to communicate effectively with study personnel. 
5.3 Screening 
Labs and/or procedures completed within the 14 days preceding the screening visit can be used to qualify the participant upon approval of the study PI (or designee). 
Screening evaluations must occur prior to the participant starting any medications, treatments, or 
interventions. Screening visit can occur up to 60 days prior to Enroll ment/Baseline Visit. 
5.3.1  Re-Screening  
Potential participants who are unable to meet protocol- defined eligibility criteria at the Screening 
Visit may be eligible to re -screen again at the investigator’s (or designee’s) discretion. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 56 of 143 
 
 If a screen failure or the failure to enroll or proceed to Day 0 is due to the inability to meet one of 
the laboratory parameters (hematology, chemistry, HIV RNA level, or CD4+ T cell count), a retest of the failed criteria may be performed one time only.  
5.3.2  Screen Failures  
Screen failures are defined as participants who consent to participate in this study  but are not 
subsequently randomly assigned t o the study intervention or entered in the study.  
Demographic, clinical, and laboratory data is collected on persons at screening. The information collected on persons who fail screening and do not enroll will be retained in the screen failure section of the study file.  
5.4 Strategies for Recruitment and Retention  
There are several venues for recruitment available to the study team:  
• In the UNC and Duke ID Clinic s and/or other local HIV clinics, there is a large pool of 
patients with long -term viral suppression on ART interested in participating in research.  
Many have previously participated in clinical research studies. These individuals will be provided with the opportunity to discuss this study with their provider and the study coordinator. 
• Individuals who signed the UNC CFAR database consent, as well as those who signed the consent for the UNC Cure and PHI studies/database, will be identified and approached abo ut the study. Primary care providers or the study coordinator, after 
consultation with their primary care provider, will provide information about the study and participation. 
• Advertisements and flyers in local clinics and with UNC and Duke HIV Community 
Outreach Organizations . 
5.4.1  Co-Enrollment Guidelines  
Co-enrollment on other studies will be addressed on a case- by-case basis with the study team. 
Due the potential interference with monitoring for the effects of this study’s treatments, participants will not b e able to participate on other studies that provide medications, with the 
exception of Phase 2 or greater ARV studies. 
Co-enrollment in the ACTG 5332 REPRIEVE study ([STUDY_ID_REMOVED]0) using FDA approved 
pi[INVESTIGATOR_429365] ≥ 4 
months. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 57 of 143 
 
 Although not a study, some FDA or EUA sanctioned COVID -19 treatments and vaccines are 
permitted  (see eligibility criteria)  but must be addressed on a case- by-case basis with the study 
team.  
6 STUDY INTERVENTION 
6.1 S tudy Intervention(s)  Administration 
6.1.1  Study Intervention Description  
Double blind, randomized, placebo-controlled, parallel design, study in which 18 participants 
with durable viral suppression are randomly assigned to receive vaccination with C62- M4, 
C1C62-M3M4, or placebo.  
Participants will be randomized 8:8:2 to one of three study arms and receive study treatment or 
placebo at D0 and D28. 
[IP_ADDRESS]  M anufacture of C62 AND C1  
The ChAdOx1.tHIVconsv1 (C1) drug substance has a genome size of 32,906 bp and is supplied 
as a slightly opaque frozen liquid, essentially free from visible particulates. The appearance is 
dependent upon the concentration of the virus ( Table 1 ). C1  was manufactured in accordance 
with GMP by [CONTACT_429430] S.r.l., Via Pontina km 30.600, [ZIP_CODE] Pomezia, Rome, 
Italy. The code name [CONTACT_429469]1.tHIVconsv1. There is no 
recommended International Non- proprietary Name (INN).  
The ChAdOx1.HIVconsv62 drug substance has a genome size of 32,846 bp and is supplied as a 
slightly opaque frozen liquid, essentially free from visible particulates. The appearance is 
dependent upon the concentration of the virus ( Table 1 ). C62  was manufactured  accordance with 
GMP  by [CONTACT_429430] S.r.l., Via Pontina km 30.600, [ZIP_CODE] Pomezia, Rome, Italy. 
The code name [CONTACT_429469]1.HIVconsv62. There is no recommended INN.  
[IP_ADDRESS]  Manufacture of M3 + M4  
The drug substance/investigational medicin al product for M3 and M4 was manufactured in 
accordance with GMP  by [CONTACT_429431] (IDT) , Am Pharmapark, [ZIP_CODE], Dessau-
Rosslau, [LOCATION_013].  
6.1.2  Dosing and Administration  
For further information on Dosing and Administration please see Section  4.1. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 58 of 143 
 
 [IP_ADDRESS]  Dosing   
All participants will receive vaccine/placebo administered  on D0 and a booster vaccine/placebo 
administered at D28 . Participants will be randomized to Arms 1, 2 or 3, respectively.   
For the purpose of this study and safety management, a maximum of 2 study participants can be 
vaccinated in one week.  
[IP_ADDRESS]  Study Treatment Administration  
C1, C62 , M3 and M4 vaccines should be thawed to room temperature and administered within 
[ADDRESS_543482] 
handled according to the relevant SOPs. 
Administer all vaccines/placebo doses at D0 and D28. Administer all vaccine/placebo doses as an IM injection in the deltoid muscle ( Table 17 ). 
Table 17  Study Treatment Administration  
STUDY ARM  DAY  Deltoid - 1 Deltoid - 2 
1. C62- M4 0 C62 (2.5 ×1010 vp) C62 (2.5 ×1010vp) 
 28 M4 (0.9 ×108 pfu) M4 (0.9 ×108 pfu) 
2. C1C62- M3M4  0 C62 (2.5 ×1010 vp) C1 (2.5 ×1010 vp) 
 28 M4 (0.9 ×108 pfu) M3 (1.0 ×108 pfu) 
3. PLACEBO  0 Saline  Saline  
 28 Saline  Saline  
The study DOES NOT ALLOW any modifications to any vaccine doses.  
[IP_ADDRESS].1  C1 and C62  
Study Arm 1: Half of the C62  vaccine will be administered into the deltoid muscle of each arm , 
with the  dose prepared  for administration by  [CONTACT_429432] ( IDS). The 
IDS will direct which arm (left or right) each syringe will go into as assigned by [CONTACT_429433]. 
Study Arm 2: C1 will be delivered in the deltoid of one arm and C62 will be delivered to the 
other arm . The dose of both products will be prepared for administration by [CONTACT_429434]. The 
IDS will direct which arm (left or right) each vaccine will go into as defined by [CONTACT_429433].  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 59 of 143 
 
 [IP_ADDRESS].2  M3 and M4  
Study Arm 1:  Half of the M4 vaccine will be adminis tered into the deltoid muscle of each  arm, 
with the dose prepared  for administration by  [CONTACT_429434]. The IDS will direct which arm (left or 
right) each syringe will go into as assigned by [CONTACT_21477]. 
Study Arm 2:  M3 will be delivered in th e deltoid of one arm  and M4  will be delivered to the 
other arm.  The dose of both products will be prepared  for administration by [CONTACT_429435]. The 
IDS will direct which arm (left or right) each syringe will go into as defined by [CONTACT_429433]. 
[IP_ADDRESS].3  Saline Placebo  
Study Arm 3:   Saline  will be administered into the deltoid muscle of each arm , prepared  for by 
[CONTACT_429435]. The IDS will direct which arm (left or right) each syringe will go into as assigned 
by [CONTACT_21477]. 
[IP_ADDRESS].4  Rescheduled Booster Vaccination  
Participants whose D28 vaccination is delayed due to toxicity or other unanticipated event; that 
has been reviewed and approved by [CONTACT_978] (or designee) will have post D28 visits at the timepoints per the original schedule of events. This m eans booster vaccination will remain Visit 
[ADDRESS_543483] prime vaccination (D0). Consequently, Visit 8 will occur 2 days after booster vaccination, Visit 9 - 7 days, Visit 10 – [ADDRESS_543484] per schedule of events based on the date of 
D28. The events will be renamed to match actual day. (i.e. D28 will remain as Visit [ADDRESS_543485] D0).  
New day numbers and timelines will be documented appropriately in study records.  
6.2 Preparation/Handling/ Storage/ Accountability  
6.2.[ADDRESS_543486] maintenance during the 
study, including documentation of the amount of both study treatments ( C1, C62 , M3  and M4) 
received in IDS and the amount administered to each participant.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 60 of 143 
 
 6.2.2  Formulation, Appearance, Packaging, and Labeling  
ChAdOx1.tHIVconsv1 vaccine (C1) was manufactured in formulation buffer at a target 
concentration of >1.1x1011 vp/mL. It is supplied at a concentration of 1.3 x1011 vp/mL. The fill 
volume is 0.65 mL. 
ChAdOx1.HIVconsv62 vaccine (C62)  was manufactured in formulation buffer at a target 
concentration of >1.1x1011 vp/mL. It is supplied at a concentration of 1.6 x1011 vp/mL. The fill 
volume is 0.65 mL. MVA.tHIVconsv3  vaccine (M3)  is a white cloudy solution, formulated in Tris- saline buffer at a 
concentration of 3.4x10
8 pfu/ml . The extractable fill volume is [ADDRESS_543487] is supplied 
in sterile rubber-stopped glass vials.  MVA.tHIVconsv4 vaccine (M4) is a white cloudy solution, formulated in Tris- saline buffer at a 
concentration of 1.8x10
8 pfu/ml . The extractable fill volume is [ADDRESS_543488] accompanying documentation indicating compliance with 
GMP and other regulatory requirements. The minimum information provided by [CONTACT_429436]:  
1. Study product name 
2. Concentration 
3. Manufacturer  
4. Date of manufacture  
5. Lot number 
6. Volume 
6.2.[ADDRESS_543489] Storage and Stability  
The investigational vaccines are shipped from manufacturing site to study site IDS pharmacy 
with temperature monitoring capacity. Once received at the IDS Pharmacy, the study vaccines 
are transferred to temperature-monitored storage.   
Vaccine accountability, storage and shipment will be in accordance with Pharmacy Manual, site 
IDS SOPs  (as applicable)  and DAIDS requirements.   
[IP_ADDRESS]  C1 and C62  
The vaccines are supplied as frozen liquid s in glass vials for IM administration and are stored at -
75°C ± 15°C in a secure freezer . The freezers are temperature monitored and if outside 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 61 of 143 
 
 designated  range appropriate action is taken in accordance with Pharmacy Manual, site IDS 
SOPs  (as applicable) and DAIDS requirements .  
[IP_ADDRESS]  M3 and M4  
The study vaccines are kept in  temperature -monitored storage at -75 °C ± 15°C in a locked 
freezer  (See IND [ZIP_CODE], Investigator Brochures ). The freezers are temperature monitored and if 
outside designated range appropriate action is taken in accordance with Pharmacy Manual, site 
IDS SOPs (as applicable) and DAIDS requirements.  
[IP_ADDRESS]  Saline  
The placebo (normal saline) will be stored at room temperature.   
6.2.4  Preparation  
[IP_ADDRESS]  Dilution of C1 and C62  
Refer to Pharmacy Manual . 
[IP_ADDRESS]  Dispensing and Handling  
1. The vaccine will be dispensed according to Study Specific Pharmacy Manual and/or study-
specific SOPs.  
2. All vaccines will be used as supplied by [CONTACT_429437]. 
3. The vaccines will be thawed to room temperature. 
4. The required dose volume will be drawn into the appropriate syringe and C1, C62, M3 and M4 vaccines will be administered within [ADDRESS_543490](s) will be un-blinded. 
5. All syringes (vaccine and placebo) will prepared per research site’s IDS Pharmacy procedures to maintain blinding.  
NOTE: When preparing the placebo, sodium chloride for injection 0.9% should be used in place of C1, C62, M3 or M4. 
Any u nused portion of entered vials and expi[INVESTIGATOR_356453]-filled syringes should be disposed of in 
accordance with institutional or pharmacy policy.  
[IP_ADDRESS]  Labeling  
Label the prepared study product or placebo with the following to maintain blinding: 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 62 of 143 
 
 1. Participant identifier( s) 
2. Study Product Name  
3. Route 
4. Site (L or R deltoid) to be administered . 
5. Expi[INVESTIGATOR_429366].  
6. Any additional information required by [CONTACT_18103].  
7. Caution: New Drug —Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use  
6.3 Measures to  Minimize Bias : Randomization and Blinding  
6.3.1  Randomization 
The 18 study participants will be randomly assigned to receive one vaccination with C62-M4 
(n=8) or C1C62 -M3M4  (n= 8) or placebo (n=2) through a blinded randomization schedule as 
further described in Section  8.2.5. When participant eligibility is confirmed, study specific 
identification numbers (SIDs) are assigned sequentially for each participant at the Enrollment 
Visit. Vaccine and placebo product will be indistinguishable and clearly labeled with the 
administration site: left deltoid or right deltoid muscle . Site and laboratory personnel and 
participants will be blinded with respect to the allocation of  vaccine or placebo. A double-blind 
placebo -controlled, permuted-block design has been chosen to minimize bias in the reporting of 
safety and immunological data. 
Participants will be randomized and assigned a R andomization ID (RID) on D0 by [CONTACT_429438]/placebo  administration .   The institutional or site IDS  will be provided a 
clearly decoded key of the three study arms in a separate file that will be maintained in a secure 
location. The randomization schedule will be generated centrall y by [CONTACT_429439]. 
6.3.[ADDRESS_543491]  participants 
to inform them of the treatment they received.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 63 of 143 
 
 6.4 Study Intervention C ompliance  
Participants will keep a daily diary of solicited AEs for local and systemic symptoms for 7 days 
after both vaccine/placebo administrations. 
6.5 C oncomitant Therapy 
Whenever a concomitant medication is initiated or the dose is changed for all participants afte r 
receipt of vaccine/placebo at D0 through D56 of the study, the PI (or designees) must review the 
concomitant medications’ most recent package inserts, investigator’s brochures, or updated information from DAIDS to obtain the most current information on drug interactions, contraindications, and precautions. 
6.5.[ADDRESS_543492] durable HIV suppression on ART for ≥ 24 months 
prior to study screening and maintain ART therapy throughout the entire study. The study will not provide ART medications.  
2. The study team will consider alternate ART regimens on a case- by-case basis prior to 
enrollment per eligibility criteria. The study permits the use of all approved PIs, NNRTIs, NRTIs, and fusion and integrase inhibitors. Als o permitted are changes to the participants’ 
ART during the study for dosing simplification, tolerability issues, and improved side effect profile or at the investigator’s discretion. If a participant develops toxicity related to his/her previously stable ART, consult the protocol team (preferably before appropriate therapy modification)  
6.5.2  Prohibited Medications  
1. Ongoing use of investigational ART with the exception of Phase II or higher studies of antiretroviral therapy.  
2. Concomitant use with oral or parental corticosteroids, immunosuppressive agents (including but not limited to azathioprine, and cyclosporine) or any immunotherapy or 
immunomodulatory agents.  
3. Inhalers or nasal sprays containing steroids from [ADDRESS_543493] vaccines (e.g., pneumococcal, Hepatitis A, Hepatitis B, influenza) are prohibited 14 days prior to enrollment through Day 56.    
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 64 of 143 
 
 6. Available COVID -19 vaccines are prohibited 14 days prior to enrollment through Day 56. 
NOTE: receipt of adenoviral vectored vaccines (i.e. A straZeneca, Janssen) should be 
deferred until [ADDRESS_543494] dose of the ChAdOx1.tHIVconsv1 vaccine (Day 90). 
7. Live vaccinations (e.g., varicella, measles, mumps, rubella, MMR , yellow fever, oral polio) 
are prohibited from 60 days prior to enrollment through D ay 56, reference Sections 5.1 and  
Section 5.2;  
8. Mpox vaccinations are prohibited from 60 days prior to enrollment through D56. 
NOTE: Administration of live vaccine for Mpox is allowed at any time  after enrollment if 
indicated for post- exposure prophylaxis.  
9. Any agent that suppresses lymphocytes or monocyte function. 
10. Chemotherapeutic agents, growth factors, cytokines, or chemokines, white lineage colony 
stimulating factors (e.g., granulocyte -colony stimulating factor [G -CSF] and GM- CSF).  
11. Chronic use of topi[INVESTIGATOR_356456] (exceeding the cumulative area of the palm of the participant’s hand).  
12. Sporadic topi[INVESTIGATOR_23225] (e.g. creams) to small areas of the skin (<225 cm
2) for 
participants who are receiving ritonavir or cobicistat as part of their current ART regimen . 
13. Any form of corticosteroid or antihistamine medications at or near the injection site, including for treatment of injection site reactions . 
14. Refer to exclusion criteria in Section  5.2. 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL  
7.1 Discontinuation of Study Intervention  
7.1.1  Premature Treatment Discontinuation Evaluations  
Study treatment intervention will occur at D0 and D28. The collection of safety labs, virologic, 
immunologic, SCA, and the 2nd leukapheresis will continue to be collected per SoA, S ection 1.3.  
Participants who do not complete both vaccine/placebo D0 and D28 injections will be replaced, provided the inability to complete the D28 vaccination visit is not due to a study- related AE.  
Participants who complete both vaccine/placebo  D0 and D28 injections but do not complete the 
D35 study visit will be replaced, provided the inability to complete the D35 visit is not due to a study- related AE.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543495] one dose of vaccine/placebo but are unable to complete either 
the D28 vaccination, the D35 visit,  the 2nd leukapheresis  or the D56 visit should be encouraged 
to continue on study for safety assessments per the SoA, S ection 1.3.  
7.1.2   Discontinuation of Antiretroviral Therapy  
If the participant discontinues ART prior to D0, DO NOT give the vaccine/placebo injection.  
If the participant discontinues ART at any time after the first vaccine or placebo administration, 
the participant should continue on study for safety follow-up as noted in the SoA, S ection  1.3. 
Collection of virologic, immunologic, SCA, and the 2nd leukapheresis samples will be determined on a case -by-case basis in discussion with the protocol team. This participant may be 
replaced.  
7.2 P articipant  Discontinuation/W ithdrawal  from the Study  
7.2.1   Enrolled Participants, who are Not Randomized and Do Not Start Study 
Treatment  
Participants who withdraw or who are withdrawn from the study after the Enrollment Visit but prior to receipt of vaccine/placebo: 
DO NOT re -use the SID.  
REPLACE the participant . 
A participant who is unable to complete the leukapheresis procedure or has less than [ADDRESS_543496] collected prior to D0 may be terminated from the study as determined by [CONTACT_978].  
If terminated:  
DO NOT re -use the SID.  
REPLACE the participant.  
Termination can also occur due to complications at the leukapheresis procedure as determined by 
[CONTACT_356504] (or designee) and the Apheresis Medical Director and can include 
contraindications for further leukapheresis pro cedures.  
Participants who complete the first leukapheresis procedure pre -vaccine but do not want to do 
the second leukapheresis procedure may be  withdrawn from the study as determined by [CONTACT_978] .  
If terminated:  
DO NOT re -use the SID.  
REPLACE the participant.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 66 of 143 
 
 7.2.2   Evaluations for Randomized Participants Who Do Not Start Study 
Treatment  
Participants who withdraw or are withdrawn after randomization but prior to starting study 
treatment (vaccine or placebo) will have no further evaluations or follow-up.  
• DO NOT r e-use the RID.  
• DO NOT re -use the SID.  
• REPLACE the participant.  
7.2.[ADDRESS_543497] no 
further research evaluations.  Continue follow-up for safety through D28 (based on review by [CONTACT_208125]) will be encouraged and if participant is unable to continue for visits through D28, they will be asked to complete EOS safety evaluation visit.   
• DO NOT re -use RID.  
• DO NOT re -use the SID.  
• REPLACE the participant.  
7.2.4   Participant May Withdraw or be Withdrawn from the Study  
• Request by [CONTACT_305687]. 
• Development of an illness that requires treatment with medications prohibited in th e study.  
• Change in the participant’s medical condition that might make continuation in the study 
harmful to participant.  
• Participant does not continue to meet eligibility requirements.  
• Participant does not complete D7 or D35 visit.  
• Request of the participant’s primary care provider if she/he thinks the study is no longer in 
the best interest of the participant.  
• Participant judged by [CONTACT_9154] (or designee) to be at significant risk of failing to comply 
with the provisions of the protocol, as to cause harm to self or seriously interfere with the validity of the study results. 
• At the discretion of the IRB/Ethics Committee, FDA, NIH, and other government agencies as part of their duties, Principal Investigator (designee), or vaccine. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 67 of 143 
 
 7.3 Premature  Study Discontinuation (D/C) Evaluations   
Participants who prematurely discontinue study participation after completing the 
vaccine/placebo prime (D0) and boost (D28) but before D196 will have premature study 
discontinuation (D/C visit) evaluations performed per the SoA for D 196.  
7.[ADDRESS_543498] to follow -up (LTFU) need to meet both of the following criteria:  
1. Failure to respond or reply to [ADDRESS_543499] attempts, followed by  
2. Failure to respond to a certified letter sent to the address provided by [CONTACT_2299].  
In scenarios in which a participant is relocated after 3 failed attempts, the study PI [INVESTIGATOR_429367] a case- by-case basis.  
8 STUDY ASSESSMENTS AN D PROCEDURES  
8.1 Exclusion Efficacy Assessments  
8.1.1  Remote Data Collection  
Study visits may be conducted remotely (e.g., telephone, facetime) in the following situations: 
a. a participant is unable to attend a visit because of a debilitating illness; the site must inform 
the protocol team in advance.  
b. the site is temporarily unable to conduct non- essential visits in the clinic per University 
policies at the time of the visit; the site must inform the protocol team in advance.  
c. at the discretion of the protocol team if the risk of an on- site visit is felt to pose more risk 
than potential benefit to the participant; a message from the team will be sent to the study team.  
Regardless  of the situation, the study team should designate which visits were conducted 
remotely and attempt to obtain as much of the visit-specific required information, based on the Schedule of Events, and record it on the relevant study specific checklist. The r eason for 
conducting the visit remotely must also be recorded and documented in the participant’s study file. 
8.1.2   Visit windows  
a. Perform visits per window listed in SoA, Section 1.3. There is no window around the D2, 
D7, D30, and D35 visits. There is a ± 2 days window around the visits at Days 14, 28, 42 
and 56.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 68 of 143 
 
 b. There is a ± 1 day window around the telephone call assessments at Days 5, 10, 18 and 22. 
See Appendix 2.  
c. There is a ± 7 days  window around the visits at Days 84 and 140. D196 has a ± [ADDRESS_543500] D28 visits are scheduled based on the date of D28 booster vaccination.  Consequently, D30 will occur exactly 2 days after booster vaccination, D35 will occur exactly 7 days after, 
D42 will occur 14 days (+/- 2 days) after, and so on.  
e. Window for D56 leukapheresis is – 7/+21 days with preference for the procedure to be completed as close to Day 56 as possible. If unable to complete the D56 leukapheresis and upon review and approval of the protocol PI, a large blood draw can be completed between 14 – 21 days after D56 (Days 70 -77). This large blood draw will be completed as close to 21 
days after D56 as possible (Section 8.2.3) 
8.1.3   Medical History  
The medical history includes all signs , symptoms and diagnoses regardless of grade within 
the 30 days prior to entry and any significant medical conditions noted in medical records 
(e.g., hospi[INVESTIGATOR_602], surgeries, prior medical history). Assessment and documentation of the medical history eval uation occurs at the screening visit. Update to medical history will 
occur at all clinical visits.  
 Document: 
a. All allergies to any medications and their formulations  
b. Date of birth, gender, race and ethnicity of participant   
c. HIV history, including acute st atus at ART initiation and HIV -1 RNA 
suppression, if available  
d. Nadir CD4 and pre- ART /peak  HIV -1 RNA level, if available (if documentation is 
not available, collect and record participant recall)  
e. Targeted Reproductive Assessment includes:  
- For women and men participating in activities that could lead to pregnancy, verify use of birth control for a minimum of [ADDRESS_543501] vaccination 
date (see Section 5.1) through the [ADDRESS_543502] menstrual period (LMP) for all women of childbearing potential (WOCBP) at all study visits as part of the complete PE or the targeted assessment.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 69 of 143 
 
 8.1.4   Medication  History  
Complete a medication history, include medication start and stop dates. Document the 
vaccine/placebo administration as indicated  Table 18 .  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 70 of 143 
 
 Table 18 Medication Complete History or Timeframe  
Medication Category  Complete History or Timeframe  
Antiretroviral Therapy  Complete History  
Immune -based Therapy  Current & within 90 days prior to screening .   
HCV antiviral therapy  Complete history  
Prescription Drugs  Within 30 days prior to screening  
Systemic Corticosteroids  Within 30 days prior to screening  
HIV- 1 related vaccines  Complete History  
Experimental non -HIV vaccine  Within the 6 months prior to screening  
Vaccines  Within 60 days prior to screening  (For Covid -19 
and Mpox vaccines, complete history)  
Experimental treatment for COVID -19 illness   Within the 90 day s prior to screening  
IgG therapy or immunization w/experimental Abs  Within 90 days prior to screening  
Non-prescription drugs (OTC)  Within 30 days of enrollment  
8.1.5   Clinical Assessment s  
a. Complete Physical Exam (PE) : A complete PE will be performed at screening and 
D196. This complete PE is to include at a minimum an examination of the skin, head, 
mouth, and neck; auscultation of the chest; cardiac exam; abdominal exam; and 
examination of the lower extremity for edema. The complete PE will also include signs and symptoms, diagnosis, weight (kg), temperature (T°C, oral) , respi[INVESTIGATOR_697] (RR), 
pulse (P), and blood pressure (BP). 
b. Targeted Physical Assessment : A targeted physical assessment is done at all 
identified visits and includes vital signs. The targeted or directed physical assessment 
addresses any previously ident ified or new event that the participant experiences since the 
last study visit or any unresolved signs or symptoms previously experienced. In addition to the vital signs, this assessment includes updates to signs and symptoms, and clinical assessment of HI V disease.  
c. Vital Signs (VS) : Perform VS at all clinical visits. VS include P, BP, RR, T, and 
weight.  Measurement of weight is required at check in  only.  
On vaccination days, vital sign measurements will be collected before vaccination . If 
individual vital sign measurements are considered clinically significant by [CONTACT_093], vaccination may be withheld that day (or, as noted for BP, delayed briefly 
pending a calming period), and participants may return on a subsequent day for re-
evaluation and vaccination, ideally, within the allowed visit window (SoA, S ection  1.3).  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 71 of 143 
 
 d. Height : Measurement of height (cm) that is required at the sc reening visit should 
be performed with shoes off. 
e. ART Adherence Assessment : This protocol requires participants take all required 
doses of ART. Document all missed doses, even if the reason/s for missing the doses are 
outside the participant’s control. Report missed doses to study PI (or designee). Study participation can be terminated if HIV medication is missed.  
f. Assess and document any missed doses while on study and discuss missed ART 
doses with study PI (or designee). Continuation on study will be cont ingent on adherence.  
g. Antiretroviral Medication Assessments : During the study, all modifications to the 
participant’s ART regimen, including any ARV interruptions, dose modifications, formulations modifications, starts, and permanent discontinuations since the last study visit or at the study visit must be recorded.  This will be checked along with the 
concomitant medications at each visit.  
h. Post Vaccine Assessment:  Assess for any injection site reactions and  systemic 
reactions . Record any reportable events . 
i. Signs and Symptoms Assessments : At entry, all signs and symptoms, regardless 
of grade, that occurred within the [ADDRESS_543503] be recorded.  
j. Solicited Adverse Events  
Local and systemic predefined solicited AEs for reactogenicity assessment (Section 8.2.10) will be collected in a Participant Symptom Diary  for [ADDRESS_543504]. 
Solicited AE s should not be reported as unsolicited AEs ( see Section  8.3).  However , 
solicited AEs should be reported as SAEs, MAAEs or AESIs if they meet criteria 
(Sections  8.3.2, 8.3.3 and 8.3.4 respectively).  
k. Unsolicited Adverse Events  
Active solicitation of AEs will be done at every study visit. Post-entry signs and 
symptoms, Grade ≥ 2, will be recorded. All signs or symptoms, definitely or possibly related to study interventions will be recorded, regardless of grade. Additionally, all signs and symptoms that lead to a change in study treatment or change in ART or discontinuance of the leukapheresis procedure, regardless of grade, must be recorded.  
l. Diagnoses
: After entry, record all diagnoses identified. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 72 of 143 
 
 m. Concomitant Medication Assessments : At screening, record all medications taken 
per medical history guidelines. Thereafter, record all new or discontinued concomitant 
medications, including prescription, dietary supplements, and over-the- counter 
medications taken or stopped since the last visit.  
8.1.6   Laboratory Studies  
a. CD4+/CD8+: All study required absolute CD4+/CD8+ count and percentages and 
CD4/CD8 ratio  must be obtained from a laboratory that possesses a CLIA certification or 
equivalent. Eligibility will be determined based on a CD4+ ≥ 350 cells/µL at screening.  
b. Plasma HIV -1 RNA : All study required HIV-[ADDRESS_543505] be performed by 
a laboratory that posse sses a CLIA certification or equivalent. Eligibility will be 
determined based on an HIV- 1 RNA value <50 at screening.  
c. Heparin P latelet Factor (PF) 4 Antibody : A test for heparin -induced 
thrombocytopenia (HIT) antibody, also called heparin-PF4 antibody, is performed to detect antibodies that develop in some people who have been treated with heparin. It is used to help establish a diagnosis of immune- mediated heparin -induced 
thrombocytopenia (HIT type II) when you have a low platelet count (thrombocytopenia) and excessive clotting (thrombosis). 
This serum sample will be colle cted at enrollment and processed and stored in the 
research lab for testing should participant develop a clotting adverse event. 
8.1.7   Research Assays  
Blood will be collected for the following research laboratory evaluations:  
a. Human Leukocyte Antigen (HLA) Typi[INVESTIGATOR_007] : HLA testing will be performed; however, if 
HLA type is available in the medical record, it does not need to be repeated. The result will be used for research purposes. 
b. CMV Testing : Cytomegalovirus (CMV) is a common virus that usually causes no 
symptoms or only mild illness. CMV testing detects antibodies in the blood that the body produces in response to the infection or detects CMV directly. In the [LOCATION_002], as many as  60% of people have been exposed to CMV at some point in their life. If positive 
CMV antibody results are available in the medical record, it does not need to be repeated.  
c. EBV Testing : The E pstein -Barr virus (EBV), also known as human herpesvirus 4, is a 
gamma herpes virus that occurs only in humans. Laboratory testing can help distinguish whether someone is susceptible to EBV infection or has a recent or past infection.  
The Anti-VCA IgG appears in the acute phase of EBV infection, peaks at two to four weeks after onset, declines slightly then persists for the rest of a person’s life. If positive 
EBV antibody results are available in the medical record, it does not need to be repeated.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 73 of 143 
 
 d. COVID -19 RT- PCR Testing : The COVID -[ADDRESS_543506] is a real -time reverse 
transcription polymerase chain reaction (rRT -PCR) test for the qualitative detection of 
nucleic acid from SARS -CoV-2 collected as upper respi[INVESTIGATOR_153194] (such as 
nasopharyngeal or oropharyngeal swabs, nasal swabs, or mid-turbinate swabs). 
Participants testing positive by [CONTACT_937] -PCR at enrollment would delay progression on study 
until 30 days from date of  diagnosis if asymptomatic or 30 days from resolution of mild 
to moderate symptoms  related to COVID -19.  
e. COVID -19 Antibody Testing : COVID -19 nucleocapsid antibody testing on stored 
plasma as indicated per the S oA, Section 1.3.  
f. Plasma/PBMC for Immunology Studies : Plasma and cryopreserved PBMC  will be 
stored for analysis of low- level viremia, T -cell specificity, phenotype and function of 
immune cells , and virologic measurements per the SoA, Section 1.3. Specific testing will 
include the following: 
1) Measurement of T cell responses pre- and post- treatment 
2) Measurement of T cell virus inhibition pre- and post- treatment  
3) Phenotypi[INVESTIGATOR_429368] a nd specific CD4+ and CD8+ T cell activation, homing 
and memory differentiation using flow cytometry pre- and post- treatment  
4) Functional analysis (e.g., anti -viral cytokine and lytic molecule release) of both 
total and specific T cells pre- and post- treatment  
5) Low-level HIV -[ADDRESS_543507]- treatment  
NOTE: Site laboratory standardized protocols will guide the performance of all research assays.  
NOTE: See Section 7.1 regarding collection of stored Plasma/PBMC for Immunology Studies 
for participants who discontinue ART or do not complete study treatment. 
8.[ADDRESS_543508] in a stepwise manner and includes the completion of inclusions and 
exclusion prior to enrollment. 8.2.2   Participant Enrollment  
Enrollment occurs within the 60 days following screening. Participants not meeting eligibility 
requirements will not continue on study.   
Once eligibility is confirmed, participant study identification numbers (SIDs) will be assigned 
sequentially as each participant enters the study.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 74 of 143 
 
 Participants testing RT-PCR positive for COVID- 19 at enrollment, will delay vaccination 
following enrollment (See Section 8.1.7D  above) , determined by [CONTACT_976] (or designee) on a case by 
[CONTACT_413]. Labs obtained at the original enrollment will not nee d to be repeated unless requested 
by [CONTACT_976] [INVESTIGATOR_429369].  
Visit 2 and all associated procedures , inclusive of leukapheresis, will occur within 60 days of 
Visit 1. If required for scheduling, the leukapheresis visit can occur separately from Visit 2 but 
within  60 days of Visit 1 and after the Enrollment/Baseline visit.  Safety labs  (chemistry, 
hematology, and COVID-19 RT- PCR)  and vital signs assessment will be done at the last visit 
prior to vaccination and D0 will be scheduled within the [ADDRESS_543509] leukapheresis occurs at or after 
Enrollment /Baseline  (Visit 2) but prior to D0. This leukapheresis provides cells needed to 
perform baseline research assays and measurements required to establish pre- treatment immune 
responses. 
Participants will be provided with institution al instructions to prepare for the procedure.  
1. Baseline Leukapheresis  
This procedure can occur at any time point within the 60 days following the Screening visit. 
It can occur at or after the Enrollment/Baseline (Visit 2).   
If leukapheresis is scheduled on a date other than the Enrollment/ Baseline visit: 
• The procedure should be scheduled after the Enrollment/Baseline visit.  
• If the leukapheresis is the last procedure done within the 60 days of screening and 
prior to the vaccination, perform safety labs (chemistry, hematology, and COVID-19 RT-PCR)  and vital signs assessment and schedule the D0 visit within 10 days of the 
leukapheresis.  
• CBC with differential is required for the completion of the leukapheresis facility and 
will be obtained per facility policies and procedures.  
• If the leukapheresis procedure is done at the Enrollment visit, collect the leukapheresis 
product in addition to the research labs. ( See Study Specific Lab Manual.)  
2. 
Day 56 (Visit 8) Leukapheresis  
If cannot be done within the D56 Visit window due to scheduling conflicts or unforeseen issues, reference procedure window in Section  8.1.2.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 75 of 143 
 
 The preference would be the completion of a second leukapheresis, however, if unable to 
perform leukapheresis, after review and approval by [CONTACT_976], a large blood draw can be completed. The amount to be drawn will be determined by [CONTACT_429440]. Total volume will not exceed 150 mL for this collection.   
8.2.4  Randomization  
The 18 study participants will be randomly assigned to C62 -M4 (n=8) or C1C62 -M3M4 (n=8) 
or placebo (n=2) through a blinded randomization schedule. The randomization schedule will be generated in SAS v ersion 9.4 or higher (Cary, NC) using a permuted-block design to ensure 
balance cumulatively. Each assignment will be given a consecutive randomization ID (RID: 1001-1018). 
The administration of the first vaccination or placebo designates D0, and the remai ning visits are 
calculated by [CONTACT_429441] D0. Participants will be randomized to Study Arm, 
and will receive secondary randomization with respect to vaccine administration sites (left and right deltoid muscles). The randomization to vacc ine administration sites that takes place at D0 
will dictate the vaccine administration sites at D28.  
Within  C1C62 -M3M4 , exactly half of the participants will be randomized to receive C62 in the 
left deltoid and  C1 in the right deltoid muscle at D0, follo wed by M4 in the left deltoid and M3  
in the right deltoid muscle at D28. The remaining half of participants will receive C62 in the 
right deltoid and C1  in the left deltoid muscle at D0, followed by M4 in the right deltoid and M3  
in the left deltoid muscle at D28.  Although no randomization to administration site is required for Study Arms C62-M4 or Placebo since the vaccine/placebo will be split between the left and 
right deltoid muscles, an administration site (right or left deltoid) will be designated on these prepared syringes to guarantee blinding. 
[IP_ADDRESS]  P articipants Randomized and Do Not Receive Study Product  
Participants randomized to receive study product but who do not receive the vaccine/placebo are 
withdrawn from the study ( Sections  7.2 and Section  7.3) and will be replaced . A new 
randomization ID (RID) will be generated and appended to the end of the randomization schedule, so that any replacements are randomized at the end of the study . 
8.2.[ADDRESS_543510] participant receives their 
vaccine/placebo booster injection and following completion of an independent SMC review.   
Unblinding of study participants can commence days after all participants have completed the 
last study visit and all queries and outstanding protocol implementation requirements have been resolved . 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 76 of 143 
 
 [IP_ADDRESS]   Emergency Unblinding 
If, in the judgment of the protocol PI [INVESTIGATOR_429370]’s medical provider and 
the site PI,  a medical event is of sufficient extreme severity that it requires the immediate 
unblinding of a participant, the site PI [INVESTIGATOR_429371] a participant per the 
instructions in the study specific SOP.   The decision to un-blind will be taken in conjunction 
with the independent members of the Study Monitoring Committee (SMC). Emergency unblinding is expected to be extremely rare. It should only occur in the setting of a potentially life-threatening clinical event, and if knowing the participant’s treatment assignment would 
affect decisions regarding the participant’s immediate medical management. Both conditions must be satisfied.  The site personnel will ensure that the reasons for un-blinding are documented 
in the clinical research chart.  
8.2.6  Unsched uled Visits  
Visit windows are defined in the protocol (Section  8.1.2) and SoA, Section 1.3. For a visit not 
performed within the window period, the interim visit will be completed and documented as a protocol deviation. If there is a missed visit that requires safety assessments or local safety labs, study staff should attempt to bring the participant in for an interim visit as soon as possible. Safety evaluations should be completed per SoA, Section 1.[ADDRESS_543511] v accine (C62 or  C1C62 ) or placebo injections are given at D0 and second vaccine ( M4 or 
M3M4 ) or placebo injections at D28.  
1. Complete required pre-vaccine/placebo assessments and blood draws ( Section 1.3) prior to 
the administration of the vaccine/placebo. 
2. At D0 and D28, record the RID and
 the vaccine/placebo injection, including dose and time of 
administration. Record where the injection was given (location). If unable to administer the entire dose for any reason, notify the study PI (or designee) and docum ent the reason.  
8.2.8   Administration of study vaccine /Post Vaccine/Injection management  
1. Observe participant and injection site for 30 minutes following each vaccine/placebo injection for clinical AEs  per SOP . 
2. Instruct participant to contact [CONTACT_429442].  
3. Provide post vaccination symptom diary and instructions for completion prior to leaving the 
clinic  per SOP: Completion of Post Vaccination Symptom Diary . 
4. Contact [CONTACT_429443] -determined by [CONTACT_429444] . 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 77 of 143 
 
 5. Following receipt of vaccine/placebo, participants will be followed with study visits through 
D196 after D0 
8.2.[ADDRESS_543512] ions (D0 and D28), after leaving the clinic and through D7 post- injection.  Temperature 
should be taken orally in the evening whenever possible. If more than one measurement is made in a day (for example due to feeling unwell), then the highest temperature taken that day should be recorded. Study staff will follow new or unresolved solicited AEs to resolution. In general, 
participants reporting any post -injection reaction greater than mild should to be evaluated by [CONTACT_83058] (or designee) within 72 hours after onset, unless the reaction is improving and/or has completely resolved.  
Initiate appropriate countermeasures, including medical intervention or procedures, if clinically indicated.  
8.2.[ADDRESS_543513] vaccine/placebo, the study coordinator will contact [CONTACT_137382] D2, D5, D10, D18, D22 and D28 to review symptoms and any issues they may be experiencing. The Post Vaccination Symptom Diary  is review ed with the participant for 
accuracy and completeness  on D7 and D35. Assessment  of local and systemic unsolicited AEs 
will be done at every visit. Participants will be asked to contact [CONTACT_429445] 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543514] Vaccination Symptom Diary , at any time point during the study.   
8.2.12  End of Study   
The End of Study (EOS) Visit will occur [ADDRESS_543515] listing the signs and symptoms 
associated wi th TTS and general instructions for care should they need to seek care outside the 
study for the development of AEs  associated with clotting disorders, neurological disorders or 
other AESI s.   
8.2.14  Laboratory Evaluations  
Details of specimen collection are in the Lab Procedures Manual.   
The study PI (or designee) assesses the results of all clinical laboratory tests to determine 
continuing eligibility or AE relatedness at specified visits. Lab results or values outside the normal reference range require the investigator (or designee) to determine if the abnormal value is clinically significant and/or related to a study intervention. All confirmed abnormal laboratory values that the investigator deems clinically significant and/or related to a study intervention must be reported as AEs, regardless of grade. Post-entry laboratory values, Grade ≥2, will be recorded. Participants and/or their primary care provider will be informed of any clinically significant laboratory test result or clinical event that occurs thro ughout the study. Participants 
will be referred for care when appropriate.  
1. Hematology
: Perform hemoglobin, hematocrit, white blood cell count (WBC), differential 
WBC, absolute neutrophil count (ANC), and platelet count in real time at the local laboratory. 
a. CBC with differential for leukapheresis procedures per collection agency policy :  
1. A STAT CBC with differential is required prior to each leukapheresis performed at the UNC Apheresis Lab unless results completed within 24 hours of the procedure are availab le to the Apheresis Lab performing the procedure.  
2. Leukapheresis procedures performed at a local apheresis collection center require a CBC within 30 days of procedure, neutrophil count (ANC), and platelet count in real time at the local laboratory.  
2. Blood Chemistries
:  Perform  the following:  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 79 of 143 
 
 a. Electrolytes (sodium, chloride, potassium, CO2/bicarbonate), glucose, blood urea 
nitrogen (BUN), creatinine, calcium, and magnesium, in real time at the local laboratory.  
b. Liver function test: ( total bilirubin, AST (SGOT), ALT (SGPT), and alkaline 
phosphatase) in real time at the local laboratory.  
Note: For participants on ritonavir boosted atazanavir, total and direct bilirubin should be 
measured.  
3. Creatinine and Creatinine Clearance : The creatinine clearance (eGFR) wil l be required for 
study enrollment eligibility. The study assesses serum creatinine level at all the safety lab checks and uses the serum creatinine value for toxicity grading .  
Creatinine clearance (eGFR) calculations will use the 2021 CKD-EPI [INVESTIGATOR_10908]. This 
calculation can be found at https://www.mdcalc.com/calc/3939/ckd -epi-equations-
glomerular -filtration -rate-gfr  
The creatinine clearance (eGFR) value reported as part of the lab report of serum creatinine 
level will be re -assessed and re-calculated if incidental finding indicates a value ≥ Grade 3. 
The re- calculated value using the [ADDRESS_543516] - Serum or Urine beta -HCG per SOE:   A negative serum pregnancy test 
(to rule out pregnancy) is required on all women at screening . A negative urine POCT 
pregnancy test on D0 and D28 will be completed on all women of childbearing potential.  
Urine test must have a sensitivity of <25 mIU/mL.   
NOTE: Confirmation of a negative urine POCT pregnancy test within [ADDRESS_543517] clinical benefit, this added prot ection 
is warranted.  
The study will use the date of LMP to rule out suspected pregnancy. Pregnancy will be suspected if >[ADDRESS_543518] menstrual period in pre-menopausal women has elapsed.  
5. Hepatitis Screen
: Both hepatitis tests (HCV AB an d HBsAg) must be negative or non-
detected to be included on the study. A positive HCV AB test reflexed to Hepatitis C RNA 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543519] onl y. 
6. RPR : Participants diagnosed with syphilis at screening may rescreen following a minimum 
of 14 days following documentation of adequate treatment of syphilis.  
7. HIV Ag/Ab Test: Complete HIV testing at screening if documentation of HIV infection is 
not available from prior records.  
8. Prothrombin time (PT), INR, and APTT : Evaluate at the Screening Visit.  
9. PF4 Antibody ELISA:  A sample will be collected and stored at enrollment and collected per 
clinical management of suspected clotting AESI. (Section 8.1.6)  
10. Estimated Blood Volumes : The estimated blood volumes associated with each study visit 
are provided Table 19 . 
Table 19 Blood Volumes Associated with Study Visits  
Day #  Approximate Blood 
Volume (mL)  Day #  Approximate Blood Volume 
(mL)  
Screen  103 Day 35  88 
Enrollment /Baseline  78 Day 42  60 
Baseline Leukapheresis  20 Day 56   42 
Day 0  77 D56 Leukapheresis  20 
Day 7  88 Large Blood Draw 1 150 
Day 14  60 Day 84 2 88 
Day 28 57 Day 140 99 
Day 30  0 Day 196 105 
1 Large blood to be completed only on approval of PI [INVESTIGATOR_429372] D56 leukapheresis ( Section  8.1.2 ) 
2 If leukapheresis at D56 occurs, blood is drawn at D84. If large blood draw is scheduled , then no D84 research blood 
draw  is performed . 
8.3 A dverse Events and S erious Adverse Events  
 
The PI [INVESTIGATOR_429373].  All AEs are considered to be unsolicited AEs (collected by ‘open question’ at study visits) unless categorized as solicited AEs  (Refere nce Table 9, Table 10, Table 11, and Table 12). 
 Solicited AEs are local or systemic predefined events for assessment of reactogenicity. Solicited AEs will be reported by [CONTACT_429446] a Post V accination Symptom Diary  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 81 of 143 
 
 (Section 8.2.9) . Solicited AEs  will be assessed separately from the unsolicited AEs collected 
during the study visits or telephone assessments. 
 General information for AEs in this protocol excludes solicited AEs.   The PI [INVESTIGATOR_429374], documenting, and recording 
events that meet the definition of an AE. 
8.3.1  Definition of Adverse Events  (AE) 
Adverse event means any untoward medical occurrence associated with the use of an 
intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). 
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal results of diagnostic procedures, including la boratory test abnormalities.  
8.3.2   Definition of Serious Adverse Events  (SAE)  
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes:  
1. Result s in death – the cause of death is the AE; death is an outcome.  
2. A life -threatening adverse event  – The term ‘life-threatening’ in the definition of ‘serious’ 
refers to an event in which the participant was at risk of death at the time of the event. It doe s 
not refer to an event, which hypothetically might have caused death, if it were more severe.    
3. Inpatient hospi[INVESTIGATOR_1081]  - In general, 
hospi[INVESTIGATOR_19949] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a com plication prolongs 
hospi[INVESTIGATOR_42979], the event is serious. When in doubt as to whether ‘hospi[INVESTIGATOR_059]’ occurred or was necessary, the AE should be considered serious. Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
baseline is not considered an SAE. 
4. A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions - The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 82 of 143 
 
 diarrhea, influenza, and accidental trauma (e.g., sprained ankle) w hich may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
5. A congenital anomaly/birth defect.  
6. Important medical events  – Important medical events  that may not result in death, be life -
threatening, or require hospi[INVESTIGATOR_708], based upon 
appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
8.3.3   Definition of Medically Attended Adverse Events (MAAEs)  
MAAEs are defined as AEs leading to medically -attended visits that were not routine visits for 
physical examination or vaccinations, such as an emergency room visit, or an otherwise unscheduled visit to from medical personnel (medical doctor) for any reason. AEs, including abnormal vital signs, identified on a routine study visit or during the scheduled illness visit will not be considered MAAEs.  
8.3.[ADDRESS_543520] (AESIs)  
An AESI (serious or non-serious) is one of scientific and medical concern specific to the 
sponsor’s product or program, for which ongoing monitoring and rapid communication by [CONTACT_429447]. Such an event might warrant further investigation in order to characterize and understand it. Depending on the nature of the event, rapid communication by [CONTACT_50459] (e.g., regulators) might also be warranted. 
AESIs will be collected according to the timepoints in the  SoA (Section 1.3).  
An AESI can be serious or non-serious. All AESIs will be recorded in the participant chart and 
the database.  
Serious AESIs will be recorded and r eported as per Section  9.5.  
AESI for this protocol include those listed below.  
1. Grade 3 or greater Injection Site Reactions  
2. Immune- related AEs of any grade  
3. Blood clot related events any grade (as per S ection 9.2.1) 
4. New onset neurological diseases of any grade (as per Section 9.2.2)  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 83 of 143 
 
 NOTE: Participants with an ongoing AESI at EOS should be followed until the AESI has 
resolved or stabilized in the opi[INVESTIGATOR_57455]. 
8.4 Time Period and Frequency for Collecting AE and SAE Information  
8.4.1  Classification of an Adverse E vent 
[IP_ADDRESS]  Severity of Event  
 
Event severity will be assigned according to the PI’s (or designee’s) assessment.  The grading 
system for drug toxicities is located in the Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events  (DAIDS AE Grading Table ), corrected Version 2.1, July 
2017, which can be found on https://rsc.niaid.nih.gov/clinical- research -sites/daids -adverse- event -
grading- tables   
Severity Grade for Parameters Not Identified in the Grading Table:  
Table 20  should be used to grade the severity of an AE that is not specifically identified in the 
grading table. In addition, all deaths related to an AE are to be classified as Grade 5. 
Table 20 Criteria for Grading the Severity of an AE  
PARAMETER  GRADE 1 MILD  GRADE 2 
MODERATE  GRADE 3 
SEVERE  GRADE 4 
POTENTIALLY 
LIFE-THREATENING  
Clinical adverse event NOT identified elsewhere in the grading table  Mild symptoms causing no or minimal interference with usual social & 
functional activities 
with intervention not indicated  Moderate symptoms causing greater than minimal interference with 
usual social & 
functional activities with intervention indicated  Severe symptoms 
causing inability to perform usual social & functional activities with 
intervention or 
hospi[INVESTIGATOR_222981] -
threatening symptoms causing inability to perform basic self -care 
functions with 
intervention indicated 
to pre vent permanent 
impairment, persistent disability, or death  
[IP_ADDRESS]  Relationship to Study Intervention  
Attribution/Assessment of Causality is a determination that describes the relationship or 
association of the study product with an adverse event.  
The PI [INVESTIGATOR_429375] /placebo  and each occurrence of 
each AE/SAE using their clinical judgement.  This assessment of causality or relationship of AEs 
to the study product is determined by 1) temporal relationship of the event to the administration 
of study product, 2) whether an alternative etiology has been identified, and 3) biological plausibility.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 84 of 143 
 
 The causality assessment categories that will be used for this study are described below.  
• Causality assessments that are consi dered not related to study product: 
1. Not related:  
The event is related to an etiology other than the study product (the alternative etiology 
must be documented in the participant’s medical record). 
If an SAE is considered "unrelated" to study product, the Investigator should offer his/her 
clinical opi[INVESTIGATOR_305638](s), agent(s), or process(s) were the likely causative mechanism for the event.  
• Causality assessments that are considered related to study product:  
1. Possible
:  
There is an association between the event and the administration of the study product and 
there is a plausible mechanism for the event to be related to study product; but there may also be alternative etiology, such as characteristics of the participant’s clinical status or under lying disease.  
2. Definite
: 
There is an association between the event and the administration of study product; a plausible mechanism for the event to be related to the study product, causes other than the study product have been ruled out, and/or the event re- appeared on re -exposure to the 
study product. 
[IP_ADDRESS]  Expectedness  
The PI (or designee) will be responsible for determining whether an adverse event (AE) is expected or unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study intervention or is not listed in the most current IBs for the study intervention. 
8.4.2  Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE ) may come to the 
attention of study personnel during study visits and interviews of a study participant  presenting 
for medical care, or upon review by a study monitor. 
AEs will be  assessed and  recorded from the time the participant is enrolled on the study through 
the date of the last participant required contact . Reference SoA , Section 1.[ADDRESS_543521].  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543522]  
MAAEs and AESIs will be assessed and  recorded starting on  Day 0  (vaccine/placebo 
administration) , through all  post treatment visits , and through the date of last participant required 
contact .  
All unsolicited AEs  not meeting the criteria for SAE s will be captured in the research record on 
the appropriate form. Information collected includes: 
1. event description,  
2. time of onset,  
3. PI’s (or designees) assessment of : 
○ severity,  
○ relationship to study product,  
○ expectedness,  
4. time of resolution/stabilization of the event.  
All AEs occurring while on study must be documented appropriately regardless of relationship.  
Any study related AE that is  unresolved at the participant’s last study visit should be followed up 
by [CONTACT_233569], but without further recording 
in the database. All study-product related AEs should be followed to adequate resolution unless 
in the investigator’s opi[INVESTIGATOR_1649], the AE is unlikely to resolve and has become a chronic underlying 
disease. AE outcomes will be documented as one of the following:  
1. Recovered/ resolved. 
2. Recovering/resolving  
3. Not recovered/not resolved 
4. Recover with sequelae/resolved with sequelae.  
5. Fatal  
6. Unknown 
The action taken with the vaccine/placebo due to the AE should be recorded using one of the 
following: 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 86 of 143 
 
 1. No action taken.  
2. Next dose delayed. 
3. Permanently discontinued/withdrawn from further study vaccination (with date) . 
4. Not applicable.  
Any medical condition that is present at the time that the participant  is screened will be 
considered baseline and not reported as an AE. However, if the study participant’s condition  
deteriorates at any time during the study, it w ill be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of 
the event at each level of severity  to be performed. AE s characterized as intermittent require 
documentation of onset and duration of e ach epi[INVESTIGATOR_1865].  
The research coordinator  will record all reportable AEs with start dates occurring any time on or 
after the enrollment visit through the last participant required contact . At each study visit, the 
research coordinator  will inquire about the occurrence of AE s and SAEs since the last visit. 
Starting with Day 0,  in addition to AEs and SAEs evaluations, the study coordinate will 
additionally assess for MAAEs and AESIs.  
If the investigator becomes aware of an SAE  or AESI with a suspected causal r elationship  to the 
study intervention that occurs after the end of the clinical study in a treated participant, the 
investigator shall, without undue delay as  described in Table 21 . 
8.4.3  Clinical Laboratory Assessments:  
Safety laboratory assessments will be carried out at UNC , Duke, or local Lab Corp and evaluated 
by [CONTACT_429448]. The investigator  is responsible for reviewing the 
results of all laboratory tests as they become available.  
a. Laboratory values that fall outside of a clinically accepted reference range or differ significant from previous values must be evaluated for clinical significance by [CONTACT_978] (or 
designee). The PI (or designee) may repeat the laboratory test or request additional tests to 
verify the results of the original laboratory tests.  
b. If the PI (or designee) determines the laboratory value to be of clinical significance for th at 
participant, it is considered an AE.  
c. Generally, Grade 1 and Grade 2 laboratory findings need not be reported as AEs unless deemed clinically significant by [CONTACT_978] (or designee).  
d. Consistent with the DAIDS designation of Grade 3 events as severe or medi cally significant 
and Grade 4 events as life-threatening, Grade 3 and Grade 4 laboratory findings should be reported as AEs or SAEs, as appropriate.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543523] result or finding should be reported as the AE. Such laboratory values should 
generally be recorded as “increased” or “decreased” (e.g., change from baseline potassium of 5.0 to 3.5 mEq/L = potassium decreased). 
9 C LINICAL MANAGEMENT  
9.1 Toxicities  
Adverse events will be graded according to the DAIDS AE Grading Table . The PI (or designee) 
is responsible for appropriate reporting of AEs to the regulatory authorities. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 88 of 143 
 
 Table 21  Expedited  Reporting Guidelines   
Entity  
(Notification Method)  Protocol Team  
(Email1) SMC  
(Email)  NIH DAIDS and 
DAIDS MO  
 University of 
Oxford  
(Email)  UNC IRB  
(PRI)  FDA2  
Personnel Responsible for 
Reporting  Site PI  [INVESTIGATOR_429376] 3 AEs (including 
local or systemic reactions)  Within 24 hours of site 
awareness  
(report again within 24 
hours if AE does not return 
to ≤G2 after 14 days)  As determined per 
protocol team  
(report again within 24 
hours if AE does not 
return to ≤G2 after 14 
days)    
  
Grade 4 AEs (including local or systemic reactions)  Within 24 hours of site 
awareness  
(report again within 24 
hours if AE does not return 
to ≤G2 after 14 days)  Within 24 hours of 
protocol team awareness  
(report again within 24 
hours if AE does not 
return to ≤G2 after 14 
days)  Within 3 days of site 
awareness  Within 3 days of site 
awareness  Report according to 
UNC IRB  Promptly 
Reportable Information 
SOPs (SOPs 1401, 
1402)  Report according to 
FDA requirements for 
IND reporting  
Grade [ADDRESS_543524] possibly related to study treatment  Within 24 hours of site 
awareness  Within 24 hours of 
protocol team awareness  Within 3 days of site 
awareness  Within 3 days of site 
awareness  Report according to 
UNC IRB Promptly 
Reportable Information 
SOPs (SOPs 1401, 
1402)  Report according to 
FDA requirements for 
IND repor ting 
AESIs  Within 24 hours of site 
awareness  
(AESI Clotting Form)   Within 24 hours of site 
awareness  Within 24 hours of 
site awareness  Within 3 days of site 
awareness  Report according to 
UNC IRB Promptly 
Reportable Information 
SOPs (SOPs 1401, 
1402)  Report according to 
FDA requirements for 
IND reporting  
SAEs  NOT related to 
study treatment  Within 24 hours of site 
awareness  As determined per 
protocol team  Within 3 days of site 
awareness  Within 3 days of site 
awareness   
 Report according to 
FDA requirements for 
IND reporting  
S[LOCATION_003]Rs  
(SAEs at least possibly 
related to study treatment)  Within 24 hours of site 
awareness  Within 24 hours of 
protocol team awareness  Within 3 days of site 
awareness  Within 3 days of site 
awareness  Report according to 
UNC IRB Promptly 
Reportable Information 
SOPs (SOPs 1401, 
1402)  Report according to 
FDA requirements for 
IND reporting  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 89 of 143 
 
 1 Email the protocol team at [EMAIL_8188] .    
2 Reference IGHID [ZIP_CODE] CQ MP for additional details.  Report according to FDA requirements for IND reporting: https://www.fda.gov/drugs/investigational -new-drug-ind-application/ind -
application- reporting -safety -reports  
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543525]  
may complete study treatment at the discretion of the site PI. Grade 1 or Grade 2 AEs that may 
be related to the vaccine/placebo injection will be handled according to standard clinical practice and documented. The adverse event will be monitored  closely .  
9.1.2   Grade 3 and Grade 4  Toxicities  
For participants who develop a Grade 3 or Grade 4 AE following administration of 
vaccine/placebo , the site PI [INVESTIGATOR_429377] [ADDRESS_543526] 
until:  
• Written consultation and approval from the study PI (and SMC, as needed)  
• The AE has returned to baseline or ≤ Grade 2 and determined clinically stable by [CONTACT_7880] (or designee).  
If any grade 3 AE has not returned to baseline or ≤ Grade [ADDRESS_543527] for the participant . 
If a participant develops a Grade 4 AE not related to study treatment, the participant may not 
receive further study produc t until:  
• Written consultation and approval from the study PI (and SMC, as needed)  
• The AE has returned to baseline or ≤ Grade 2 and determined clinically stable by [CONTACT_47808] (or designee).  
Ideally, the booster vaccination is administered within 30 days of the Day 28 visit window but 
can be delayed up to 60 days after Day 28 visit window 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 91 of 143 
 
 9.2 AESI  
9.2.1  Potential  blood clots  AESIs and Thrombosis with Thrombocytopenia 
Syndrome (TTS)  
A high index of suspi[INVESTIGATOR_429378] (TTS), after  
receiving vaccine/placebo on study . The PI [INVESTIGATOR_429379] . Signs and symptoms include : shortness of breath ; chest pain ; blurred vision  or 
other vision changes; swelling, pain or erythema in a limb; severe or p ersistent abdominal pain; 
nausea or vomiting ; dizziness ; mental status changes; s eizure, severe or persistent headache; easy 
bruising and/or bleeding ; microhemorrhage  beside the site of vaccination. If a participant 
experiences new onset (acute or subacute) symptoms listed above, there should be prompt evaluation, and consideration of prompt imaging to evaluate for the diagnoses listed below and hematolo gy consultation. Associated diagnoses include: 
• Deep vein thrombosis (DVT) – symptoms depend on location of thrombosis such as: swelling, pain, warmth of an extremity; headache, visual disturbances, seizures for sinus vein thrombosis; abdominal pain for intraabdominal thrombosis 
• Pulmonary thromboembolism – sudden onset of shortness of breath, pleuritic chest pain, sudden death/pulseless electrical activity arrest  
• Stroke or cerebral venous sinus thrombosis  
• Myocardial infarction  
• Arterial thrombosis  
Initial evaluation should include the following:  
• CBC with manual count 
• D-dimer  
• PT/INR  
• PF4 antibody ELISA 
• Fibrinogen 
For any suspected TTS, WITHOLD further doses of vaccine/placebo until diagnostic evaluation 
has been completed and etiology of the signs and symptoms has been determined.  
In cases of concern for TTS, see Appendix 5 for a recommended testing algorithm. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 92 of 143 
 
 For this study, Vaccine-induced immune thrombotic thrombocytopenia (VITT) will be defined as 
the following: 
• Platelet count <150 x 109/L with a  confirmatory peripheral smear showing reduced 
platelets with no evidence of clumpi[INVESTIGATOR_007] (that could indicate falsely low platelet 
count) 
• Presence of thrombosis/thromboembolism (refer to the list of MedDRA Preferred Terms proposed by [CONTACT_6750]; See Appendix 6) confirmed by: 
1) Imaging (i.e. ultrasound, CT scan, magnetic resonance imaging or venography or 
arteriography, echocardiogram, perfusion V/Q scan, conventional angiography, etc) 
2) Surgical Procedure (confirming presence of thrombus), i.e. thrombectomy 
 Pathologic examination, i.e. biopsy or autopsy 
 PFA antibody positive 
Study staff will complete an AESI clotting form using the list of MedDRA Preferred Terms 
(Appendix 6) to ensure complete documentation of the event. 
If evaluation provides evidence that TTS is unlikely, it is important to document the scientific evidence for and treat per standard clinical practice. Participants may continue study procedures unless clinically contraindicated.  
If TTS is confirmed or probable, the participant should not receive additional vaccine/placebo, but should be followed for safety per the SOA and as clinically indicated. See Section 9.[ADDRESS_543528] commonly based on clinical symptoms.  
If a participant experiences new onset (acute or subacute) motor or sensory disturbances (i.e., weakness, numbness, dysarthria, dysphagia, paresthesias, hypoesthesia, hyperesthesia, 
dysesthesias), bowel/bladder dysfunction, gait impairment, visual disturbance, or any event of myelitis, encephalomyelitis, transverse myelitis, or other sudden neurological deficit, there should be prompt neurological evaluation, including referral to a neurology specialist for further evaluation , testing and treatment, as clinically indicated. In cases of concern for spi[INVESTIGATOR_429380], see Appendix 4 for a recommended testing algorithm which would be shared with 
providers caring for the participant. 
For new onset neurological symptoms, proceed with the following: 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 93 of 143 
 
 • WITHHOLD furth er doses of vaccine/placebo until clinical and laboratory 
evaluation are completed and etiology of the symptoms or laboratory abnormalities 
are defined  
• Consultation with neurology immediately  
If neurological disease is confirmed or probable, the participant should not receive additional vaccine/placebo, but should be followed for safety per the SOA and as clinically indicated. See Section 9.5 for expedited reporting as an AESI.  
9.2.3   Delayed Dose  
In the event of acute illness or inability to return for Day 28, the booster vaccination can be delayed . The booster vaccine should ideally b e given within 30 days after the Day 28 visit 
(booster vaccine dose) but can be extended up to [ADDRESS_543529] been met:   
1. Study treatment related Grade ≥ 1 AE  
2. Grade ≥ 2 AEs  
3. Autoimmune- related AEs regardless of grade  
4. MAAEs regardless of grade  
5. AESIs regardless of grade  
6. HIV viral loads ≥ 50 copi[INVESTIGATOR_014]/mL 
7. Injection R eactions regardless of grade  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 94 of 143 
 
 8. AEs that led to a change in study treatment/intervention regardless of grade 
9. AEs meeting SAE definition  
 
9.3.1   Local or Systemic Reactions to Vaccine/Placebo Injections  
[IP_ADDRESS]  Grade 1 or 2  
Local reactions of Grade 1 or Grade 2 severity will usually resolve spontaneously. If needed, 
they may be managed with local application of cold packs, oral acetaminophen, oral non-
steroidal anti-inflammatory agents, or a combination of these measures as appropr iate. 
NOTE: Topi[INVESTIGATOR_429381]. 
[IP_ADDRESS]  Grade 3 or 4  
Grade 3 or Grade 4 local reactions  (Table 9  and Table 11) should be reported as described in 
Table 21  (AESI per definition in Section 8.3.4) . For Grade 4 local reactions, notify site PI [INVESTIGATOR_429382] (or Emergency response team, as appropriate) as definitive medical and/or 
surgical intervention should be undertaken as appropriate.  
Grade 3  and Grade 4  systemic reactions ( Table 10  and Table 12 ) should be reported as described 
in Table 21 . The common systemic adverse events usually seen with ChAdV- vectored vaccines  
and MVA- vectored vaccines are listed in  Section  2.3.2 ( Table 9 , Table 10 , Table 11 , and Table 
12). These events usually occur within [ADDRESS_543530] 
vaccination will be mild in intensity. However, there is a possibility of moderate or severe 
headache or malaise.  
[IP_ADDRESS]  Injection Site Reaction  
Injection Site Erythema or Redness and Injection Site Induration or Swelling will not be considered an AE if there is no interference with usual social and f unctional activities such that:  
1. Grade 1: 2.5 to < 5 cm in diameter OR 6.25 to < 25 cm
2 surface area;  
2. Grade 2: ≥ 5 to < 10 cm in diameter OR ≥ 25 to < 100 cm2 surface area;  
3. Grade 3: ≥ 10 cm in diameter OR ≥ 100 cm2 surface area OR Ulceration OR Secondary 
infection OR Sterile abscess OR Drainage;  
4. Grade 4: Potentially life -threatening consequences (e.g., abscess, exfoliative dermatitis, 
necrosis involving dermis or deeper tissue) 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543531] all allergic and hypersensitivity reactions with both grade severity and attribution.  
Serious allergic or hypersensitivity reactions (≥ Grade 3) that are deemed possibly related to the study treatment by [CONTACT_978] (or designee) will be reported as described in Table 21  and as detailed 
at 
https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting- safety -
reports .  
9.3.3   Monitoring HIV RNA levels  
In the event of viremia of ≥ 50 copi[INVESTIGATOR_014]/mL the following should occur per standard of care: 
a. Adherence to A RT should be carefully assessed and documented.  
b. A standard HIV RNA assay should be repeated within 1- 4 weeks.  
c. HIV resistance testing will be performed at the time of drawing a confirmatory sample and as indicated for persistent viremia. 
d. For HIV RNA confirmed >200 copi[INVESTIGATOR_014]/mL on repeat testing, stored samples may be tested 
for the presence of one or more ARV drugs in the participant’s regimen. 
e. HIV RNA will be repeated every 2 weeks, or sooner as clinically indicated, until <50 copi[INVESTIGATOR_014]/mL and the particip ant can continue on study. 
f. In the event of confirmed viremia and documented adherence to ART, ART should be managed by [CONTACT_356509]. The results of the HIV resistance tests will be shared with the participants  and their care providers.  
The protocol t eam will monitor the conduct and safety of the study via monthly meetings and 
regular summaries. Accrual, baseline characteristics, conduct of the study (including premature study discontinuations), any interruptions of ART, virologic failures, and all reported toxicities and events will be monitored during the study and discussed monthly with the protocol team or more frequently, if needed.  
The protocol team will review the individual safety data monthly to assess relation of all reported 
toxicities and AEs to th e study treatment. A study unique independent Safety Monitoring 
Committee (SMC) will receive quarterly  study progress and safety monitoring reports. Study 
feasibility and the achievement of study milestones will be assessed in these reports.  The DAIDS 
program and medical officers will review and assess the monthly safety reports, as well as SAE  
reports for potential impact on the study participant safety and protocol conduct as per DAIDS 
policies, guidance documents, and SOPs, as applicable. 
9.[ADDRESS_543532] possibly related to study treatment will be considered unexpected and be 
reported as S[LOCATION_003]Rs within the regulatory timelines  outlined in Table 21 .  
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543533] abilization  recorded in the source 
documents. In addition, the investigator should report all follow-up for reportable SAEs to the UNC IRB. Resolution of an event is defined as the return to pre- treatment status or stabilization 
of the condition with the e xpectation that it will remain chronic.  
All SAEs determined as  possibly related to the vaccine/placebo that have not resolved by [CONTACT_429449], or that have not resolved upon discontinuation of the participant's participation in the study, must be followed until any of the following occurs: 
1. The event resolves.  
2. The event stabilizes.  
3. The event returns to baseline, if a baseline value/status is available.  
4. The event can be attributed to etiology other than the vaccine/placebo or to factors unrelated 
to study conduct. 
5. It becomes unlikely that any additional information can be obtained (participant’s or health care practitioner’s refusal to provide additional information, or lost to follow- up after 
demonstration of due diligence with follow- up efforts)  
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the 
course of a participant's participation in a study must be reported as an SAE, except hospi[INVESTIGATOR_23741]: 
1.  Hospi[INVESTIGATOR_429383] (e.g., social reasons 
such as pending placement in long- term facility)  
2. Surgery or procedure planned before entry into the study (must be documented in the source 
document) 
The protocol PI (or designee) will be responsible for notifying the UNC IRB, FDA, the 
University of Oxford, and DAIDS of any unexpected fatal or life-threatening SAEs  as soon as 
possible, but in no case later than the timelines described in Table [ADDRESS_543534] 
notify the FDA in an IND safety report of potential serious risks, from clinical trials or any other 
source, as soon as possible, but in no case later than 15 calendar days after the  sponsor 
determines that the information qualifies for reporting . 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 97 of 143 
 
 9.5 AESI reporting 
If an AESI occurs , the study coordinator, in collaboration with the site PI [INVESTIGATOR_1461], will 
evaluate the severity and seriousness of the AE and the relationship to the study treatment, and 
will document the findings. The protocol team should be contact[CONTACT_11252] 24 hours of notification of any AESIs (reference Section 8.3.4 ). 
All AESIs  occurring during the study must be reported to the UNC IRB per the UNC IRB 
reporting requirements. A written report will be submitted to the DAIDS MO  and the IRB  
within [ADDRESS_543535] be reported using the same reporting process as for SAE reporting.  
9.6 Other Reporting Situations  
9.6.1   Reporting to DAIDS  
The Protocol Team will be responsible for reporting to DAIDS the following information via 
email to DAIDSRSCSafetyOffice@tech -res.com .  
a. Monthly listing of all AEs within [ADDRESS_543536] of each month . 
b. Monthly Line listing of SAEs including suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs)  within [ADDRESS_543537] regular (annual or more 
frequent) presentations with the local and national HIV-infected and affected community. Due to 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543538] had no relevant or study- related SA Es to report. 
We would inform all study participants by [CONTACT_429450].  
9.6.3   Reporting of Pregnancy  
If the participant becomes pregnant during the study, vaccine/placebo will not be administered. Although not considered an adverse experience, it is the responsibility of investigators or their designees to report any pregnancy in a participant or participant’s partner (spontaneously reported to them) that occurs during the study or within [ADDRESS_543539] be followed to the completion/termination of the pregnancy. If the pregnancy continues to term, the outcome (health of infant) must also be reported the UNC IRB, the DAIDS Medical Officer, and the FDA 
(US Food and Drug Administration). 
If a male participant impregnates his partner while he is participating in this study, the pregnancy 
must be reported and the study PI (or designee) should make a concerted eff ort to follow the 
pregnancy and outcome. The study PI (or designee) will make every effort to obtain a medical release and a separate pregnancy outcome consent from the pregnant partner granting permission to follow the health of both the pregnant partner and her unborn child to the UNC IRB, DAIDS, study product sponsor, and FDA without delay and within 24 hours if the outcome is an SAE (e.g. death, abortion, congenital anomaly, or other disabling or life- threatening complication to 
the mother or newborn). 
Pregnancy and pregnancy outcome will be recorded. Pregnancies that occur on study should be 
reported prospectively to the Antiretroviral Pregnancy Registry. More information is available at www.apregistry.com. Telephone: [PHONE_894]; Fax: [PHONE_8928].  
9.6.[ADDRESS_543540] should be obtained. If pregnancy is confirmed, then further study treatment will be discontinued and the woman should continue on study (off study product) safety follow-up visits as noted in the SOE. Stored plasma/PBMC for stored plasma for virologic studies sh ould not be obtained to minimize blood 
volume. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543541] her regarding pregnancy outcomes at the end of pregnancy. A visit 6 months following the end of pregnancy will be conducted to assess for evidence of adverse events (AEs) in the participant and infant and documented. 
9.6.[ADDRESS_543542] quality complaint (PQC) is any written, electronic or oral communication that states 
possible deficiencies of a study product related to manufacturing, labeling, or packaging, i.e., any 
dissatisfaction relative to the identity, quality, durability, or reliability of a product, including its labeling or package integrity. A PQC may have an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and analysis of PQC information from studies is crucial for investigators, the manufacturer and IND sponsor UNC, and for the protection of the participants’ rights, welfare and well -being; a nd is mandated by [CONTACT_67819]. 
UNC has established procedures in conformity with regulatory requirements to ensure appropriate reporting of PQC information and all trials will be conducted in accordance with those procedures. 
All initial PQCs must be reported to DAIDS by [CONTACT_1758] -site personnel  within [ADDRESS_543543] report the PQC to 
DAIDS the sponsor according to the SAE reportin g timelines (refer to Section  9.4, S AEs). A 
sample of the suspected product should be maintained under correct storage conditions for 
further investigation if request ed by [CONTACT_106898] . 
UNC must report any self -identified or site personnel-reported PQC to DAIDS within one 
business days of being made aware of the complaint and include notifications regarding immediate action taken.  
9.7 New Safety Information  
9.7.1   Definition of New S afety Information ( NSI) 
The Office for Human Research Protections (OHRP) considers new safety Information  involving 
risks to participants or others as NSI and this includes, in general, any incident, experience, or outcome that meets all of the following criteria:  
1. Unexpected in terms of nature, severity, or frequency given (a) the research procedures/study treatment that are described in the protocol- related documents, such as the IRB -approved 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 100 of 143 
 
 research protocol, the informed consent document, and IB; and (b) the characteristics of the 
participant population being studied. 
2. Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_356512]/treatment involved in the research); and 
3. Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
4. Please reference the UNC Office for Human Research Ethics SOP 1401 to address  Promptly 
Reportable Information. This SOP provides definitions and procedures for the reporting 
promptly reportable information to the UNC- Chapel Hill IRB.  
9.8 NSI Reporting  
The investigator will report NSI to the UNC IRB. The NSI report will include the following information: 
1. Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number. 
2. A detailed description of the event, incident, experience, or outcome.  
3. An explanation of the basis for determining that the event, incident, experience, or outcome represents an NSI;  
4. A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the NSI. 
To satisf y the requirement for prompt reporting, NSI reports will be reported using the following 
timeline:  
1. NSI that are SAEs will be reported to the IRB and the DAIDS MO within 3 business days of the investigator becoming aware of the event.  
2. Any other NSI will b e reported to the IRB and to the DAIDS MO within 7 business days of 
the investigator becoming aware of the event.  
3. All NSI should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written reporting procedures), the NIH MO (or designee), and the OHRP within 30 business days of the IRB’s review and determination that the report of the problem from the investigator imposed a safety risk. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 101 of 143 
 
 9.9 Reporting NSI to Participants  
We would inform all study participants by [CONTACT_429451].  
10 STATISTICAL CONSIDER ATIONS   
10.1 Statistical Hypotheses 
1. Vaccination with either C62 -M4 or C1C62- M3M4 will be safe and well tolerated  
2. Both C62-M4 and C1C62- M3M4 vaccination will increase the frequency of circulating HIV -
specific T cells  
3. C1C62- M3M4 will induce a greater breadth of T cells targeting conserved regions of HIV 
than C62- M4 
 
10.2 Endpoints  
Primary Safety  Endpoint:  
• Occurrence of at leas t one ≥ Grade 3 Adverse Event (AE) including signs/symptoms, lab 
toxicities, and/or clinical events, that is possibly or definitely related to study treatment any time from the first day of treatment (D0) through [ADDRESS_543544] vaccination or D56. 
Secondary Efficacy Endpoint(s): 
• Occurrence of any ≥ Grade 1 AE including signs/symptoms, lab toxicities, and/or clinical 
events, that is possibly or definitely related to study treatment any time from the first day of treatment (D0) through D1 96 (Week 2 8). 
Secondary Immunogenicity Endpoint(s): 
• Relative change in magnitude of T cell responses to HIV -1 conserved regions from baseline 
(before C62 or C1C62 vaccination) to post-boost vaccination at D35 and D42. 
• Change in breadth of T cell responses targeting HIV conserved regions from baseline (before 
C62 or C1C62 vaccination) to post-boost vaccination at D56. 
10.3 Sample Size  Determination  
The proposed number of 8 vaccinee s per arm and 2 placebo controls was determin ed to be 
sufficient to evaluate the risk of common SAEs or severe local or systemic reactions based on 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 102 of 143 
 
 early phase trials of  simian adenovirus- and MVA- vectored vaccines, given alone or serially (59, 
64, 92-94, 97, 121, 125-128, 136-139).  
Enrollment into the trial will be suspended if two or more participants experience a study 
treatment -related AE of Grade [ADDRESS_543545] one-sided binomial 95% upper 
confidence limit for the probability of a safety event will be 31%. If one participant experiences a safety event, the corresponding one-sided 95% upper confidence limit will be 47%. If no safety events are observed in the two vaccine arms and data is pooled across arms (n=16), then the exact one-sided 95% upper confidence limit will be 17%. 
10.4 Procedure for missing and invalid data  
There is very little missing or invalid data in our concurrent study using MVA- vectored vaccines 
([STUDY_ID_REMOVED]; IND [ZIP_CODE]), so it is anticipated that this study will be similar. Due to the small 
sample size, formal imputation methods will not be used. However, if there is concern that key findings are sensitive to missing data, missing values can be replaced with the best (worst) rank 
in the C62 -M4 arm and the wor st (best) rank in the C1C62 -M3M4  arm to determine if findings 
are sensitive to missingness.  
Safety analyses will include all evaluable participants regardless of whether they are replaced or missing for additional endpoints. In order to achieve the planne d evaluable sample size, 
participants who do not receive both sets of vaccines at D0 and D28 will be replaced. 
10.5 Study Duration and Accrual  
Participants will be screened approximately 60 days prior to vaccination and will be followed for 
196 days after vaccination. The total study duration from screening to completion of follow-up 
per participant will be approximately 36 weeks ( approx imately  9 months). Given the focus of 
this study is on safety and potential adverse events, accrual will be staggered such that a maximum of up to 2 participant s per week will receive the Day 0 vaccination .   
10.6 Randomization 
Following enrollment, the 18 study participants will be randomly assigned to receive vaccination with either C62-M4 (n=8), C1C62 -M3M4  (n=8), or  placebo (n=2) through a double-blinded, 
randomized block design. As detailed in ( Section 7.2.1), participants who do not receive both 
sets of vaccines at D0 and D28 will be replaced. In cases such as these, the unblinded statistician will generate a new randomization ID that will serve as a replacement for the investigational product assigned to the dropout.   
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543546] methods that do not rely on large sample assumptions will be used for statistical inference and presented with descriptive statistics and/or data visualization. When 
feasible, graphs will present data at the participant -level with summary statistics. Emphasis will 
be placed on descriptive summaries and estimated effect sizes.  
For inferential tests, a significance level of 0.[ADDRESS_543547] scientifically meaningful effects at a significance level of 0.05. Since this is a small study with multiple exploratory endpoints, adjustment for multiple hypothesis tes ting will not be performed. Results should be interpreted 
within the context of the protocol- defined eligibility criteria and the target population available 
and willing to participant in this double-blinded, placebo- controlled, randomized clinical trial.  
10.7.2  Analysis of the Primary Safety Endpoint(s)  
The probability of a primary safety event (≥ Grade 3 AE) from D0 through D56 ( or 28 days 
following the second vaccination) will be estimated with a proportion and corresponding one-sided exact binomial 95% upper c onfidence limit. These estimates will be calculated separately 
for C62 (D0) followed by M4 (D28) and C1C62  (D0) followed by M3M4  (D28) in PWH  on 
ART.  
NOTE: The occurrence of a Grade 3 elevated blood pressure during a study- related 
leukapheresis that resolv es following completion of the procedure will not be included as a 
primary safety endpoint. 
10.7.3  Analysis of the Secondary Safety  Endpoints  
The probability of a secondary safety event (≥ Grade 1 AE) from D0 through D196 will be 
estimated with a proportion and corresponding one-sided exact binomial 95% upper confidence limit. These estimates will be calculated separately for C62 ( D0) followed by M4  (D28) and 
C1C62 (D0) followed by M3M4  (D28) in PWH on ART. 
 
NOTE: Safety  events  include i ncidence and grade  of all  reportable unsolicited  and solicited  
adverse events  including SAEs, MAAEs, and AESIs post first dose of C1 and/or C62 through 
Day 1 96. 
 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 104 of 143 
 
 10.7.4  Analysis of Secondary Immunogenicity  Endpoints  
[IP_ADDRESS]  T cell magnitude  
To evaluate changes in HIV -1 epi[INVESTIGATOR_9230]- specific CD8+ T cell responses detected in IFN -γ ELISpot 
assays from baseline (pre -vaccination) to post-boost vaccination (D35 and D42), the relative 
change within participants will be estimated using a geometric mean ratio (GMR , also known as 
fold change ) and evaluated with an exact two -sided Wilcoxon signed-rank test for within- arm 
comparisons and an exact two -sided Wilcoxon rank- sum test for between -arm comparisons. The 
Wilcoxon signed- rank test assumes symmetry of the change in natural log -transformed summed 
HIV-1 specific T cell response (estimated by [CONTACT_429452]) under the null. If this assumption is violated, 
then a sign test will be conducted as a sensitivity analysis.  
[IP_ADDRESS]  P ower Calculations  
To compute power for a continuous covariate, such as T cell magnitude, a meaningful effect size 
must be determined ahead of time. Comparing T-cell responses within participants, an average fold change of at least 2 (GMR ≥ 2) is anticipated to be scientifically meaningful. Baseline HIV-specific T cell  responses from HIV- infected durably -suppressed PWH  (53) were used to inform 
power calculations. A between -participant standard deviation of 0.[ADDRESS_543548]-vaccine measurements, using 10,000 simulated datasets for 
n=8 participants provides 87% power to detect a GMR of 2 or greater. For a smaller within -
participant correlation of 0.8, there is >95% power to detect a GMR of 2 or greater. 
[IP_ADDRESS]  T cell Breadth 
To evaluate change in breadth in the number of T cell responses targeting HIV -conserved 
regions from baseline ( pre-vaccination) to post-vaccination (D56),  
an exact two -sided Wilcoxon signed- rank test will be used for within -arm comparisons and an 
exact two -sided Wilcoxon rank- sum test will be used for between -arm comparisons. 
.  [IP_ADDRESS]  P ower Calculations  for T cell Breat h 
Baseline HIV -specific T cell breadth from durably -suppressed PWH  were used to inform power 
calculations (50). In this study, reactive H IV T cell epi[INVESTIGATOR_429384] (Clade B 
consensus and autologous reservoir virus) were defined in 25 PWH  on ART.  
For the C62 -M4 and C1C62 -M3M4  arms , we anticipate that vaccination will induce a change of 
breadth (the detection of a new reactive T cell epi[INVESTIGATOR_9230]) ranging from 0 -3 epi[INVESTIGATOR_429385] 2-6 
epi[INVESTIGATOR_322], respectively.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 105 of 143 
 
 • We anticipate that C62-M4 will induce a change in breadth with the following frequen cy 
distribution: 0 (20% of participants), 1 (50%), 2 (20%), and 3 (10%).  
• We anticipate that C1C62 -M3M4  will induce a change in breadth with the following 
frequency distribution: 2 (30% of participants), 3 (40%), 4 (15%), 5 (10%), and 6 (5%).  
Given these assumptions, n=8 evaluable participants per treatment arm provides 95% power to 
detect a difference between arms using an exact two -sided Wilcoxon rank-sum test (at a 0.05 
significance level).  
10.7.5  Safety Analyses  
For the safety endpoints, we will describe all study treatment-related AEs through D56 (primary 
endpoint) and the end of study at D196 or 24 weeks  following the second vaccination (secondary 
endpoint). AEs will be coded per the Medical Dictionary for Regulatory Activities (MedDRA). Events prior to treatment (e.g., due to study- related procedure) will be listed separately in an 
appendix to the final clinical study report. The following tables of AE data will be created to summarize the number and percent of participants who experience at least one event of each of the following types:  
• Study treatment -related AEs by [CONTACT_86953]  
• All SAEs (this may be a listing if there are few events)  
• Study treatment -related SAEs  
• Fatal AEs (this may be a listing if there are few events)  
• AEs that result in study discontinuation or study treatment discontinuation 
• AESI s 
• MAAEs  
• AEs with severity Grade 3 or greater  
• Study treatment -related AEs with severity Grade 3 or greater  
• All treatment- related AEs with severity Grade 1 or greater  
All of these tables will display the  number and percent of participants that experience the given 
event and will display events by [CONTACT_1196] (SOC) and Preferred Term (PT). Events 
will be displayed alphabetically for SOC and in descending order of overall PT incidence within each SOC . 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 106 of 143 
 
 10.7.6  Baseline Descriptive Statistics  
Participant data will be summarized using the following baseline characteristics: gender, 
ethnicity, race (% Hispanic or Latino), onset of ART (number of acute versus chronic), age, CD4 nadir, and years of ART suppression. 
10.7.7  Planned Interim Analyses  
There are no planned formal interim analyses.  
10.7.8  Tabulation of Individual participant  Data  
Individual participant data will be listed by [CONTACT_8707].  
10.7.9  E xploratory Analysis  
Other objectives or exploratory analysis can be grouped into additional immunological measures 
and virologic measures. [IP_ADDRESS]  I mmunologic Measures  
Kinetic data will be analyzed by [CONTACT_429453]. Other observed 
immunologic measurements, such as virus inhibition, may not be norma lly distributed or may be 
partially censored due to assay limits of quantification  (LoQ) . Thus, an exact two-sided 
Wilcoxon signed-rank test will be used for within-participant comparisons. If the assumption of symmetry of differences (required for the Wilcoxon signed-rank test) is violated, then a sign test will be conducted as a sensitivity analysis. For censored data, we will impute half the limit of detection.  
[IP_ADDRESS]  V irologic Measures  
Virologic measures such as cell -associated HIV -1 RNA will be log -transformed prior to 
analyses. The analysis method chosen for plasma HIV -1 RNA SCA will depend on the number 
of results that fall below the assay limit of quantification. For example, if a substantial fraction (~50%) are below the assay limit of quantification, the analysis will focus on estimating the proportion of participants with SCA above the LoQ at various time points and comparison between arms will use Fisher’s exact test. Otherwise, changes within participants will be summarized and compared between arms using Wilcoxon rank- sum tests.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 107 of 143 
 
 11 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
11.1 Regulatory, Ethica l, and Study Oversight Considerations  
11.1.1  Informed Consent Process  
[IP_ADDRESS]  Consent  and Other Informational Documents Provided to Participants  
Consent forms describing in detail the study intervention, study procedures, and risks are given 
to the participant and written documentation of informed consent is required prior to any screening procedures and prior to starting study intervention/administering study intervention.   
[IP_ADDRESS]  Consent Procedures and Documentation  
Informed consent is a process initiated prior to individuals agreeing to participate in the study 
and continues throughout the individual’s study participation. The consent forms are UNC IRB -approved and the participant will be asked to read and review the document. The study investigator (or designee) and/or study coordinator will explain the research study to the participant and answer any questions that may arise. A verbal explanation will be provided in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have the opportunity to carefully review the written consent form  and ask questions prior to signing. The participants are 
provided the opportunity to discuss the study with their family, primary care provider, or significant other or to just think about the study and its requirements prior to agreeing to participate. T he participant signs the informed consent document prior to any procedures being 
done specifically for the study. Participants are informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the informed consent document will be given to the participants.  
The informed consent process will be conducted and documented in the source document, and 
the consent form signed, before the participant undergoes any study- specific procedures. The 
study P I (or designee) or the research coordinator will inform participants that the quality of their 
medical care will not be adversely affected if they decline to participate in this study, thus emphasizing the protection of the rights and welfare of the participants. 
11.1.2  Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause.  Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_21224], funding agency (NIH), the FDA, the University of Oxford, and the UNC IRB. If the study is prematurely terminated or suspended, the study PI (or designee) will promptly inform study participants, the UNC IRB, and DAIDS and will provide the reason(s) for the termination or 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 108 of 143 
 
 suspension.  Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to 
the study visit schedule. 
Circumstances that may warrant termination or suspension include but are not limited to:  
1. Determination of unexpected, significant, or unacceptable risk to participants 
2. Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]    
3. Insufficient compliance to protocol requirements 
4. Data that are not sufficiently complete and/or evaluable  
5. Determination that the primary endpoint has been met 
6. Determination of futility  
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the sponsor, the UNC IRB, DAIDS, and/or the Food and Dr ug 
Administration (FDA).  
11.[ADDRESS_543549] by [CONTACT_3486], their study staff, and the sponsor(s)/funding source(s) and their representatives. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information 
concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor, representatives of the UNC 
IRB, regulatory agencies, or pharmaceutical company supplying study product may inspect all documents and records required to be maintained by [CONTACT_9154], including but not limited to, medical records and IDS pharmacy records for the participants in this study. The clinical study 
site will permit access to such records.  
The study participants’ contact [CONTACT_429454]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor requirements. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 109 of 143 
 
 Study participant research data,  which is for purposes of statistical analysis and scientific 
reporting, will be stored at the Goonetilleke Laboratory located on the campus of UNC  in Chapel 
Hill. This will not include the participants’ contact [CONTACT_1290]. Rather, individual 
participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_429455] p rotected. At the end of the 
study, all study databases will be de -identified and archived. 
11.2.[ADDRESS_543550] access to research records to refuse to disclose identifying information on research participation in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or local level. By [CONTACT_429456] s, Certificates of Confidentiality help achieve the  research objectives and 
promote participation in studies by [CONTACT_4205][INVESTIGATOR_411621].  
11.3 Future Use of Stored Specimens  and Data   
Data collected for this study will be analyzed and stored at the Goonetilleke Laboratory at  UNC, 
Chapel Hill. After the study is completed, the de -identified, archived data will be stored in the 
UNC Database, for use by [CONTACT_429457]. 
Permission to transmit data to researchers outside the study collaboratory team will require review and approval by [CONTACT_206549]. In some circumstances, we will need to obtain additional consent from participants to share samples collected for the purpose of this study.   
With the participants’ approval and as approved by [CONTACT_206549], de- identified biological 
samples will be stored at the Goonetilleke Laborator y on the campus of UNC Chapel Hill. These 
samples could be used to research the causes of HIV cure for which individuals with HIV 
infection can greatly benefit. These samples may also be used for genetic testing. The Goonetilleke Research Laboratory will also be provided with a code- link that will allow linking 
the biological specimens with the phenotypic data from each participant, maintaining the blinding of the identity of the participant.  
During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens stored for future research. However, withdrawal of consent with regard to biological sample storage may not be possible after the study is completed.  
When the study is completed, access to study data and/or samples will be provided through the Goonetilleke Laboratory.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 110 of 143 
 
 11.4 Key Roles  and Study Governance  
Provided in Table 22 are the key roles for the study governance. 
Table 22 Key Roles for Clinical Study  
Protocol Principal Investigator  [INVESTIGATOR_305641], MD, MPH  Nilu Goonetilleke, PhD  
Associate Professor, Medical Director HIV Cure 
Center  Assistant Professor, Dept. of Microbiology & Immunology/Medicine  
University of North Carolina at Chapel Hill  University of North Carolina at Chapel Hill  
[ADDRESS_543551] agents, and target population under study. 
During the trial, the SMC will review:   
1. Real-time and cumula tive safety data for evidence of study -related adverse events;  
2. Adherence to the protocol;  
3. Factors that might affect the study outcome or compromise the trial data (such as protocol 
violations, losses to follow-up, etc.). 
4. Review the achievement of enrollment benchmarks  
The SMC will receive quarterly  reports via email for review and comments. The SMC will be 
contact[CONTACT_156887] (and possibly via teleconferencing) for any event or situation that impacts participant safety throughout the study and specified interventions or study participation will be suspended or terminated dependent on the response of the SMC. 
The study will undergo review at least annually by [CONTACT_4484]. The SMC will review information 
on accrual, baseline characteristics, conduct o f the study (including premature study 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 111 of 143 
 
 discontinuations and premature study treatment discontinuations), AEs by [CONTACT_2939] 
(including protocol team assessment of relationship to study treatment), virologic failures, and HIV-1 RNA levels over time, and completeness of follow-up. 
11.5.1  Safety Pause  
Enrollment into the study and treatment injections will be temporarily suspended and the Study Monitoring Committee (SMC), unblinded to treatment assignment, will be asked to review all safety data. Review will includ e the relation to study treatment of the event(s) thought by [CONTACT_429458] a primary safety outcome, if any of the following occur: 
1. Two or more participants experience a primary safety outcome measure that is a Grade ≥3 
AE possibly related to study treatment (as judged by [CONTACT_356522], blinded to treatment arm); or  
2. One or more participants experience an SAE possibly related to study treatment (as judged by [CONTACT_356522], blinded to treatment arm).  
Following the review, the SMC will recommend  if and how the study should proceed with 
respect to resuming enrollment and continuing study treatment. 
11.6 Clinical Monitoring  
To ensure the safety of participants in the study, compliance with applicable regulations, and to 
ensure accurate, complete, and reliable data, the protocol PI [INVESTIGATOR_305647], clinical notes, and participant medical records in the participant files as source documents for the study.  
An independent study monitor will monitor the study on a regular basis throughout the study period according to the study monitoring plan. The protocol PI (or designee) will allocate adequate time for such monitoring activities. The study monitor periodically will conduct a review of a sample of the participant data recorded on source documents at the study site. The protocol PI (or designee) will also ensure that the monitor is given access to all the above noted study-related documents, source documents (regardless of media), and study- related facilities 
(e.g., IDS pharmacy, etc.), and has adequate space to conduct the monitoring visit. Queries may be raised if any datum is unclear or contradictory. The protocol PI [INVESTIGATOR_429386] a timely manner.  
Participation as an Investigator in this study imp lies acceptance of the potential for inspection by 
[CONTACT_356523], US or non-US government regulatory authorities, IRB, and applicable compliance and quality assurance offices. The protocol PI (or designee) will 
permit study -related audits and inspections and will provide access to all study- related 
documents (e.g., source documents, regulatory documents, data collection instruments, study data, etc.). The protocol PI [INVESTIGATOR_287131] -related 
facilities (e.g., IDS pharmacy, CTRC, etc.).  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543552] of this study include:  
1. Informing participants about risks so they can recognize and report harms in partnership w ith 
the study team;  
2. respecting local/national blood draw limits;  
3. direct observation of participants after vaccine/placebo administration and collection of 
information regarding side effects for several days post product administration; 
4. having study staff properly trained in administering study procedures that may cause physical harm or psychologic distress, such as blood draws and injections; and 
5. providing study monitoring. 
11.6.[ADDRESS_543553] Operating Procedures (SOPs) for quality management. Clinica l research 
files verify and insure that the clinical trial is conducted per protocol and that data is generated and biological specimens collected, documented (recorded), and reported in compliance with the protocol, International Conference on Harmonization Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., GLP, GMP). Data Quality is monitored per the data quality management plan with routine and specific research chart review.  
The study staff will be educated on the protocol and training will be provided as needed to implement protocol procedures. The study data management team will be responsible for addressing QA issues (e.g., correcting procedures that are not in compliance with the protocol) and QC issues (e.g., correcting errors in data entry). Documentation, as required, will be 
maintained in the regulatory files.  
UNC will provide direct access to all trial-related sites, source data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_287180], and inspection by [CONTACT_3482].  
11.6.[ADDRESS_543554]  Keepi[INVESTIGATOR_007]   
[IP_ADDRESS]  Data Collection and Management Responsibilities  
The clinical research staff is responsible for data collection under the supervision of the site study PI (or designee). The study PI (or designee) is responsible for ensuring the accuracy, 
completeness, legibility, and timeliness of the data reported.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543555] copi[INVESTIGATOR_429387].  Data recorded in the 
electronic case report form derived from source documents should be consistent with the data recorded on the source documents.  
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse 
reactions data) and clinical laboratory data will be entered into a UNC School of Medicine Database housed in Advarra Ele ctronic Data Capture (EDC) . EDC  includes password protection. 
Clinical data will be entered directly from the source documents.  
[IP_ADDRESS]  Study Records Retention  
Per ICH guidelines, all essential documents, including source documents (regardless of media), signed I CFs, and laboratory test results, should be retained by [CONTACT_9154] (or designee) for at 
least [ADDRESS_543556] elapsed since formal discontinuation of clinical development of the investigational products. 
11.7 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, International 
Conference on Harmonization Good Clinical Practice (ICH GCP), or Manual of Procedures (MOP) requirements. The noncompliance may be on the part of the participant, the investigators, or the study site staff. As a result of deviations, corrective actions will be developed and implemented promptly, when necessary.  
These practices are consistent with ICH GCP:  
It is the responsibility of the site PI (or designee) to use continuous vigilance to identify and 
report deviations at the annual renewal of the protocol, provided there is no impact on participant safety as a result of the deviation. All deviations must be addressed in study source documents. Protocol deviations are sent to the UNC IRB per their policies. The site PI [INVESTIGATOR_356470]. Further details about the handling of protocol deviations will be included in the SOP. 
11.8 Publication and Data Sharing Policy  
This study will be conducted in accordance with the following publication and data sharing 
policies and regulations: 
1. National Institutes of Health (NIH) Public Access Policy, which ensures that the public has 
access to the published results of NIH-funded research. It requires scientists to submit final 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 114 of 143 
 
 peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed 
Central upon acceptance for publication. 
2. NIH Data Sharing Policy and Policy on the Dissemination of NIH- Funded Clinical Trial 
Information and the Clinical Trials Registration and Results Information Submission rule. As 
such, this tria l will be registered at ClinicalTrials.gov, and results information from this trial 
will be submitted to ClinicalTrials.gov, if required.  
3. NIH Genomic Data Sharing Policy, which applies to all NIH- funded research that generates 
large- scale human or non-human genomic data, as well as the use of these data for 
subsequent research. Large- scale data include genome-wide association studies (GWAS), 
single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epi[INVESTIGATOR_141214], and gene expression data. 
11.[ADDRESS_543557] will arise from the research enterprise, from technology transfer activities, and from the many facets of our investigators’ profe ssional activities. UNC seeks to identify and manage these conflicting 
relationships, restricting activities where necessary, to preserve transparency, independent decision -making, protection of research participants, and integrity of the educational exper ience. 
UNC’s Conflict of Interest Program will have oversight over this study.  
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543558]  
CFAR  Center for AIDS Research  
CFR Code of Federal Regulations  
ChAd V Simian Adenovirus  of chimpanzee origin  
CIDP  Chronic Inflammatory Demyelinating  Polyneuropathy  
CLIA  Clinical Laboratory Improvement Amendments  
CLS  Capi[INVESTIGATOR_429388] (CK)  
CRF Case Report Form  
CRP  C-Reactive Protein  
CSF Cerebral Spi[INVESTIGATOR_17106]  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 116 of 143 
 
 CSRC  (DAIDS) Clinical Science Review Committee  
CT Computed Tomography  
CTRC  Clinical and Translational Research Center  
CVST  Cerebral Venous Sinus Thrombosis  
D196  Day 196 or End of Study  
DAIDS  Division of AIDS  
D/C Discontinue  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DNCB  Dinitrochlorobenzene  
DSMB  Data Safety Monitoring Board  
DRE  Disease -Related Event  
DVT  Deep Vein Thrombosis  
DWI  Diffusion Weighted Image  
  
EBV  Epstein -Barr Virus  
E/CIA  Enzyme or Chemiluminescence Immunoassay  
EC Ethics Committee  
ECG Electrocardiogram  
eCRF  Electronic Case Report Forms  
eGFR  Estimated Glomerular Filtration Rate  
ED Emergency Department  
EMA  European Medicines Agency  
ENA  Extractable Nuclear Antigen Antibodies  
EOS End of Study  or Day [ADDRESS_543559]  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543560] generation conserved -region immunogen  
HLA  Human Leukocyte Antigen  
HSV  Herpes Simplex Virus  
IB Investigator’s Brochure  
IBC Institutional Biosafety Committee  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
ICMJE  International Committee of Medical Journal Editors  
ID Intradermal  
ID Clinic  Infectious Diseases Clinic  
IDS Investigational Drug Service  
IgG Immunoglobulin G  
IFN-γ Interferon gamma  
IgG Immunoglobulin G  
IDS Investigational Drug Services  
IL-[ADDRESS_543561] to Follow -up 
M3 MVA.tHIVconsv3  
M4 MVA.tHIVconsv4  
MAAEs  Medically Attended Adverse Events  
MedDRA  Medical Dictionary for Regulatory Activities  
mg/dL  milligram per deciliter  
ml/min . milliliter per minute  
mm Hg  millimeters of mercury  
MMR  Measles, Mumps, Rubella  
MO Medical Officer  
MOG  Myelinoligodendrocyte Glycoprotein  
MOI Multiplicity of Infection  
MOP  Manual of Procedures  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 118 of 143 
 
 MSDS  Material Safety Data Sheet  
MRI  Magnetic Resonance Image  
MVA  Modified Vaccinia virus (Ankara strain)  
MVA.HIVA  MVA expressing the HIVA immunogen, comprising clade A p24 
and HIV epi[INVESTIGATOR_356471].HIVconsv  MVA expressing the 1st generation conserved HIV immunogen, 
HIVconsv  
MVA.tHIVconsv3  MVA expressing a 2nd generation conserved HIV immunogen, 
tHIVconsv3  
MVA.tHIVconsv4  MVA expressing a 2nd generation conserved HIV immunogen, 
tHIVconsv4  
NCT National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
NMOSD  Neuromyelitis Optica Spectrum Disorder  
NNRTI  Non-nucleoside Reverse Transcriptase Inhibitor  
NRTI  Nucleoside Reverse Transcriptase Inhibitor  
NSI New Safety Information  
OHRP  Office for Human Research Protections  
OSP Office of Science Policy  
OTC Over the Counter  
P Pulse  
PBMC  Peripheral Blood Mononuclear Cells  
PCR  Polymerase Chain Reaction  
PE Physical Exam  
PF4 antibody ELISA  Platelet Factor [ADDRESS_543562] Quality Complaint  
PT Preferred Term  
PT Prothrombin time  
QA Quality Assurance  
QC Quality Control  
RID  Randomization Identification Number  
rMVA  Recombinant  MVA  
RF Rheumatoid Factor  
RFP Red Fluorescent Protein  
RPR Rapid Plasma Reagent  
RR Respi[INVESTIGATOR_429389]-forming units  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543563]  
UP Unanticipated Problem  
US [LOCATION_002]  
VDRL  Venereal Disease Research Laboratories  
VITT  Vaccine -Induced Immune Thrombotic Thrombocytopenia  
VS Vital Signs  
VZV  Varicella Zoster Virus  
WHO  World Health Organization  
WOCBP  Women of Child Bearing Potential  
 
  
 
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543564]-2022  Updated Protocol Team Roster, Section 1.3, 
Section 3, Section 5.1, Section 5.2, Section 6.1.2, Section 6.2.4, Section 6.3, Section 6.5.2, Section 7.2.2, Section 7.2.3, Section 
8.1, Section 8.2, Section 8.4.3, Section 10.2, 
Section 10.7.4, Section 11.5, Section 11.6.3, Appendix 1, Appendix 2 Modified exclusion criterion #[ADDRESS_543565] timing of live vaccines prior to enrollment and address monkeypox vaccines , provide  clarification  and 
resolve discrepancies.  
3.0 12-Jun-2023  Updated Section 1.1 , Section 2.2 , Section 
2.3, Section 5.1 , Section 5.2 , Section 6.1 , 
Section 6.5.2, 8.1 , Section 8.3 , Section 8.4 , 
Section 9.1, Section 9.2, Section 9.3, 
Section 9.4, Section 9.5, Section 10.5, Section 11.4, Appendix 2  Updated C1 -C62 risks section per C1 
IB v4 dated 09- Dec- 2022 and C62 IB 
v3 dated 09- Dec- 2022. Incorporate d 
CM#1 dated 27- Feb-2023.  Removed 
contradictory language for allowable Mpo x vaccine window . Clarified AE 
and SAE reporting guidelines.  Provide 
clarification and resolve discrepancies.  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543566] HC.  1999. HIV-1 and T cell 
dynamics after i nterruption of highly active antiretroviral therapy (HAART) in patients 
with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96:[ZIP_CODE]-14. 
2. Crowell TA, Colby [CONTACT_328056], Pi[INVESTIGATOR_429390] S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong 
K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J, Group RVS. 2019. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV 6:e297-e306. 
3. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, 
Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria- Rose NA, Bailer RT, 
Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW. 2016. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med 375:2037-2050. 
4. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Pi[INVESTIGATOR_429391] M, Shaw A, 
Dalmau J, Zangger N, Martinez -Pi[INVESTIGATOR_56992] J, Zurakowski R, Yu XG, Telenti A, Walker BD, 
Rosenberg ES, Lichterfeld M. 2014. Long -term antiretroviral treatment initiated at 
primary HIV -1 infection affects the size, composition, and decay kinetics of the reservoir 
of HIV -1-infected CD4 T cells. Journal of virology 88:[ZIP_CODE]-65. 
5. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, 
Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-8. 
6. Finzi D, Hermankova M, Pi[INVESTIGATOR_98803] T, Carruth LM, Buck C, Chaisson RE, Quinn TC, 
Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF.  1997. Identification of a reservoir for HIV -1 in patients on highly 
active antiretroviral therapy. Science 278:1295-300. 
7. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange 
SJ, Siliciano RF.  2003. Long -term follow -up studies confirm the st ability of the latent 
reservoir for HIV -1 in resting CD4+ T cells. Nat Med 9:727-8. 
8. Eisele E, Siliciano RF.  2012. Redefining the viral reservoirs that prevent HIV-1 
eradication. Immunity 37:377-88. 
9. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker 
DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-5. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543567] L, Tolstrup M. 2015. The Depsipeptide Romidepsin Reverses HIV- 1 Latency In Vivo. PLoS 
Pathog 11:e1005142. 
11. Elliott J, Solomon A, Wightman F, Smith M, Palmer S, Prince M, Watson J, Hoy J, 
McMahon M, Lewin S. The Safety and Effect of Multiple Doses of Vorinostat on HIV Transcript oin in HIV-Infected Patients receiving Combination Antiretroviral Therapy, p. 
In (ed),   
12. Bruner KM, Hosmane NN, Siliciano RF. 2015. Towards an HIV- 1 cure: measuring the 
latent reservoir. Trends Microbiol 23:192-203. 
13. Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, 
Margolis DM, Bosch RJ, Archin NM. 2015. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. J Infect Dis doi:10.1093/infdis/jiv218. 
14. Siliciano JD, Siliciano RF.  2005. Enhanced culture assay for detection and quantitation of 
latently infected, resting CD4+ T -cells carrying replication -competent virus in HIV-1-
infected individuals. Methods Mol Biol 304:3-15. 
15. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, 
Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1- specific cytolytic T lymphocytes 
facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:[ADDRESS_543568] Dis 
doi:10.1093/infdis/jiv022. 
17. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, 
Hahn BH, Oldstone MB, Shaw G M. 1997. Antiviral pressure exerted by [CONTACT_10840]-1- specific 
cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by [CONTACT_429459]. Nat Med 3:205-11. 
18. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus- specific CD8+ 
cytotoxic T -lymphocyte activity associated with control of viremia in primary human 
immunodeficiency virus type 1 infection. J Virol 68:6103-10. 
19. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham 
CR, Phillips RE. 1997. Positive selection of HIV- 1 cytotoxic T lymphocyte escape 
variants during primary infection. Proc Natl Acad Sci U S A 94:1890-5. 
20. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho 
DD. 1994. Temporal association of cellular immune responses with the initial control of 
viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650-5. 
21. Goonetilleke N, Liu MK, Salazar -Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele 
BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S, B CCC, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV -1 infection. J 
Exp Med 206:1253-72. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543569] 123:380-93. 
23. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, 
Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3:212-7. 
24. Carrington M, O'Brien SJ. 2003. The influence of HLA genotype on AIDS. Annu Rev 
Med 54:535-51. 
25. Smith NM, Mlcochova P, Watters SA, Aasa-Chapman MM, Rabin N, Moore S, Edwards 
SG, Garson JA, Grant PR, Ferns RB, Kashuba A, Mayor NP, Schellekens J, Marsh SG, McMichael AJ, Perelson AS, Pi[INVESTIGATOR_140195] D, Goonetilleke N, Gupta RK. 2015. Proof-of-Principle for Immune Control of Global HIV-[ADDRESS_543570] Dis doi:10.1093/cid/civ219. 
26. Apetrei C, Sumpter B, Souquiere S, Chahroudi A, Makuwa M, Reed P, Ribeiro RM, 
Pandrea I, Roques P, Silvestri G. 2011. Immunovirological analyses of chronically simian immunodeficiency virus SIVmnd -1- and SIVmnd-2- infected mandrills 
(Mandrillus sphinx). J Virol 85:[ZIP_CODE]-87. 
27. Cartwright EK, Spi[INVESTIGATOR_18551] L, Smith SA, Lee D, Fast R, Paganini S, Lawson BO, Nega M, 
Easley K, Schmitz JE, Bosinger SE, Paiardini M, Chahroudi A, Vanderford TH, Estes JD, Lifson JD, Derdeyn CA, Silvestri G. 2016. CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV- Infected Macaques Treated with Short -Term 
Antiretroviral Therapy. Immunity 45:656-668. 
28. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King 
A, Lechner F, Spi[INVESTIGATOR_429392], Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland- Jones SL. 2002. 
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8:379-85. 
29. Estcourt MJ, McMichael AJ, Hanke T.  2004. DNA vaccines against human 
immunodeficiency virus type 1. Immunol Rev 199:144-55. 
30. Harari A, Rozot V, Cavassini M, Bellutti Enders F, Vigano S, Tapia G, Castro E, Burnet 
S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart PA. 2012. NYVAC immunization in duces polyfunctional HIV- specific T -cell responses in 
chronically -infected, ART -treated HIV patients. Eur J Immunol 42:3038-48. 
31. Honda M, Wang R, Kong WP, Kanekiyo M, Akahata W, Xu L, Matsuo K, Natarajan K, 
Robinson H, Asher TE, Price DA, Douek DC, Marg ulies DH, Nabel GJ.  2009. Different 
vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epi[INVESTIGATOR_76802]. J Immunol 183:2425-34. 
32. Peng B, Wang LR, Gomez -Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman 
VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M.  2005. Replicating rather than nonreplicating adenovirus-human 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 124 of 143 
 
 immunodeficiency virus recombinant vaccines are better at eliciting potent cellular 
immunity and priming high-titer antibodies. J Virol 79:[ZIP_CODE]-9. 
33. Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF, Berglund P, Gibbs J, 
Bennink JR, Yewdell JW. 2004. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304:1318-21. 
34. Shen L, Rock KL. 2004. Cellular protein is the source of cross-priming antigen in vivo. 
Proc Natl Acad Sci U S A 101:3035-40. 
35. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. 2004. Antigen 
bias in T cell cross -priming. Science 304:1314-7. 
36. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, 
Fuerst TR, Lifson JD, Pi[INVESTIGATOR_429393] M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G.  1996. Host range restricted, non- replicating vaccinia virus vectors  as 
vaccine candidates. Adv Exp Med Biol 397:7-13. 
37. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama 
JR, Marmor M, Del Rio C, McElrath MJ, [COMPANY_017]o DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, Step Study Protocol T. 2008. Efficacy assessment of a cell -
mediated immunity HIV -1 vaccine (the Step Study): a double-blind, randomised, 
placebo -controlled, test- of-concept trial. Lancet 372:1881-93. 
38. [COMPANY_017]o DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, Chen M, Long R, 
McKelvey T, Chastain M, Gurunathan S, Tartaglia J, Emini EA, Shiver J. 2004. Heterologous human immunodeficiency virus type 1 priming- boosting immunization 
strategies involving replication -defective adenovirus and poxvirus vaccine vectors. J 
Virol 78:[ZIP_CODE]-8. 
39. Bridgeman A, Roshorm Y, Lockett LJ, Xu ZZ, Hopkins R, Shaw J, Both GW, Hanke T. 
2009. Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV -1 vaccine. Vaccine 28:474-83. 
40. Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga 
MJ, Barouch DH. 2006. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by [CONTACT_429460] -reactivity. J Virol 
80:[ZIP_CODE]-16. 
41. Amara RR, V illinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu 
Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69 -74. 
42. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L.  2007. Clinical experience with 
plasmid DNA - and modified vaccinia virus Ankara-vectored human immunodeficiency 
virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 88:1-12. 
43. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, Hill AV, Smith 
GL, McMichael A.  1998. Enhancement of MHC class I- restricted peptide- specific T cell 
induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439-45. 
44. Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, 
Korber B, McMichael AJ, Hanke T.  2007. Design and pre- clinical evaluation of a 
universal HIV- 1 vaccine. PLoS One 2:e984. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 125 of 143 
 
 45. Santra S, Sun Y, Korioth-Schmitz B, Fitzgerald J, Charbonneau C, Santos G, Seaman 
MS, Ratcliffe SJ, Montefiori DC, Nabel GJ, Ertl HC, Letvin NL. 2009. Heterologous 
prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27:5837-45. 
46. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AV. 2005. 
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174:449-55. 
47. Deeks SG, Walker BD.  2007. Human immunodeficiency virus controllers: mechanisms 
of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-16. 
48. Kiepi[INVESTIGATOR_245036] P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy 
S, de Pi[INVESTIGATOR_429394] C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13:46-53. 
49. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, van der Stok M, 
Mncube Z, Brander C, Rousseau C, Mullins JI, Kaslow R, Goepfert P, Allen S, Hunter E, Mulenga J, Kiepi[INVESTIGATOR_245036] P, Walker BD, Goulder PJ. 2007. Compensatory mutation partially 
restores fitness and delays reversion of escape mutation within the immunodominant HLA -B*5703- restricted Gag epi[INVESTIGATOR_429395] 1 
infection. J Virol 81:8346-51. 
50. Warren J. 2020. The HIV- [ADDRESS_543571] CTL response is required to clear latent HIV-1 due to 
dominance of escape mutation s. Nature 517:381-5. 
52. Warren JA, Zhou S, Xu Y, Moeser MJ, MacMillan DR, Council O, Kirchherr J, Sung 
JM, Roan NR, Adimora AA, Joseph S, Kuruc JD, Gay CL, Margolis DM, Archin N, Brumme ZL, Swanstrom R, Goonetilleke N. 2020. The HIV- 1 latent reservoir is largely 
sensitive to circulating T cells. Elife 9.  
53. Xu Y, Trumble IM, Warren JA, Clutton G, Abad-Fernandez M, Kirchnerr J, Adimora 
AA, Deeks SG, Margolis DM, Kuruc JD, Gay CL, Archin NM, Mollan KR, Hudgens M, Goonetilleke N. 2019. HIV- Specific T Cell Responses Are Highly Stable on 
Antiretroviral Therapy. Mol Ther Methods Clin Dev 15:9-17. 
54. Ondondo B, Murakoshi H, Clutton G, Abdul- Jawad S, Wee EG, Gatanaga H, Oka S, 
McMichael AJ, Takiguchi M, Korber B, Hanke T. 2016. Novel Conserved-region T- cell 
Mosai c Vaccine With High Global HIV -1 Coverage Is Recognized by [CONTACT_429461]. Mol Ther 24:832-42. 
55. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreno J, Bach V, Zuniga R, 
Perez -Alvarez S, Berger CT, Puertas MC, Martinez -Pi[INVESTIGATOR_56992] J, Rolland M, Farfan M, 
Szinger JJ, Hildebrand WH, Yang OO, Sanchez-Merino V, Brumme CJ, Brumme ZL, Heckerman D, Allen TM, Mullins JI, Gomez G, Goulder PJ, Walker BD, Gatell JM, 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 126 of 143 
 
 Clotet B, Korber BT, Sanchez J, Brander C. 2011. Definition of the viral targets of 
protective HIV -1-specific T cell responses. J Transl Med 9:208. 
56. Hanke T, Szawlowski P, Randall RE. 1992. Construction of solid matrix-antibody-
antigen complexes containing simian immunodeficiency virus p27 using tag- specific 
monoclonal antibody and tag-linked antigen. J Gen Virol 73 ( Pt 3):653-60. 
57. Afolabi MO, Ndure J, Drammeh A, Darboe F, Mehedi SR, Rowland- Jones SL, 
Borthwick N, Black A, Ambler G, John- Stewart GC, Reilly M, Hanke T, Flanagan KL.  
2013. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS One 8:e78289. 
58. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pi[INVESTIGATOR_17872] S, 
Gillespie G, Brown D, Loach V, Roberts J, Guima raes-Walker A, Hayes P, Loughran K, 
Smith C, De Bont J, Verlinde C, Vooijs D, Schmidt C, Boaz M, Gilmour J, Fast P, Dorrell L, Hanke T, McMichael AJ. 2006. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)- specific T cells capable of  proliferation in 
healthy subjects by [CONTACT_2329] a prime-boost regimen of DNA- and modified vaccinia virus Ankara- vectored vaccines expressing HIV -1 Gag coupled to CD8+ T-cell epi[INVESTIGATOR_322]. J 
Virol 80:4717-28. 
59. Njuguna IN, Ambler G, Reilly M, Ondondo B, Kanyugo M, Lohman-Payne B, Gichuhi C, Borthwick N, Black A, Mehedi SR, Sun J, Maleche-Obimbo E, Chohan B, John-Stewart GC, Jaoko W, Hanke T. 2014. PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi. Vaccine 32:5801-8. 
60. Weiss R, Durnberger J, Mostbock S, Scheiblhofer S, Hartl A, Breitenbach M, Strasser P, 
Dorner F, Livey I, Crowe B, Thalhamer J. 1999. Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by [CONTACT_356528]- targeting leader sequence. 
Vaccine 18:815 -24. 
61. Hanke T.  2019. Aiming for protective T- cell responses: a focus on the first generation 
conserved -region HIVconsv vaccines in preventive and therapeutic clinica l trials. Expert 
Rev Vaccines 18:1029-1041. 
62. Mohamed YS, Borthwick NJ, Moyo N, Murakoshi H, Akahoshi T, Siliquini F, Hannoun 
Z, Crook A, Hayes P, Fast PE, Mutua G, Jaoko W, Silva-Arrieta S, Llano A, Brander C, Takiguchi M, Hanke T. 2020. Specificity of CD8(+) T -Cell Responses Following 
Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya. Vaccines (Basel) 8. 
63. Borthwick NJ, Lane T, Moyo N, Crook A, Shim JM, Baines I, Wee EG, Hawkins PN, 
Gillmore JD, Hanke T, Pepys MB. 2018. Randomized phase I trial HIV -CORE 003: 
Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV -1. PLoS One 13:e0197299. 
64. Mothe B, Rosas-Umbert M, Coll P, Manzardo C, Puertas MC, Moron-Lopez S, Llano A, 
Miranda C, Cedeno S, Lopez M, Alarcon-Soto Y, Melis GG, Langohr K, Barriocanal AM, Toro J, Ruiz I, Rovira C, Carrillo A, Meulbroek M, Crook A, Wee EG, Miro JM, Clotet B, Valle M, Martinez -Pi[INVESTIGATOR_56992] J, Hanke T, Brander C, Molto J, Investigators BCNS. 
2020. HIVconsv Vaccines and Romidepsin in Early- Treated HIV -1-Infected Individuals: 
Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Front Immunol 11:823. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543572] R, Wu G, Kaye S, Wills M, Babiker A, Frater J, group Rts. 2020. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet 395:888-898. 
66. Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Moron-Lopez S, Puertas MC, 
Rosas -Umbert M, Cobarsi P, Escrig R , Perez -Alvarez N, Ruiz I, Rovira C, Meulbroek M, 
Crook A, Borthwick N, Wee EG, Yang H, Miro JM, Dorrell L, Clotet B, Martinez-Pi[INVESTIGATOR_56992] J, Brander C, Hanke T. 2019. Therapeutic Vaccination Refocuses T- cell 
Responses Towards Conserved Regions of HIV- 1 in Earl y Treated Individuals (BCN 01 
study). EClinicalMedicine 11:65 -80. 
67. Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, 
Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L.  2018. A Novel Vaccine Strategy Employing Serologically 
Different Chimpanzee Adenoviral Vectors for the Prevention of HIV- 1 and HCV 
Coinfection. Front Immunol 9:3175. 
68. Hancock G, Moron-Lopez S, Kopycinski J, Puertas MC, Giannoulatou E, Rose A, 
Salgado M, Hayton EJ, Crook A, Morgan C, Angus B, Chen F, Yang H, Martinez- Pi[INVESTIGATOR_56992] 
J, Hanke T, Dorrell L. 2017. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral 
therapy -treated subjects. J Int AIDS Soc 20:[ZIP_CODE]. 
69. Mutua G, Farah B, Langat R, Indangasi J, Ogola S, Onsembe B, Kopycinski JT, Hayes P, 
Borthwick NJ, Ashraf A, Dally L, Barin B, Tillander A, Gilmour J, De Bont J, Crook A, Hannaman D, Cox JH, Anzala O, Fast PE, Reilly M, Chinyenze K, Jaoko W, Hanke T, Hiv-Core [ADDRESS_543573] HIV-1 inhibition in vitro by [CONTACT_29298]- elicited 
CD8(+) T cells in African adults. Mol Ther Methods Clin Dev 3:[ZIP_CODE]. 
70. Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, Hayton EJ, Black 
A, Bridgeman A, Rosario M, Hill AV, Berrie E, Moyle S, Frahm N, Cox J, Colloca S, Nicosia A, Gilmour J, McMichael AJ, Dorrell L, Hanke T. 2014. Vaccine- elicited human 
T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22:464-75. 
71. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, 
Sinden R, Smith GL, Hill AV. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by [CONTACT_429462]. Nat Med 4:397-402. 
72. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, 
Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ.  2012. [COMPANY_006] Ad5/HIV induces broad innate 
immune activation that predicts CD8(+) T -cell responses but is attenuated by [CONTACT_429463]5 immunity. Proc Natl Acad Sci U S A 109:E3503-12. 
73. Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, 
Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gomez CE, Esteban M, Wyatt LS, Moss B, Morgan C, Roederer M, Bailer 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 128 of 143 
 
 RT, Nabel GJ, Koup RA, Seder RA. 2013. Comparative analysis of the magnitude, 
quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human -, simian -, and chimpanzee- derived recombinant 
adenoviral vector immunization. J Immunol 190:2720-35. 
74. Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, 
Cottingham MG.  2012. A novel chimpanzee adenovirus vector with low human 
seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7:e40385. 
75. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, 
Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, L illie PJ, 
Mallory R, Mendes AVA, Milan EP, Minassian AM, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV- 2: an interim analysis of 
four randomised controlled trials in Brazil, South Africa, and the [LOCATION_006]. Lancet 397:99-111. 
76. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, 
Voysey M, Aley PK, Angus B, Babbage G, Belij- Rammerstorfer S, Berry L, Bibi S, 
Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, et al.  2021. Safety and immunogenicity of ChAdOx1 nCoV- [ADDRESS_543574] regimen in young and old adults (COV002): a single-blind, 
randomised, controlled, phase 2/3 trial. Lancet 396:1979-1993. 
77. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete 
S, Van Damme W, Leroux -Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon 
J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormi er E, Scheper 
G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H. 2021. Interim Results of a Phase 1 -2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med 
doi:10.1056/NEJMoa2034201. 
78. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, 
Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL, Gam C- VVTG.  2021. 
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID -19 vaccine: an interim analysis of a randomised controlled phase 3 trial in 
Russia. Lancet 397:671-681. 
79. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a 
D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 129 of 143 
 
 Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural 
J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, 
Goudsmit J. 2011. International seroepi[INVESTIGATOR_429396] 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203-9. 
80. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, 
Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, [COMPANY_017]o DR, Step Study Protocol T. 2008. HIV- [ADDRESS_543575]-of- concept Step Study: a case -cohort analysis. Lancet 372:1894-
1905. 
81. Iampi[INVESTIGATOR_429397], Larocca RA, Provine NM, Abbink P, Kang ZH, Bricault CA, Barouch DH. 
2018. Immunogenicity and Cross- Reactivity o f Rhesus Adenoviral Vectors. J Virol 92. 
82. Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, Iampi[INVESTIGATOR_429397], Barouch DH. 2013. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacit y compared to Ad5 vectors. J Virol 
87:1373-84. 
83. Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page- Shipp L, Walsh SR, 
Nyombayire J, Anzala O, Roux S, Laher F, Innes C, Seaman MS, Cohen YZ, Peter L, Frahm N, McElrath MJ, Hayes P, Swann E, Grunenberg N, Grazia- Pau M, Weijtens M, 
Sadoff J, Dally L, Lombardo A, Gilmour J, Cox J, Dolin R, Fast P, Barouch DH, Laufer DS, Group BIHS. 2016. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV -1 Prevention: A Randomized Trial. Ann Intern Med 164:313-
22. 
84. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, 
Thomas W, Lester W.  2021. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 
nCoV-19 Vaccination. N Engl J Med doi:10.1056/NEJMoa2105385. 
85. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.  2021. 
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med doi:10.1056/NEJMoa2104840. 
86. Bourguignon A, Arnold DM, Warkentin TE, Smith JW, Pannu T, Shrum JM, Al 
Maqrashi ZAA, Shroff A, Lessard MC, Blais N, Kelton JG, Nazy I. 2021. Adjunct 
Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med doi:10.1056/NEJMoa2107051. 
87. Kilpelainen A, Saubi N, Guitart N, Moyo N, Wee EG, Ravi K, Hanke T, Joseph J. 2019. 
Priming With Recombinant BCG Expressing Novel HIV -1 Conserved Mosaic 
Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T -Cell Responses in BALB/c Mice. Front Immunol 10:923. 
88. Sutter G, Moss B. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant 
genes. Proc Natl Acad Sci U S A 89:[ZIP_CODE]-51. 
89. Drexler I, Heller K, Wahren B, Erfle V, Sutter G.  1998. Highly attenuated modified 
vaccinia virus Ankara replicates in baby [CONTACT_301330], a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79:347-52. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 130 of 143 
 
 90. Antoine G, Scheiflinger F, Dorner F, Falkner FG.  1998. The complete genomic sequence 
of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 
244:365-96. 
91. Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne R, 
Venkatraman N, de Barra E, Snudden CM, Poulton ID, de Graaf H, Sukhtankar P, Roberts R, Ivinson K, Weltzin R, Rajkumar BY, Wille -Reece U, Lee C, Ockenhouse C, 
Sinden RE, Gerry S, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Cooke GS, Faust SN, Gilbert S, Hill AV. 2016. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd- MVA Vectored 
Vaccines Expressing ME -TRAP. J Infect Dis doi:10.1093/infdis/jiw244. 
92. Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nebie I, Bliss C, Hodgson 
SH, Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo M, N jie-Jobe J, Diarra A, Duncan CJ, Cortese R, Nicosia A, Roberts R, 
Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AV, Bojang K, Sirima SB.  2016. Safety and Immunogenicity of ChAd63 
and MVA ME -TRAP in West Africa n Children and Infants. Mol Ther 
doi:10.1038/mt.2016.83. 
93. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dieye S, Dieye TN, Esmail 
H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H, investigators MAt.  2015. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine 
MVA85A in healthy adults infected with HIV -1: a randomised, placebo-controlled, phase 
2 trial. Lancet Respir Med 3:190-200. 
94. Mothe B, Climent N, Plana M, Rosas M, Jimenez JL, Munoz- Fernandez MA, Puertas 
MC, Carrillo J, Gonzalez N, Leon A, Pi[INVESTIGATOR_69936] J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcami J, Martinez -Pi[INVESTIGATOR_56992] J, Alvarez -Fernandez C, Sanchez -Palomino S, Guardo AC, 
Pena J, Benito JM, Rallon N, Gomez CE, Perdiguero B, Garcia- Arriaza J, Esteban M, 
Lopez Bernaldo de Quiros JC, Brander C, Garcia F, Group R- S. 2015. Safety and 
immunogenicity of a modified vaccinia Ankara- based HIV -1 vaccine (MVA -B) in HIV -
1-infected patients alon e or in combination with a drug to reactivate latent HIV -1. J 
Antimicrob Chemother 70:1833-42. 
95. Hodgson SH, Choudhary P, Elias SC, Milne KH, Rampling TW, Biswas S, Poulton ID, 
Miura K, Douglas AD, Alanine DG, Illingworth JJ, de Cassan SC, Zhu D, Nicosia A, Long CA, Moyle S, Berrie E, Lawrie AM, Wu Y, Ellis RD, Hill AV, Draper SJ. 2014. Combining viral vectored and protein- in-adjuvant vaccines against the blood- stage 
malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther 22:2142-54. 
96. Hayto n EJ, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A, Black AP, Dorrell 
L, Hanke T. 2014. Safety and tolerability of conserved region vaccines vectored by [CONTACT_356526], simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One 9:e101591. 
97. Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill 
AV, Gilbert SC.  2014. Coadministration of seasonal influenza vaccine and MVA -
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 131 of 143 
 
 NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 
22:233-8. 
98. Rowland R, Pathan AA, Satti I, Poulton ID, Matsumiya MM, Whittaker M, Minassian 
AM, O'Hara GA, Hamill M, Scott JT, Harris SA, Poyntz HC, Bateman C, Me yer J, 
Williams N, Gilbert SC, Lawrie AM, Hill AV, McShane H.  2013. Safety and 
immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG- vaccinated healthy adults: a phase I clinical 
trial. Hum Vaccin Immunother 9:50-62. 
99. Dieye TN, Ndiaye BP, Dieng AB, Fall M, Brittain N, Vermaak S, Camara M, Diop-
Ndiaye H, Ngom- Gueye NF, Diaw PA, Toure -Kane C, Sow PS, Mboup S, McShane H. 
2013. Two doses of candidate TB vaccine MVA85A in antiretroviral therap y (ART) 
naive subjects gives comparable immunogenicity to one dose in ART+ subjects. PLoS One 8:e67177. 
100. Ratto -Kim S, Currier JR, Cox JH, Excler JL, Valencia- Micolta A, Thelian D, Lo V, 
Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA. 2012. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One 7:e45840. 
101. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, 
Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV.  2012. Clinical assessment of a recombinant 
simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205:772-81. 
102. Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, 
Milicic A, Price DA, Hill AV, Gilbert SC.  2012. A T cell-inducing influenza vacc ine for 
the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 7:e48322. 
103. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, 
Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, La wrie AM, Berrie E, 
Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ. 2011. Phase Ia clinical evaluation of the Plasmodium falciparum blood- stage antigen 
MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19:2269-76. 
104. Howl es S, Guimaraes -Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, 
Hayes P, Gilmour J, Bridgeman A, Hanke T, McMichael A, Dorrell L. 2010. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-[ADDRESS_543576] vector- speci fic T cell responses in human subjects. Vaccine 28:7306-12. 
105. Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber 
BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV. 2010. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by [CONTACT_429464], poxvirus, and protein- in-adjuvant vaccines. J Immunol 185:7583-95. 
106. Guimaraes -Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, Barin 
B, McMichael A, Weber J, Legg K, Babiker A, Hayes P, Gotch F, Smith C, Dally L, 
Dorrell L, Cebere I, Kay R, Winstone N, Moore S, Goonetilleke N, Fast P, Group I- S. 
2008. Lessons from IAVI -006, a phase I clinical trial to evaluate the safety and 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543577] 
strategy to induce HIV- 1 specific T -cell responses in healthy volunteers. Vaccine 
26:6671-7. 
107. Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker 
P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K, Pediatr ic ACTGPT.  2008. Safety and 
immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly 
active antiretroviral therapy. Vaccine 26:6883 -93. 
108. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, 
Naylor S, Me lcher A, Nicholls J, Wassan H, Habib N, Anthoney A. 2007. Vaccination of 
colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13:4487-94. 
109. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, Conlon C, Hanke T, McMichael A. 
2007. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV -1 gag/multiepi[INVESTIGATOR_356475] (MVA.HIVA) in HIV-1-infected persons 
receiving combination antiretroviral therapy. Vaccine 25:3277-83. 
110. Ondondo BO, Yang H, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, 
Rowland-Jones SL, Hanke T, McMichael AJ, Dorrell L. 2006. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV- [ADDRESS_543578] functional CD4+ T cell responses. Eur J Immunol 36:2585-94. 
111. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, 
Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. 2006. A DNA prime -modified vaccinia virus ankara boost vaccine encoding thrombospondin-
related adhesion protein but not circumsporozoite protein partially protects healthy malaria -naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 
74:5933-42. 
112. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, 
Dorrell L, McShane H, Schm idt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-
Jones SL, Bwayo JJ, McMichael AJ, Hanke T. 2004. A human immunodeficiency virus 1 (HIV -1) clade A vaccine in clinical trials: stimulation of HIV -specific T -cell responses by 
[CONTACT_429465] (MVA) vaccines in humans. J Gen Virol 85:911-9. 
113. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, 
Hill AV.  2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A 
boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10:1240-4. 
114. Moorthy VS, McConkey S, Roberts M, Gothard P, Arulanantham N, Degano P, 
Schneider J, Hannan C, Roy M, Gilbert SC, Peto TE, Hill AV. 2003. Safety of DNA and modified vaccinia virus Ankara vaccines against liver -stage P. falciparum malaria in non -
immune volunteers. Vaccine 21:2004-11. 
115. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, 
Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 133 of 143 
 
 MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. 2003. 
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by [CONTACT_429466]. Nat Med 9:729-35. 
116. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, Sutter G, Goebel FD, Erfle V. 
2003. Therapeutic vaccination with MVA- HIV-1 nef elicits Nef -specific T -helper cell 
responses in chronically HIV -1 infected individuals. Vaccine 22:21-9. 
117. Stickl HA.  1974. Smallpox vaccination and its consequences: first experiences with the 
highly attenuated smallpox vaccine "MVA". Prev Med 3:97-101. 
118. Abdul-Jawad S, Ondondo B, van Hateren A, Gardner A, Elliott T, Korber B, Hanke T. 
2016. Increased Valency of Conserved- mosaic Vaccines Enhances the Breadth and Depth 
of Epi[INVESTIGATOR_429398]. Mol Ther 24:375-84. 
119. Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, Crome SJ, Edlin A. 
2002. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA - and modified vaccinia virus Ankara (MVA)- based HIV vaccines for 
Kenya. Vaccine 21:108 -14. 
120. Hanke T, McMichael AJ, Dennis MJ, Sharpe SA, Powell LA, McLoughlin L, Crome SJ. 
2005. Biodistribution and persistence of an MVA- vectored candidate HIV vaccine in 
SIV-infected rhesus macaques and SCID mice. Vaccine 23:1507-14. 
121. Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, Sheehan S, Thomas ZM, 
Wrigh t D, Stockdale L, Hamidi A, O'Shea MK, Dwivedi K, Behrens HM, Davenne T, 
Morton J, Vermaak S, Lawrie A, Moss P, McShane H. 2020. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy [LOCATION_006] adults. Vaccine 38:779-789. 
122. Mensah VA, Roetynck S, Kanteh EK, Bowyer G, Ndaw A, Oko F, Bliss CM, Jagne YJ, 
Cortese R, Nicosia A, Roberts R, D'Alessio F, Leroy O, Faye B, Kampmann B, Cisse B, Bojang K, Gerry S, Viebig NK, Lawrie AM, Clarke E, Imoukhuede EB, Ewer KJ, Hill AVS, Afolabi MO.  2017. Safety and Immunogenicity of Malaria Vectored Vaccines 
Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. Front Immunol 8:1551. 
123. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly 
F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny MP, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AV, Ballou WR, Sullivan N, Graham B, Levine MM. 2016. Use of ChAd3- EBO -Z 
Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-
blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 16:[ADDRESS_543579] S N, Hill AV.  2015. 
Evaluation of the efficacy of ChAd63- MVA vectored vaccines expressing 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543580] Dis 211:1076-86. 
125. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, 
Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, 
Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.  2014. A human vaccine strategy based on 
chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6:261ra153. 
126. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins 
KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ,  Chilengi R, Hill AV, Bojang K.  2013. Safety and immunogenicity of 
heterologous prime- boost immunisation with Plasmodium falciparum malaria candidate 
vaccines, ChAd63 ME- TRAP and MVA ME -TRAP, in healthy Gambian and Kenyan 
adults. PLoS One 8:e57726. 
127. Tiono AB, Nebie I, Anagnostou N, Coulibaly AS, Bowyer G, Lam E, Bougouma EC, 
Ouedraogo A, Yaro JBB, Barry A, Roberts R, Rampling T, Bliss C, Hodgson S, Lawrie A, Ouedraogo A, Imoukhuede EB, Ewer KJ, Viebig NK, Diarra A, Leroy O, Bejon P, Hill AVS, Sirima SB.  2018. First field efficacy trial of the ChAd63 MVA ME- TRAP 
vectored malaria vaccine candidate in 5 -17 months old infants and children. PLoS One 
13:e0208328. 
128. de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A, Berrie E, Lawrie 
AM, Gilber t SC, Nicosia A, McConkey SJ, Hill AV. 2014. A phase Ia study to assess the 
safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One 9:e115161. 
129. Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes -
Sandoval A. 2014. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin- related anonymous protein as 
assessed with transgenic Plasmodium berghei parasites. Infect Im mun 82:1277-86. 
130. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer 
KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ.  2012. Phase Ia clinical evaluation of the safety and 
immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7:e31208. 
131. Schneider J, Gilbert SC, Hannan CM, Degano P, Prieur E, Sheu EG, Plebanski M, Hill 
AV. 1999. Induction of CD8+ T cells using heterologous prime-boost immunisation 
strategies. Immunol Rev 170:29-38. 
132. Xu Y, Trumble IM, Warren J, Clutton G, Abad-Fernandez M, Kirchnerr J, Adimora AA, 
Deeks S, Margolis D, Kuruc J, Gay C, Archin N, Mollan KR, Hudgens M, N G. 2019. HIV-specific T cell responses are highly stable on antiretroviral therapy. Molecular 
Therapy Methods and Clinical Development doi:https://doi.org/10.1016/j.omtm.2019.07.008. 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 135 of 143 
 
 133. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz 
HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC.  2011. Potent CD8+ T- cell 
immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-
NP+M1. Clin Infect Dis 52:1-7. 
134. Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, Harris S, Poyntz H, 
Hamill M, Griffiths K, Sander CR, Ambrozak DR, Price DA, Hill BJ, Casazza JP, Douek DC, Koup RA, Roederer M, Winston A, Ross J, Sherrard J, Rooney G, Williams N, Lawrie AM, Fletcher HA, Pathan AA, McShane H.  2011. A Phase I study evaluating the 
safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV- infected adults. 
BMJ Open 1:e000223. 
135. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alde r N, Van Wijgerden 
J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H. 2009. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 179:724-33. 
136. Folegatti PM, E wer KJ, Aley PK, Angus B, Becker S, Belij -Rammerstorfer S, Bellamy 
D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford CVTG. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-[ADDRESS_543581] SARS-CoV-2: a preliminary report of a phase 1/2, single -blind, randomised controlled trial. Lancet 396:467-478. 
137. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, 
Payne R, Fehling SK, Strecker T, Biedenkopf N, Krahling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbe G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra -Davidson K, Powlson J, Berrie E, Tedder 
R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, et al. 2016. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374:1635-46. 
138. Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I. 2016. Immunogenicity and 
efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother 65:701-13. 
139. Satti I, Meyer J, Harris SA, Manjaly Thomas ZR, Griffiths K, Antrobus RD, Rowland R, 
Ramon RL, Smith M, Sheehan S, Bettinson H, McShane H. 2014. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by [CONTACT_429467] -vaccinated healthy adults: a phase 1, double-blind, randomi sed controlled trial. 
Lancet Infect Dis 14:939 -46. 
 
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 136 of 143 
 
 Appendix 1  
Rationale for Protocol Version 3.0 
The rationale for this amendment is to update C1-C62 risks section per C1 IB v4 and C62 IB v3, 
incorporated clarification memo #1 dated 27- Feb-2023, to clarify AE/SAE reporting, to remove 
contradictory language fo r allowable Mpox vaccine window, and to resolve discrepancies and 
provide clarifications. The table below outlines substantive and non-substantive changes to the protocol. Other minor typographical and/or editorial changes have been made. A redline version showing detailed changes to the protocol is available on request. 
Summary of Changes in IGHID [ZIP_CODE] Protocol Version 3.0 
Section  Summary of changes and rationale  
Section 1.1 Description of Sites Enrolling Participants  
Clarified  Duke is also a study site.  
Section 1.1 
Section  10.5  Description of Study Intervention  
Clarified vaccination that a maximum of two participants per week will initiate study 
treatment at Day 0.  
Section 1.1 
Section  10.5  Participant Study Duration  
Corrected duration of participation to be approximately 36 weeks (9 months).  
Section 2.2.2,  
Section 6.1.1  C1-C62 Manufacturer  
Updated the name [CONTACT_4007] C1 and C62 manufacturer from Advent Srl to Advaxia 
Biologics Srl per Clarification Memo #1 dated February 17, 2023  
Section 2.3.1  Known Potential Risks of C1 and C62 Vaccines  
Updated potential risks to include transient lymphopenia as reported in C1 IB v4 
dated 09- Dec-2022 and C62 IB v3 dated 09- Dec-2022   
Secti on 5.1, 
Section 5.2 Inclusion and Exclusion Criteria  
Adjusted inclusion and exclusion timelines for IC #13 and #23 as well as EC #3, #5, 
#6, #8, #10, #12, #13, #14, #16, and #18.  Adjusted IC #[ADDRESS_543582] be > LLN.   Clarified which investigational ART is allowed in EC #13.  
Section  6.5.2  Prohibited Medications  
Removed conflicting information regarding allowable window for Mpox vaccination. Adjusted prohibited medication windows for vaccine to align with 
eligibility criteria. Clarified allowed investigational ART.  
Section 8.1.2, 
Appendix 2  Visit windows  
Clarified visit windows for telephone call visits (D 2, D5, D10, D18, D22, and D30) 
per Clarification Memo #1 dated February 17, 2023  
Section 8.1.3  Medical History  
Clarified medical history to include significant medical history condition in noted in 
medical records.  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543583] -vaccine 
assessment.  
Section 8.2.14  Laboratory Evaluations  
Clarified Hepatitis C screening requirements.  
Section 8.3, 
Section 8.4, 
Section 9.1, 
Section 9.3, 
Section 9.4, 
Section 9.5 Adverse Event Reporting  
Created Table 21 to summarize adverse event reporting requirements and timelines 
for Grade 3 or 4 AEs, hypersensitivity o r allergic reactions, SAEs, and AESIs.  
Removed redundant reporting requirements consolidated in Table 21. Adjusted 
reporting timeline s for UNC IRB and FDA in alignment with agency policies.   
Section 9.1.1  
Section 9.1.2  
Section 9.3.1  Adverse Event Toxicity Management  
Clarified Grade 1 and Grade 2 toxicity management for events related and unrelated 
to study treatment. Harmonized Grade 3 and Grade 4 AE toxicity management for AEs in Section 9.1.2 and solicited AEs (local or systemic reactions) in Section 9.3.1. 
Added note to reference Table 21 (AESI reporting) for Grade [ADDRESS_543584]. Removed references to Day 196.  
Section 9.2.3  Delayed Dose  
Added reference to Section 9.1.2 for additional instructions regarding delayed 
booster dose in the event of a prior Grade 3 or 4 AE.  
Section  11.4  Table 22 
Adjusted table numbering after adding Table 21.  
  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543585] C62 and C1C62 Vaccine Adverse Reactions 
I. Telephone Assessment Schedule  
 Day 2 Day 5  Day 10  Day 18 Day 22 
Visit Window    ± 1 D  ± 1 D   ± 1 D   ± [ADDRESS_543586] vaccine for development 
of symptoms associated with clotting disorder  X X X X X 
II. Telephone Assessment for Local and Systemic Reactions (Reference Participant 
Symptom Diary )  
1. Review Solicited AE assessment diary on the phone with the participant.   a. Observation of solicited AEs?   
• Systemic solicited AEs include increased body temperature, malaise, fatigue, 
myalgia, arthralgia, headache, nausea, and feverishness .    
• Local solicited AEs include erythema, swelling, pain, pruritus, and warmth at 
infusion site.  
b. Observation of other signs/symptoms   
III. Telephone Assessment for Development of Symptoms Associated with Clotting Disorder  
1. Assess for the following signs and symptoms  
a. Shortness of breath  
b. Chest pain  
c. Blurred vision or other vision changes  
d. Swelling, pain or erythema in a limb  
e. Severe or persistent abdominal pain  
f. Nausea or vomiting  
g. Dizziness  
h. Mental status changes  
i. Seizure  
j. Severe or persistent headaches  
k. Easy bruising  and/or bleeding  
l. Microhemorrhage beside the site of vaccination  
m. Change in gait; problem with walking, balance or coordination 
n. Weakness  
o. Facial weakness  
p. Numbness or tingling 
q. Difficulty swallowing or slurring of your speech  
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543587] study staff immediately for clinical 
evaluation. If symptoms develop after clinical hours or on the weekend the participant should seek immediate medical attention if they develop any of the above.  
Appendix  3  SARS -CoV-2 Pandemic Considerations  
Sites should follow local guidelines regarding management of participants during periods of 
SARS -CoV- 2 activity (or other public health emergencies), and all applicable DAIDS 
guidelines. 
Participants diagnosed with or suspected of having SARS- CoV- 2 infection  
Participants with suspected SARS -CoV-2 infection should be offered testing using locally 
available, FDA -approved or FDA- EUA assays. Participants who become infected with SARS -
CoV-2 may remain on study. Sites should follow local guidelines for management of participants 
in consultation with primary care providers, local specialists, and the protocol team. 
Screening and Enrollment  
Participants acquiring SARS -CoV-2 during the screening window may complete 
screening/enrollment, but no study visits should occur while the participant is deemed to be 
infectious using local guidelines. Screening and enrollment periods can be extended to a llow for 
recovery. However, all entry criteria must be met as described in the protocol. The participant may be required to repeat screening labs and evaluations at a later time point, based on time of initial screening evaluations and recovery from illnes s, per site investigator discretion.  
Intervention Period (Day 0 through Day 35)  
Participants acquiring SARS -CoV-2 during study intervention period should not return for study 
visits until the participant is deemed to be no longer infectious. Participants  should be followed 
using remote visits (e.g., telephone or video) at least weekly to follow the clinical course of 
disease and to monitor any ongoing AEs. No study treatment should be administered while the infection is thought to be ongoing. This may lead to missing the Day 28 vaccine, in this scenario the participant can receive the booster dose preferably within the 30 days after the Day 28 visit, but can be extended out 60 days, if needed. 
Immunogenicity Follow up Period (Day 42 through Day 196) Partic ipants with suspected SARS-CoV-[ADDRESS_543588] vaccine 
leukapheresis procedure when they are recovered from their illness per site investigator discretion. Participants should be followed using remote visits (e.g., telephone or video) at least weekly to follow the clinical course of disease and to monitor any ongoing AEs. 
SARS -CoV-2 vaccination 
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) booste d with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page [ADDRESS_543589] study assessments remotely. Sites should follow FDA guidance (https://www.fda.gov/media/136238/download or use the more recent FDA updates) for conducting assessments of study endpoints during a public health emergency. Sites can obtain study- required plasma HIV -1 levels and safety laboratories through alternative sites such as a 
commercial laboratory near the participant’s home. The decision to do the test at a commercial laboratory is made by [CONTACT_429468]. The site should take into account any change in blood volume required based on the laboratory selected.
16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 141 of 143 
 
 Appendix 4  Neurolog y Testing  
 
 

16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ ChAdOx1.tHIVconsv1 boosted with 
M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 142 of 143 
 
 Appendix 5  Diagnosis and Management  
 
 

16.1.1 Protocol   
IGHID -[ZIP_CODE] - The CM ( HIV-CORE  008) Study  Version 3.0 
ChAdOx1.HIVconsv62 (C62) boosted with MVA.tHIVconsv4 (M4) or C62+ 
ChAdOx1.tHIVconsv1 boosted with M4+MVA.tHIVconsv3 (M3)  Confidential  
 Page 143 of 143 
 
 Appendix 6  MedDRA Preferred Terms (PTs) for TTS  
I. MedDRA PTs for large vessel thrombosis and embolism in unusual locations  
Aortic embolus, aortic thrombosis, aseptic cavernous sinus thrombosis, brain stem 
embolism, brain stem thrombosis, carotid arterial embolus, carotid artery thrombosis, cavern ous sinus thrombosis, cerebral artery thrombosis, cerebral venous sinus 
thrombosis, cerebral venous thrombosis, superior sagittal sinus thrombosis, transverse sinus thrombosis, mesenteric artery embolism, mesenteric artery thrombosis, mesenteric vein thrombosis, splenic artery thrombosis, splenic embolism, splenic thrombosis, thrombosis mesenteric vessel, visceral venous thrombosis, hepatic artery embolism, hepatic artery thrombosis, hepatic vein embolism, hepatic vein thrombosis, portal vein embolism, portal vein thrombosis, portosplenomesenteric venous thrombosis, splenic vein thrombosis, spontaneous heparin-induced thrombocytopenia syndrome, femoral artery embolism, iliac artery embolism, jugular vein embolism, jugular vein thrombosis, subclavian artery embolism, subclavian vein thrombosis, obstetrical pulmonary embolism, pulmonary artery thrombosis, pulmonary thrombosis, pulmonary venous thrombosis, renal artery thrombosis, renal embolism, renal vein embolism, renal vein thrombosis, brachiocephalic vein thrombosis, vena cava embolism, vena cava thrombosis, truncus coeliacus thrombosis  
II. MedDRA PTs for more common thrombotic events 
 Axillary vein thrombosis, deep vein thrombosis, pulmonary embolism  
III. MedDRA PTs for thrombocytopenia  Autoimmune heparin- induced  thrombocytopenia, Heparin-induced thrombocytopenia, 
Immune thrombocytopenia, Nonimmune heparin associated thrombocytopenia, 
Spontaneous heparin-induced thrombocytopenia syndrome, Thrombocytopenia, Thrombocytopenic purpura  
IV. Text string for  
“thrombocytopenia” or “low platelets” in symptom text  
 
 
  
Page 1 of 2   IGHID [ZIP_CODE] – THE CM (HIV -CORE 008) STUDY – PROTOCOL VERSION 3.0  
CLARIFICATION MEMO  
DATE:   January 22, [ADDRESS_543590]:   Clarification Memo #1 for IGHID-[ZIP_CODE] Protocol Version 3.0 
This clarification memo (CM) does not result in a change in the protocol informed consent document. 
Each site should file a copy of this CM with the protocol for reference. The protocol clarification 
contained in this memo should be implemented immediately.  
This clarification memo further clarifies adverse events are the defined reactogenicity adverse events 
beginning within 7-days following vaccination.  In addition, it updates Appendix 6, MedDRA Preferred 
Terms (PTs) for Thrombosis with Thrombocytopenia  Syndrome (TTS) events . These updates are 
inclusive of Coagulopathy PTs from CDC Vaccine Adverse Event Reporting System (VAERS) Standard 
Operating Procedures for COVID-19 (as of 02Feb2022) and Standardised MedDRA Query (SMQ)  for 
embolic and thrombotic events.   
Text noted below with a strikethrough represents deletion; text appearing below in bold represents an addition. 
1. 
Section 4.1, Overall Design, page 46 
Safety will be assessed for the duration of the study. Solicited AEs will be recorded for 28 days 
after each dose of study intervention (through Day 57), and  AEs,  SAEs, MAAEs, and AESIs will 
be recorded through  the EOS.   
2. Section 8.1.5.j, Solicited Adverse Events, page 71: 
Local and systemic predefined solicited AEs for reactogenicity assessment (Sectio n 8.2.10) will 
be collected in a Participant Symptom Diary for [ADDRESS_543591].   
3. Section 8.4.2, Time Period and Frequency for Event Assessment and Follow- Up, page 85: 
Solicited AEs will be assessed and recorded for [ADDRESS_543592]. 
4. Section 10.2, Endpoints, page 101:  
Secondary Safety Efficacy  Endpoint(s):  
• Occurrence of any ≥ Grade 1 AE including signs/symptoms, lab toxicities, and/or 
clinical events, that is possibly or definitely related to study treatment any time from the first day of treatment (D0) through D196 (Week 28).  
5. 
Appendix 6, MedDRA Preferred Terms (PTs) for Thrombosis with Thrombocytopenia Syndrome 
(TTS) events , page 143:  
I. MedDRA PTs for large vessel thrombosis and embolism in unusual locations  
Aortic embolus, aortic thrombosis, aseptic cavernous sinus thrombosis, brain stem 
embolism, brain stem thrombosis, carotid arterial embolus, carotid artery thrombosis, cavernous sinus thrombosis, cerebral artery thrombosis, cerebral venous sinus 
Page 2 of 2  thrombosis, cerebral venous thrombosis, superior sagittal sinus thrombosis, transverse 
sinus thrombosis, mesenteric artery embolism, mesenteric artery thrombosis, mesenteric 
vein thrombosis, splenic artery thrombosis, splenic embolism, splenic thrombosis, 
thrombosis mesenteric vessel, visceral venous thrombosis, hepatic artery embolism, 
hepa tic artery thrombosis, hepatic vein embolism, hepatic vein thrombosis, portal vein 
embolism, portal vein thrombosis, portosplenomesenteric venous thrombosis, splenic 
vein thrombosis, spontaneous heparin-induced thrombocytopenia syndrome, femoral 
artery emb olism, iliac artery embolism, jugular vein embolism, jugular vein thrombosis, 
subclavian artery embolism, subclavian vein thrombosis, obstetrical pulmonary embolism, pulmonary artery thrombosis, pulmonary thrombosis, pulmonary venous 
thrombosis, renal artery thrombosis, renal embolism, renal vein embolism, renal vein thrombosis, brachiocephalic vein thrombosis, vena cava embolism, vena cava 
thrombosis, truncus coeliacus thrombosis ,
 embolism venous, intracranial venous sinus 
thrombosis  
II. MedDRA PTs for more co mmon thrombotic events 
Axillary vein thrombosis, deep vein thrombosis, disseminated intravascular 
coagulation, pulmonary embolism , thrombosis, venous thrombosis  
III. MedDRA PTs for thrombocytopenia  
Acquired amegakaryocytic thrombocytopenia, Amegakaryocytic thr ombocytopenia,  
Autoimmune heparin-induced thrombocytopenia, Heparin-induced thrombocytopenia, 
Immune thrombocytopenia, Nonimmune heparin associated thrombocytopenia, Severe 
fever with thrombocytopenia syndrome, Spontaneous heparin-induced 
thrombocytopenia syndrome, Thrombocytopenia, Thrombocytopenic purpura , 
Thrombotic thrombocytopenic purpura  
IV. Text string for  
“thrombocytopenia” or “low platelets” in symptom text 
V. Reference additional PTs included in the Standardised MedDRA Query (SMQ) for 
Embolic and thrombotic events 